

Calendar No. 398

115TH CONGRESS 2D SESSION

S. 2680

To address the opioid crisis.

IN THE SENATE OF THE UNITED STATES

APRIL 16, 2018

Mr. Alexander (for himself, Mrs. Murray, Mr. Isakson, Mr. Cassidy, Mr. Heller, Mr. Manchin, Ms. Baldwin, Mr. Kaine, Ms. Heitkamp, Mrs. Capito, Mr. Jones, Ms. Murkowski, Mr. Hatch, Ms. Smith, Ms. Collins, Mr. Rubio, Mr. Casey, and Mrs. McCaskill) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

May 7, 2018

Reported by Mr. ALEXANDER, with an amendment

[Strike out all after the enacting clause and insert the part printed in italic]

A BILL

To address the opioid crisis.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
- 4 (a) SHORT TITLE.—This Act may be cited as the
- 5 "Opioid Crisis Response Act of 2018".

1 (b) Table of Contents of contents of

2 this Act is as follows:

Sec. 1. Short title; table of contents.

TITLE I—REAUTHORIZATION OF CURES FUNDING

Sec. 101. State response to the opioid abuse erisis.

TITLE II—RESEARCH AND INNOVATION

Sec. 201. Advancing cutting-edge research.

Sec. 202. Pain research.

TITLE HI—MEDICAL PRODUCTS AND CONTROLLED SUBSTANCES $\frac{\text{SAFETY}}{\text{SAFETY}}$

Sec. 301. Clarifying FDA regulation of non-addictive pain products.

Sec. 302. Clarifying FDA packaging authorities.

Sec. 303. Strengthening FDA and CBP coordination and capacity.

Sec. 304. Clarifying FDA post-market authorities.

Sec. 305. First responder training.

Sec. 306. Disposal of controlled substances of a deceased hospice patient by employees of a hospice program.

Sec. 307. GAO study and report on hospice safe drug management.

Sec. 308. Delivery of a controlled substance by a pharmacy to be administered by injection, implantation, or intrathecal pump.

TITLE IV—TREATMENT AND RECOVERY

Sec. 401. Comprehensive opioid recovery centers.

Sec. 402. Program to support coordination and continuation of care for drug overdose patients.

Sec. 403. Alternatives to opioids.

Sec. 404. Peer support technical assistance.

Sec. 405. Medication-assisted treatment for recovery from addiction.

Sec. 406. National recovery housing best practices.

Sec. 407. Addressing economic and workforce impacts of the opioid crisis.

Sec. 408. Youth prevention and recovery.

Sec. 409. Plans of safe care.

Sec. 410. Regulations relating to special registration for telemedicine.

Sec. 411. National Health Service Corps behavioral and mental health professionals providing obligated service in schools and other community-based settings.

Sec. 412. Loan repayment for substance use disorder treatment providers.

Sec. 413. Improving treatment for pregnant and postpartum women.

Sec. 414. Early interventions for pregnant women and infants.

TITLE V—PREVENTION

Sec. 501. Study on prescribing limits.

Sec. 502. Programs for health care workforce.

Sec. 503. Education and awareness campaigns.

Sec. 504. Enhanced controlled substance overdoses data collection, analysis, and dissemination.

Sec. 505. Preventing overdoses of controlled substances.

Sec. 506.	CDC surveillance and data collection for child, youth, and adult trau-
	ma.
Sec. 507.	Reauthorization of NASPER.
Sec. 508.	Jessie's Law.
Sec. 509.	Development and dissemination of model training programs for sub-
	stance use disorder patient records.
Sec. 510.	Communication with families during emergencies.

Sec. 511. Prenatal and postnatal health.

1

2

Sec. 512. Surveillance and education regarding infections associated with injection drug use and other risk factors.

Sec. 513. Task force to develop best practices for trauma-informed identification, referral, and support.

Sec. 514. Grants to improve trauma support services and mental health care for children and youth in educational settings.

Sec. 515. National Child Traumatic Stress Initiative.

TITLE I—REAUTHORIZATION OF

CURES FUNDING

3	SEC. 101. STATE RESPONSE TO THE OPIOID ABUSE CRISIS.
4	(a) In General.—Section 1003 of the 21st Century
5	Cures Act (Public Law 114–255) is amended—
6	(1) in subsection (a)—
7	(A) by striking "the authorization of ap-
8	propriations under subsection (b) to carry out
9	the grant program described in subsection (e)"
10	and inserting "subsection (h) to carry out the
11	grant program described in subsection (b)";
12	and
13	(B) by inserting after "and Indian tribes"
14	after "States";
15	(2) by striking subsection (b);
16	(3) by redesignating subsections (e) through (e)
17	as subsections (b) through (d), respectively;

1	(4) by redesignating subsection (f) as sub-
2	section (j);
3	(5) in subsection (b), as so redesignated—
4	(A) in paragraph (1)—
5	(i) in the paragraph heading, by in-
6	serting "AND INDIAN TRIBE" after
7	"STATE";
8	(ii) by striking "States for the pur-
9	pose of addressing the opioid abuse crisis
10	within such States" and inserting "States
11	and Indian tribes for the purpose of ad-
12	dressing the opioid abuse crisis within such
13	States and Indian tribes";
14	(iii) by inserting "or Indian tribes"
15	after "preference to States"; and
16	(iv) by inserting before the period of
17	the second sentence "or other Indian
18	tribes, as applicable"; and
19	(B) in paragraph (2)—
20	(i) in the matter preceding subpara-
21	graph (A), by striking "to a State";
22	(ii) in subparagraph (A), by striking
23	"State";
24	(iii) in subparagraph (C), by inserting
25	"preventing diversion of controlled sub-

1	stances," after "treatment programs,";
2	and
3	(iv) in subparagraph (E), by striking
4	"as the State determines appropriate, re-
5	lated to addressing the opioid abuse crisis
6	within the State" and inserting "as the
7	State or Indian tribe determines appro-
8	priate, related to addressing the opioid
9	abuse crisis within the State, including di-
10	recting resources in accordance with local
11	needs related to substance use disorders";
12	(6) in subsection (c), as so redesignated, by
13	striking "subsection (e)" and inserting "subsection
14	(b)";
15	(7) in subsection (d), as so redesignated—
16	(A) in the matter preceding paragraph (1),
17	by striking "the authorization of appropriations
18	under subsection (b)" and inserting "subsection
19	(h)"; and
20	(B) in paragraph (1), by striking "sub-
21	section (e)" and inserting "subsection (b)"; and
22	(8) by inserting after subsection (d), as so re-
23	designated, the following:
24	"(e) Indian Tribes.—

- 1 "(1) DEFINITION.—For purposes of this sec-2 tion, the term 'Indian tribe' has the meaning given 3 such term in section 4 of the Indian Self-Determina-4 tion and Education Assistance Act (25 U.S.C. 5 5304).
- 6 "(2) APPROPRIATE MECHANISMS.—The Sec-7 retary, in consultation with Indian tribes, shall iden-8 tify and establish appropriate mechanisms for tribes 9 to demonstrate or report the information as required 10 under subsections (b), (c), and (d).
- "(f) Report to Congress.—Not later than 1 year after the date on which amounts are first awarded, after the date of enactment of the Opioid Crisis Response Act of 2018, pursuant to subsection (b), and annually there15 after, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report summarizing the information provided to the Secretary in reports made pursuant to subsection (c), including the purposes for which grant funds are awarded under this section and the activities
- 23 "(g) TECHNICAL ASSISTANCE.—The Secretary, in-24 cluding through the Tribal Training and Technical Assist-25 ance Center of the Substance Abuse and Mental Health

of such grant recipients.

- 1 Services Administration, shall provide State agencies and
- 2 Indian tribes, as applicable, with technical assistance con-
- 3 cerning grant application and submission procedures
- 4 under this section, award management activities, and en-
- 5 hancing outreach and direct support to rural and under-
- 6 served communities and providers in addressing the opioid
- 7 erisis.
- 8 "(h) AUTHORIZATION OF APPROPRIATIONS.—For
- 9 purposes of carrying out the grant program under sub-
- 10 section (b), there are authorized to be appropriated
- 11 \$500,000,000 for each of fiscal years 2019 through 2021,
- 12 to remain available until expended.
- 13 "(i) SET ASIDE.—Of the amounts made available for
- 14 each fiscal year to award grants under subsection (b) for
- 15 a fiscal year, 5 percent of such amount for such fiscal year
- 16 shall be made available to Indian tribes, and up to 15 per-
- 17 cent of such amount for such fiscal year may be set aside
- 18 for States with the highest age-adjusted mortality rate as-
- 19 sociated with opioid use disorders based on the ordinal
- 20 ranking of States according to the age-adjusted overdose
- 21 mortality rates of the Centers for Disease Control and
- 22 Prevention.".
- 23 (b) Previously Appropriated Amounts.—
- 24 (1) Appropriation of amounts remaining
- 25 IN ACCOUNT.—Any unobligated amounts remaining,

1 on the date of enactment of this Act, in the Account 2 For the State Response to the Opioid Abuse Crisis 3 established under section 1003(b) of the 21st Cen-4 tury Cures Act (Public Law 114-255) (as in effect 5 on the day before the date of enactment of this Act) 6 are hereby appropriated to the Secretary of Health 7 and Human Services for purposes of carrying out 8 the grant program under subsection (b) of section 9 1003 of the 21st Century Cures Act (Public Law 10 114-255) (as redesignated by subsection (a)(3) of 11 this section).

- (2) AVAILABLE UNTIL EXPENDED.—Amounts appropriated under paragraph (1) of this subsection or section 1003(b)(3) of the 21st Century Cures Act (as in effect on the day before the date of enactment of this Act) shall remain available until expended.
- (e) Conforming Amendment.—Section 1004(e) of the 21st Century Cures Act (Public Law 114–255) is amended by striking ", the FDA Innovation Account, or the Account For the State Response to the Opioid Abuse Crisis" and inserting "or the FDA Innovation Account".

12

13

14

15

TITLE II—RESEARCH AND 1 **INNOVATION** 2 3 SEC. 201. ADVANCING CUTTING-EDGE RESEARCH. 4 Section 402(n)(1) of the Public Health Service Act (42 U.S.C. 282(n)(1)) is amended— 5 6 (1) in subparagraph (A), by striking "or"; 7 (2) in subparagraph (B), by striking the period 8 and inserting "; or"; and 9 (3) by adding at the end the following: 10 "(C) high impact cutting-edge research 11 that fosters scientific creativity and increases 12 fundamental biological understanding leading to 13 the prevention, diagnosis, or treatment of dis-14 eases and disorders, or research urgently re-15 quired to respond to a public health threat.". 16 SEC. 202. PAIN RESEARCH. 17 Section 409J(b) of the Public Health Service Act (42) U.S.C. 284q(b)) is amended— 18 19 (1) in paragraph (5)— 20 (A) in subparagraph (A), by striking "and 21 treatment of pain and diseases and disorders 22 associated with pain" and inserting "treatment, 23 and management of pain and diseases and dis-24 orders associated with pain, including informa-

tion on best practices for utilization of non-

1	pharmacologie treatments, non-addictive med-
2	ical products, and other drugs approved, or de-
3	vices approved or cleared, by the Food and
4	Drug Administration";
5	(B) in subparagraph (B), by striking "on
6	the symptoms and causes of pain;" and insert-
7	ing the following: "on—
8	"(i) the symptoms and causes of pain;
9	"(ii) the diagnosis, prevention, treat-
10	ment, and management of pain; and
11	"(iii) risk factors for, and early warn-
12	ing signs of, substance use disorders; and";
13	(C) by striking subparagraphs (C) through
14	(E) and inserting the following:
15	"(C) make recommendations to the Direc-
16	tor of NIH—
17	"(i) to ensure that the activities of the
18	National Institutes of Health and other
19	Federal agencies are free of unnecessary
20	duplication of effort;
21	"(ii) on how best to disseminate infor-
22	mation on pain care; and
23	"(iii) on how to expand partnerships
24	between public entities and private entities

1	to expand collaborative, cross-cutting re-
2	search.";
3	(2) by redesignating paragraph (6) as para-
4	graph (7); and
5	(3) by inserting after paragraph (5) the fol-
6	lowing:
7	"(6) REPORT.—The Director of NIH shall en-
8	sure that recommendations and actions taken by the
9	Director with respect to the topics discussed at the
10	meetings described in paragraph (4) are included in
11	appropriate reports to Congress.".
12	TITLE III—MEDICAL PRODUCTS
12	
	AND CONTROLLED SUB-
13	AND CONTROLLED SUB- STANCES SAFETY
13 14 15	
13 14	STANCES SAFETY
13 14 15	STANCES SAFETY SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICT-
13 14 15 16 17	STANCES SAFETY SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICT- IVE PAIN PRODUCTS.
13 14 15 16 17	STANCES SAFETY SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICT- IVE PAIN PRODUCTS. (a) Public Meetings.—Not later than 1 year after
13 14 15 16 17 18	STANCES SAFETY SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICTORY IVE PAIN PRODUCTS. (a) Public Meetings.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health
13 14 15 16 17 18 19 20	STANCES SAFETY SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICTORY IVE PAIN PRODUCTS. (a) Public Meetings.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the
13 14 15 16 17 18 19 20 21	SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICTORY IVE PAIN PRODUCTS. (a) PUBLIC MEETINGS.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the "Secretary"), acting through the Commissioner of Food
13 14 15 16 17 18 19 20 21	STANCES SAFETY SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICTORY IVE PAIN PRODUCTS. (a) PUBLIC MEETINGS.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the "Secretary"), acting through the Commissioner of Food and Drugs, shall hold not less than one public meeting

(1) the manner by which the Secretary may incorporate the risks of misuse and abuse of a controlled substance (as defined in section 102 of the Controlled Substances Act (21 U.S.C. 802) into the risk benefit assessment under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), section 510(k) of such Act (21 U.S.C. 360(k)), or section 515(e) of such Act (21 U.S.C. 360e(e)), as applicable;

- (2) the application of novel clinical trial designs (consistent with section 3021 of the 21st Century Cures Act (Public Law 114–255)), use of real world evidence (consistent with section 505F of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355g)), and use of patient experience data (consistent with section 569C of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–8c)) for the development of non-addictive medical products intended to treat pain or addiction;
- (3) the evidentiary standards and the development of opioid sparing data for inclusion in the labeling of medical products; and
- (4) the application of eligibility criteria under sections 506 and 515B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356, 360e-3) for non-

1	addictive medical products intended to treat pain or
2	addiction.
3	(b) GUIDANCE.—Not less than one year after the
4	public meetings are conducted under subsection (a) the
5	Secretary shall issue one or more final guidance docu-
6	ments, or update existing guidance documents, to help ad-
7	dress challenges to developing non-addictive medical prod-
8	ucts to treat pain or addiction. Such guidance documents
9	shall include information regarding—
10	(1) how the Food and Drug Administration
11	may apply sections 506 and 515B of the Federal
12	Food, Drug, and Cosmetic Act (21 U.S.C. 356,
13	360e-3) to non-addictive medical products intended
14	to treat pain or addiction, including the cir-
15	cumstances under which the Secretary—
16	(A) may apply the eligibility criteria under
17	such sections 506 and 515B to non-opioid or
18	non-addictive medical products intended to
19	treat pain or addiction;
20	(B) considers the risk of addiction of con-
21	trolled substances approved to treat pain when
22	establishing unmet medical need; and
23	(C) considers pain, pain control, or pain
24	management in assessing whether a disease or

condition is a serious or life-threatening disease
 or condition;

(2) the methods by which sponsors may evaluate acute and chronic pain, endpoints for non-addictive medical products intended to treat pain, the manner in which endpoints and evaluations of efficacy will be applied across and within review divisions, taking into consideration the etiology of the underlying disease, and the manner in which sponsors may use surrogate endpoints, intermediate endpoints, and real world evidence;

(3) the manner in which the Food and Drug Administration will assess evidence to support the inclusion of opioid sparing data in the labeling of non-addictive medical products intended to treat pain, including—

(A) data collection methodologies, including the use of novel clinical trial designs (consistent with section 3021 of the 21st Century Cures Act (Public Law 114-255)), and real world evidence (consistent with section 505F of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355g)), as appropriate, to support product labeling;

1	(B) ethical considerations of exposuring
2	subjects to controlled substances in clinical
3	trials to develop opioid sparing data and consid-
4	erations on data collection methods that reduce
5	harm, which may include the reduction of
6	opioid use as a clinical benefit;
7	(C) endpoints, including primary, sec-
8	ondary, and surrogate endpoints, to evaluate
9	the reduction of opioid use;
10	(D) best practices for communication be-
11	tween sponsors and the agency on the develop-
12	ment of data collection methods, including the
13	initiation of data collection; and
14	(E) the appropriate format to submit such
15	data results to the Secretary; and
16	(4) the circumstances under which the Food
17	and Drug Administration considers misuse and
18	abuse of drugs in making determinations of safety
19	under paragraphs (2) and (4) of subsection (d) of
20	section 505 of the Federal Food, Drug, and Cos-
21	metic Act (21 U.S.C. 355) and in finding that a
22	drug is unsafe under paragraph (1) or (2) of sub-
23	section (e) of such section.
24	(c) DEFINITIONS In this section

1 (1) the term "medical product" means a drug (as defined in section 201(g)(1) of the Federal 2 3 Drug, and Cosmetic Act (21) Food, U.S.C. 4 321(g)(1)), biological product (as defined in section 5 351(i) of the Public Health Service Act (42 U.S.C. 6 262(i)), or device (as defined in section 201(h) of 7 the Federal Food, Drug, and Cosmetic Act (21) 8 U.S.C. 321(h))); and 9 (2) the term "opioid sparing" means reducing, 10 replacing, or avoiding the use of opioids or other 11 controlled substances. SEC. 302. CLARIFYING FDA PACKAGING AUTHORITIES. 13 Section 505–1(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1(e)) is amended by adding 14 15 at the end the following: 16 "(4) SERIOUS ADVERSE DRUG EXPERIENCE.— 17 The Secretary may require a risk evaluation mitiga-18 tion strategy for a drug for which there is a serious 19 risk of an adverse drug experience described in sub-20 paragraph (B) or (C) of subsection (b)(1), taking 21 into consideration the factors described in subpara-22 graphs (C) and (D) of subsection (f)(2), which may 23 include requiring that— 24 "(A) the drug be made available for dis-25 pensing to certain patients in unit dose packaging, packaging that provides a set duration,
or other packaging system that the Secretary
determines may help mitigate such serious risk;
or

"(B) the drug be dispensed to certain patients with a safe disposal packaging or safe disposal system for purposes of rendering unused drugs non-retrievable (as defined in section 1300.05 of title 21, Code of Federal Regulations (or any successor regulation)) if the Secretary has determines that such safe disposal packaging or system may help mitigate such serious risk and exists in sufficient quantities, in consultation with other relevant Federal agencies with authorities over drug packaging.".

SEC. 303. STRENGTHENING FDA AND CBP COORDINATION

17 AND CAPACITY.

18 (a) IN GENERAL.—The Secretary of Health and
19 Human Services (referred to in this section as the "Sec20 retary"), acting through the Commissioner of Food and
21 Drugs, shall coordinate with the Secretary of Homeland
22 Security to carry out activities related to customs and bor23 der protection and response to illegal controlled substances
24 and drug imports, including at sites of import (such as
25 international mail facilities). Such Secretaries may carry

1	out such activities through a memorandum of under-
2	standing between the Food and Drug Administration and
3	the United States Customs and Border Protection.
4	(b) FDA IMPORT FACILITIES AND INSPECTION CA-
5	PACITY.—In carrying out this section, the Secretary
6	shall—
7	(1) in collaboration with the Secretary of
8	Homeland Security and the Postmaster General of
9	the United States Postal Service, provide that im-
10	port facilities in which the Food and Drug Adminis-
11	tration operates or carries out activities related to
12	drug imports within the international mail facilities
13	include
14	(A) facility upgrades and improved capac-
15	ity in order to increase and improve inspection
16	and detection capabilities, which may include,
17	as the Secretary determines appropriate—
18	(i) improvements to facilities, such as
19	upgrades or renovations, and support for
20	the maintenance of existing import facili-
21	ties and sites to improve coordination be-
22	tween Federal agencies;
23	(ii) the construction of, or upgrades
24	to, laboratory capacity for purposes of de-
25	tection and testing of imported goods;

1	(iii) upgrades to the security of import
2	facilities; and
3	(iv) innovative technology and equip-
4	ment to facilitate improved and near-real-
5	time information sharing between the Food
6	and Drug Administration, the Department
7	of Homeland Security, and the United
8	States Postal Service; and
9	(B) provide import facilities in which the
10	Food and Drug Administration operates or car-
11	ries out activities related to drug imports within
12	the international mail facilities with innovative
13	technology, including controlled substance de-
14	tection and testing equipment and other appli-
15	cable technology, and collaborate with United
16	States Customs and Border Protection to share
17	near-real-time information, including informa-
18	tion about test results, as appropriate, provided
19	that such technology is interoperable with tech-
20	nology used by other relevant Federal agencies,
21	including the United States Customs and Bor-
22	der Protection, as applicable, and is used in the
23	time and manner that the Secretary determines
24	appropriate.

1	(e) REPORT.—Not later than 6 months after the date
2	of enactment of this Act, the Secretary, in consultation
3	with the Secretary of Homeland Security and the Post-
4	master General of the United States Postal Service, shall
5	report to the relevant committees of Congress on the im-
6	plementation of this section, including a summary of
7	progress made towards near-real-time information sharing
8	and the interoperability of such technologies.
9	(d) Authorization of Appropriations.—Out of
10	amounts otherwise available to the Secretary, the Sec-
11	retary may allocate such sums as may be necessary for
12	purposes of earrying out this section.
13	SEC. 304. CLARIFYING FDA POST-MARKET AUTHORITIES.
14	Section 505–1(b)(1)(E) of the Federal Food, Drug,
15	and Cosmetic Act (21 U.S.C. 355–1(b)(1)(E)) is amended
16	by striking "of the drug" and inserting "of the drug,
17	which may include reduced effectiveness that is not in ac-
18	cordance with the labeling of such drug".
19	SEC. 305. FIRST RESPONDER TRAINING.
20	Section 546 of the Public Health Service Act (42
21	U.S.C. 290ce—1) is amended—
22	(1) in subsection (e)—
23	(A) in paragraph (2), by striking "and" at

the end;

1	(B) in paragraph (3), by striking the pe-
2	riod and inserting "; and"; and
3	(C) by adding at the end the following:
4	"(4) train and provide resources for first re-
5	sponders and members of other key community sec-
6	tors on safety around fentanyl and other dangerous
7	illicit drugs to protect themselves from exposure to
8	fentanyl and respond appropriately when exposure
9	occurs.";
10	(2) in subsection (d), by inserting ", and safety
11	around fentanyl and other dangerous illicit drugs"
12	before the period;
13	(3) in subsection (f)—
14	(A) in paragraph (3), by striking "and" at
15	the end;
16	(B) in paragraph (4), by striking the pe-
17	riod and inserting a semicolon; and
18	(C) by adding at the end the following:
19	"(5) the number of first responders and mem-
20	bers of other key community sectors trained on safe-
21	ty around fentanyl and other dangerous illicit
22	drugs."; and
23	(4) in subsection (g), by striking "\$12,000,000
24	for each of fiscal years 2017 through 2021" and in-

1	serting "\$36,000,000 for each of fiscal years 2019
2	through 2023".
3	SEC. 306. DISPOSAL OF CONTROLLED SUBSTANCES OF A
4	DECEASED HOSPICE PATIENT BY EMPLOY-
5	EES OF A HOSPICE PROGRAM.
6	(a) In General.—Section 302(g) of the Controlled
7	Substances Act (21 U.S.C. 822(g)) is amended by adding
8	at the end the following:
9	"(5)(A) An employee of a qualified hospice program
10	acting within the scope of employment may handle, in the
11	place of residence of a hospice patient, any controlled sub-
12	stance that was lawfully dispensed to the hospice patient,
13	for the purpose of assisting in the disposal of the con-
14	trolled substance after the hospice patient's death.
15	"(B) In this paragraph:
16	"(i) The term 'employee of a qualified hospice
17	program' means a physician, physician assistant, or
18	nurse who—
19	"(I) is employed by, or is acting pursuant
20	to arrangements made with, a qualified hospice
21	program; and
22	"(II) is licensed or certified to perform
23	such employment or acts in accordance with ap-
24	plicable State law.

1	"(ii) The terms 'hospice care' and 'hospice pro-
2	gram' have the meanings given those terms in sec-
3	tion 1861(dd) of the Social Security Act (42 U.S.C.
4	$\frac{1395x(dd))}{dd}$
5	"(iii) The term 'hospice patient' means an indi-
6	vidual receiving hospice care.
7	"(iv) The term 'qualified hospice program'
8	means a hospice program that—
9	"(I) has written policies and procedures for
10	employees of the hospice program to use assist-
11	ing in the disposal of the controlled substances
12	of a hospice patient after the hospice patient's
13	death;
14	"(II) at the time when the controlled sub-
15	stances are first ordered—
16	"(aa) provides a copy of the written
17	policies and procedures to the hospice pa-
18	tient or hospice patient representative and
19	the family of the hospice patient;
20	"(bb) discusses the policies and proce-
21	dures with the hospice patient or hospice
22	patient's representative and the hospice
23	patient's family in a language and manner
24	that such individuals understand to ensure
25	that such individuals are informed regard-

1	ing the safe disposal of controlled sub-
2	stances; and
3	"(ee) documents in the clinical record
4	of the hospice patient that the written poli-
5	eies and procedures were provided and dis-
6	cussed with the hospice patient or hospice
7	patient's representative; and
8	"(III) at the time when an employee of the
9	hospice program assists in the disposal of con-
10	trolled substances of a hospice patient, docu-
11	ments in the clinical record of the hospice pa-
12	tient a list of all controlled substances disposed
13	of.
14	"(C) The Attorney General may, by regulation,
15	include additional types of licensed medical profes-
16	sionals in the definition of the term 'employee of a
17	qualified hospice program' under subparagraph
18	(B).".
19	(b) No Registration Required.—Section 302(c)
20	of the Controlled Substances Act (21 U.S.C. 822(e)) is
21	amended by adding at the end the following:
22	"(4) An employee of a qualified hospice pro-
23	gram for the purpose of assisting in the disposal of
24	a controlled substance in accordance with subsection
25	(g)(5).".

1	(e) Guidance.—The Attorney General may issue
2	guidance to qualified hospice programs to assist the pro-
3	grams in satisfying the requirements under paragraph (5)
4	of section 302(g) of the Controlled Substances Act (21
5	U.S.C. 822(g)), as added by subsection (a).
6	(d) STATE AND LOCAL AUTHORITY.—Nothing in this
7	section or the amendments made by this section shall be
8	construed to prevent a State or local government from im-
9	posing additional controls or restrictions relating to the
10	regulation of the disposal of controlled substances in hos-
11	pice care or hospice programs.
12	SEC. 307. GAO STUDY AND REPORT ON HOSPICE SAFE
13	DRUG MANAGEMENT.
	DRUG MANAGEMENT. (a) STUDY.—
13	
13 14	(a) Study.—
13 14 15	(a) Study.— (1) In General.—The Comptroller General of
13 14 15 16	(a) STUDY.— (1) IN GENERAL.—The Comptroller General of the United States (in this section referred to as the
13 14 15 16 17	(a) STUDY.— (1) IN GENERAL.—The Comptroller General of the United States (in this section referred to as the "Comptroller General") shall conduct a study on the
13 14 15 16 17	(a) STUDY.— (1) IN GENERAL.—The Comptroller General of the United States (in this section referred to as the "Comptroller General") shall conduct a study on the requirements applicable to and challenges of hospice
13 14 15 16 17 18	(a) STUDY.— (1) IN GENERAL.—The Comptroller General of the United States (in this section referred to as the "Comptroller General") shall conduct a study on the requirements applicable to and challenges of hospice programs with regard to the management and dis-
13 14 15 16 17 18 19 20	(1) In General.—The Comptroller General of the United States (in this section referred to as the "Comptroller General") shall conduct a study on the requirements applicable to and challenges of hospice programs with regard to the management and disposal of controlled substances in the home of an in-
13 14 15 16 17 18 19 20 21	(a) STUDY. (1) IN GENERAL.—The Comptroller General of the United States (in this section referred to as the "Comptroller General") shall conduct a study on the requirements applicable to and challenges of hospice programs with regard to the management and disposal of controlled substances in the home of an individual.

(A) an overview of challenges encountered
by hospice programs regarding the disposal of
controlled substances, such as opioids, in a
home setting, including any key changes in poli-
cies, procedures, or best practices for the dis-
posal of controlled substances over time; and

(B) a description of Federal requirements, including requirements under the Medicare program, for hospice programs regarding the disposal of controlled substances in a home setting, and oversight of compliance with those requirements.

(b) REPORT.—Not later than 18 months after the
date of enactment of this Act, the Comptroller General
shall submit to Congress a report containing the results
of the study conducted under subsection (a), together with
recommendations, if any, for such legislation and administrative action as the Comptroller General determines appropriate.

1	SEC. 308. DELIVERY OF A CONTROLLED SUBSTANCE BY A
2	PHARMACY TO BE ADMINISTERED BY INJEC-
3	TION, IMPLANTATION, OR INTRATHECAL
4	PUMP.
5	(a) In General.—The Controlled Substances Act is
6	amended by inserting after section 309 (21 U.S.C. 829)
7	the following:
8	"DELIVERY OF A CONTROLLED SUBSTANCE BY A
9	PHARMACY TO AN ADMINISTERING PRACTITIONER
10	"Sec. 309A. (a) In General.—Notwithstanding
11	section 102(10), a pharmacy may deliver a controlled sub-
12	stance to a practitioner in accordance with a prescription
13	that meets the requirements of this title and the regula-
14	tions issued by the Attorney General under this title, for
15	the purpose of administering of the controlled substance
16	by the practitioner if—
17	"(1) the controlled substance is delivered by the
18	pharmacy to the prescribing practitioner or the prac-
19	titioner administering the controlled substance, as
20	applicable, at the location listed on the practitioner's
21	certificate of registration issued under this title;
22	"(2)(A) in the case of administering of the con-
23	trolled substance for the purpose of maintenance or
24	detoxification treatment under section 303(g)(2)—
25	"(i) the practitioner who issued the pre-
26	scription is a qualifying practitioner authorized

1	under, and acting within the scope of that sec-
2	tion; and
3	"(ii) the controlled substance is to be ad-
4	ministered by injection or implantation; or
5	"(B) in the case of administering of the con-
6	trolled substance for a purpose other than mainte-
7	nance or detoxification treatment, the controlled
8	substance is to be administered by a practitioner
9	through use of an intrathecal pump;
10	"(3) the pharmacy and the practitioner are au-
11	thorized to conduct the activities specified in this
12	section under the law of the State in which such ac-
13	tivities take place;
14	"(4) the prescription is not issued to supply any
15	practitioner with a stock of controlled substances for
16	the purpose of general dispensing to patients;
17	"(5) except as provided in subsection (b), the
18	controlled substance is to be administered only to
19	the patient named on the prescription not later than
20	14 days after the date of receipt of the controlled
21	substance by the practitioner; and
22	"(6) notwithstanding any exceptions under sec-
23	tion 307, the prescribing practitioner, and the prac-
24	titioner administering the controlled substance, as
25	applicable, maintain complete and accurate records

1	of all controlled substances delivered, received, ad-
2	ministered, or otherwise disposed of under this see-
3	tion, including the persons to whom controlled sub-
4	stances were delivered and such other information as
5	may be required by regulations of the Attorney Gen-
6	eral.
7	"(b) Modification of Number of Days Before
8	WHICH CONTROLLED SUBSTANCE SHALL BE ADMINIS
9	TERED.—
10	"(1) Initial 2-YEAR PERIOD.—During the 2-
11	year period beginning on the date of enactment of
12	this section, the Attorney General, in coordination
13	with the Secretary, may reduce the number of days
14	described in subsection (a)(5) if the Attorney Gen-
15	eral determines that such reduction will—
16	"(A) reduce the risk of diversion; or
17	"(B) protect the public health.
18	"(2) Modifications after submission of
19	REPORT.—After the date on which the report de-
20	scribed in subsection (e) is submitted, the Attorney
21	General, in coordination with the Secretary, may
22	modify the number of days described in subsection
23	(a)(5)

1	"(3) MINIMUM NUMBER OF DAYS.—Any modi-
2	fication under this subsection shall be for a period
3	of not less than 7 days.".
4	(b) STUDY AND REPORT.—Not later than 2 years
5	after the date of enactment of this section, the Comp-
6	troller General of the United States shall conduct a study
7	and submit to Congress a report on access to and potential
8	diversion of controlled substances administered by injec-
9	tion, implantation, or through the use of an intrathecal
10	pump.
11	(c) Technical and Conforming Amendment.
12	The table of contents for the Comprehensive Drug Abuse
13	Prevention and Control Act of 1970 is amended by insert-
14	ing after the item relating to section 309 the following
	"Sec. 309A. Delivery of a controlled substance by a pharmacy to an administering practitioner.".
15	TITLE IV—TREATMENT AND
16	RECOVERY
17	SEC. 401. COMPREHENSIVE OPIOID RECOVERY CENTERS.
18	(a) In General.—Part D of title V of the Public
19	Health Service Act is amended by adding at the end the
20	following new section:
21	"SEC. 550. COMPREHENSIVE OPIOID RECOVERY CENTERS.
22	"(a) In General.—The Secretary, acting through
23	the Assistant Secretary for Mental Health and Substance
24	Use, shall award grants on a competitive basis to eligible

- 1 entities to establish or operate a comprehensive opioid re-
- 2 covery center (referred to in this section as a 'Center').
- 3 A Center may be a single entity or an integrated delivery
- 4 network.
- 5 "(b) Grant Period.—
- 6 "(1) IN GENERAL.—A grant awarded under
- 7 subsection (a) shall be for a period not more than
- $8 \frac{5}{9} ext{ years.}$
- 9 "(2) RENEWAL.—A grant awarded under sub-
- 10 section (a) may be renewed, on a competitive basis,
- 11 for additional periods of time, as determined by the
- 12 Secretary. In determining whether to renew a grant
- 13 under this paragraph, the Secretary shall consider
- the data submitted under subsection (h).
- 15 "(e) Minimum Number of Grants.—The Secretary
- 16 shall allocate the amounts made available under sub-
- 17 section (j) such that not fewer than 10 grants may be
- 18 awarded. Not more than one grant shall be made to enti-
- 19 ties in a single State for any one period.
- 20 "(d) APPLICATION.—In order to be eligible for a
- 21 grant under subsection (a), an entity shall submit an ap-
- 22 plication to the Secretary at such time and in such manner
- 23 as the Secretary may require. Such application shall in-
- 24 clude—

- 1 "(1) evidence that such entity carries out, or is 2 capable of coordinating with other entities to carry
- 3 out, the activities described in subsection (g); and
- 4 "(2) such other information as the Secretary
- 5 may require.
- 6 "(e) Priority.—In awarding grants under sub-
- 7 section (a), the Secretary shall give priority to eligible enti-
- 8 ties located in a State with an overdose mortality rate that
- 9 is above the national overdose mortality rate, as deter-
- 10 mined by the Director of the Centers for Disease Control
- 11 and Prevention.
- 12 "(f) Preference.—In awarding grants under sub-
- 13 section (a), the Secretary may give preference to eligible
- 14 entities utilizing technology-enabled collaborative learning
- 15 and capacity building models, including such models as de-
- 16 fined in section 2 of the Expanding Capacity for Health
- 17 Outcomes Act (Public Law 114-270; 130 Stat. 1395), to
- 18 conduct the activities described in this section.
- 19 "(g) CENTER ACTIVITIES.—Each Center shall, at a
- 20 minimum, earry out the following activities directly,
- 21 through referral, or through contractual arrangements,
- 22 which may include earrying out such activities through
- 23 technology-enabled collaborative learning and capacity
- 24 building models described in subsection (f):

1	"(1) Treatment and recovery services.—
2	Each Center shall—
3	"(A) ensure that intake and evaluations
4	meet the individualized clinical needs of pa-
5	tients, including by offering assessments for
6	services and care recommendations through
7	independent, evidence-based verification proc-
8	esses for reviewing patient placement in treat-
9	ment settings;
10	"(B) provide the full continuum of treat-
11	ment services, including—
12	"(i) all drugs approved by the Food
13	and Drug Administration to treat sub-
14	stance use disorders;
15	"(ii) medically supervised withdrawal
16	management that includes patient evalua-
17	tion, stabilization, and readiness for and
18	entry into treatment;
19	"(iii) counseling provided by a pro-
20	gram counselor or other certified profes-
21	sional who is licensed and qualified by edu-
22	eation, training, or experience to assess the
23	psychological and sociological background
24	of patients, to contribute to the appro-

1	priate treatment plan for the patient, and
2	to monitor patient progress;
3	"(iv) treatment, as appropriate, for
4	patients with co-occurring substance use
5	and mental health disorders;
6	"(v) residential rehabilitation, and
7	outpatient and intensive outpatient pro-
8	grams;
9	"(vi) recovery housing;
10	"(vii) community-based and peer re-
11	covery support services;
12	"(viii) job training, job placement as-
13	sistance, and continuing education assist-
14	ance to support reintegration into the
15	workforce; and
16	"(ix) other best practices to provide
17	the full continuum of treatment and serv-
18	ices, as determined by the Secretary;
19	"(C) periodically conduct patient assess-
20	ments to support sustained and clinically sig-
21	nificant recovery, as defined by the Assistant
22	Secretary for Mental Health and Substance
23	Use;

1	"(D) administer an onsite pharmacy and
2	provide toxicology services, for purposes of ear-
3	rying out this section; and
4	"(E) operate a secure, confidential, and
5	interoperable electronic health information sys-
6	tem.
7	"(2) Outreach.—Each Center shall carry out
8	outreach activities to publicize the services offered
9	through the Centers, which may include—
10	"(A) training and supervising outreach
11	staff, as appropriate, to work with State and
12	local health departments, health care providers,
13	State and local education agencies, institutions
14	of higher education, State and local workforce
15	development boards, State and local community
16	action agencies, public safety officials, first re-
17	sponders, child welfare agencies, as appropriate,
18	and other community partners and the public,
19	including patients, to identify and respond to
20	community needs, and ensuring that such enti-
21	ties are aware of the services of the Center; and
22	"(B) disseminating and making publicly
23	available, including through the internet, evi-
24	dence-based resources that educate profes-
25	sionals and the public on opioid use disorder

1	and other substance use disorders, including co-
2	occurring substance use and mental health dis-
3	orders.
4	"(h) Data Reporting and Program Over-
5	SIGHT.—With respect to a grant awarded under sub-
6	section (a), not later than 90 days after the end of the
7	first year of the grant period, and annually thereafter for
8	the duration of the grant period (including the duration
9	of any renewal period for such grant), the entity shall sub-
10	mit data, as appropriate, to the Secretary regarding—
11	"(1) the programs and activities funded by the
12	grant;
13	"(2) health outcomes of the population of indi-
14	viduals with a substance use disorder who received
15	services from the Center, evaluated by an inde-
16	pendent program evaluator through the use of out-
17	comes measures, as determined by the Secretary;
18	"(3) the retention rate of program participants;
19	and
20	"(4) any other information that the Secretary
21	may require for the purpose of ensuring that the
22	Center is complying with all the requirements of the
23	grant, including providing the full continuum of
24	services described in subsection (g)(1)(B).

1	"(i) Privacy.—The provisions of this section, includ-
2	ing with respect to data reporting and program oversight,
3	shall be subject to all applicable Federal and State privacy
4	laws.
5	"(j) AUTHORIZATION OF APPROPRIATIONS.—There
6	is authorized to be appropriated \$10,000,000 for each of
7	fiscal years 2019 through 2023 for purposes of earrying
8	out this section.".
9	(b) Reports to Congress.—
10	(1) Preliminary report.—Not later than 3
11	years after the date of the enactment of this Act, the
12	Secretary of Health and Human Services shall sub-
13	mit to Congress a preliminary report that analyzes
14	data submitted under section 550(h) of the Public
15	Health Service Act, as added by subsection (a).
16	(2) Final Report.—Not later than 2 years
17	after submitting the preliminary report required
18	under paragraph (1), the Secretary of Health and
19	Human Services shall submit to Congress a final re-
20	port that includes—
21	(A) an evaluation of the effectiveness of
22	the comprehensive services provided by the Cen-
23	ters established or operated pursuant to section
24	550 of the Public Health Service Act, as added

by subsection (a), on health outcomes of the

1	population of individuals with substance use
2	disorder who receive services from the Center
3	which shall include an evaluation of the effec-
4	tiveness of services for treatment and recovery
5	support and to reduce relapse, recidivism, and
6	overdose; and
7	(B) recommendations, as appropriate, re-
8	garding ways to improve Federal programs re-
9	lated to substance use disorders, which may in-
10	clude dissemination of best practices for the
11	treatment of substance use disorders to health
12	care professionals.
10	CEC 400 DDCCDAW WO CUDDODW COODDINATION AND
13	SEC. 402. PROGRAM TO SUPPORT COORDINATION AND
	CONTINUATION OF CARE FOR DRUG OVER
131415	
14	CONTINUATION OF CARE FOR DRUG OVER
14 15 16	CONTINUATION OF CARE FOR DRUG OVER DOSE PATIENTS.
14 15 16 17	CONTINUATION OF CARE FOR DRUG OVER DOSE PATIENTS. (a) IN General.—The Secretary of Health and
14 15 16 17	CONTINUATION OF CARE FOR DRUG OVER DOSE PATIENTS. (a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the "Sec-
14 15 16 17	CONTINUATION OF CARE FOR DRUG OVER DOSE PATIENTS. (a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the "Secretary") shall identify or facilitate the development of best
114 115 116 117 118	CONTINUATION OF CARE FOR DRUG OVER DOSE PATIENTS. (a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the "Secretary") shall identify or facilitate the development of best practices for—
14 15 16 17 18 19 20	CONTINUATION OF CARE FOR DRUG OVER DOSE PATIENTS. (a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the "Secretary") shall identify or facilitate the development of best practices for— (1) emergency treatment of known or suspected
114 115 116 117 118 119 220 221	CONTINUATION OF CARE FOR DRUG OVER DOSE PATIENTS. (a) IN GENERAL.—The Secretary of Health and Human Services (referred to in this section as the "Secretary") shall identify or facilitate the development of best practices for— (1) emergency treatment of known or suspected drug overdose;

1 (3) the provision of overdose reversal medica-2 tion, as appropriate.

(b) Grant Establishment and Participation.—

- (1) IN GENERAL.—The Secretary shall award grants on a competitive basis to eligible entities to support implementation of voluntary programs for care and treatment of individuals after an opioid overdose, as appropriate, which may include implementation of the best practices described in subsection (a).
- (2) ELIGIBLE ENTITY.—In this section, the term "eligible entity" means an entity that offers treatment or other services for individuals in response to, or following, drug overdoses or a drug overdose.
- (3) APPLICATION.—An eligible entity desiring a grant under this section, in consultation with the principal agency of a State in which such entity offers treatment or other services that is responsible for carrying out the block grant for prevention and treatment of substance abuse under subpart H of part B of title XIX of the Public Health Service Act (42 U.S.C. 300x-21 et seq.), shall submit an application to the Secretary, at such time and in such

1	manner as the Secretary may require, that in-
2	cludes —
3	(A) evidence that such eligible entity car-
4	ries out, or is capable of coordinating with
5	other entities to earry out, the activities de-
6	scribed in paragraph (4); and
7	(B) such additional information as the Sec-
8	retary may require.
9	(4) Use of grant funds.—An eligible entity
10	awarded a grant under this section shall use such
11	grant funds to—
12	(A) hire or utilize recovery coaches to help
13	support recovery, including by—
14	(i) connecting patients to a continuum
15	of eare services, such as—
16	(I) treatment and recovery sup-
17	port programs;
18	(II) programs that provide non-
19	clinical recovery support services;
20	(III) peer support networks;
21	(IV) recovery community organi-
22	zations;
23	(V) health care providers, includ-
24	ing physicians and other providers of
25	behavioral health and primary care;

1	(VI) educational and vocational
2	schools;
3	(VII) employers;
4	(VIII) housing services; and
5	(IX) child welfare agencies;
6	(ii) providing education on overdose
7	prevention to patients; and
8	(iii) providing other services the Sec-
9	retary determines necessary to help ensure
10	continued connection with recovery support
11	services;
12	(B) establish policies and procedures that
13	address the provision of overdose reversal medi-
14	cation, the administration of all drugs approved
15	by the Food and Drug Administration to treat
16	substance use disorder, and subsequent continu-
17	ation of, or referral to, evidence-based treat-
18	ment for patients with a substance use disorder
19	who have experienced a non-fatal drug over-
20	dose, in order to prevent relapse, and reduce re-
21	cidivism and future overdose;
22	(C) develop or implement best practices for
23	treating non-fatal drug overdoses, including,
24	with respect to care coordination and integrated
25	care models, for long term treatment and recov-

1	ery options for individuals with a substance use
2	disorder who have experienced a non-fatal drug
3	overdose; and
4	(D) establish integrated models of care for
5	individuals who have experienced a non-fatal
6	drug overdose which may include patient as-
7	sessment, follow up, and transportation to and
8	from treatment facilities.
9	(5) Additional Permissible Uses.—In addi-
10	tion to the uses described in paragraph (4), a grant
11	awarded under this section may be used, directly or
12	through contractual arrangements, to provide—
13	(A) all drugs approved by the Food and
14	Drug Administration to treat substance use dis-
15	orders, pursuant to Federal and State law;
16	(B) withdrawal and detoxification services
17	that include patient evaluation, stabilization,
18	and preparation for treatment of substance use
19	disorder, including treatment described in sub-
20	paragraph (A), as appropriate; or
21	(C) mental health services provided by a
22	program counselor, social worker, therapist, or
23	other certified professional who is licensed and
24	qualified by education, training, or experience
25	to assess the psychosocial background of pa-

1	tients, to contribute to the appropriate treat
2	ment plan for patients with substance use dis-
3	order, and to monitor patient progress.
4	(6) Preference.—In awarding grants under
5	this section, the Secretary shall give preference to el-
6	igible entities that meet any or all of the following
7	criteria:
8	(A) The eligible entity is a critical access
9	hospital (as defined in section 1861(mm)(1) of
10	the Social Security Act (42 U.S.C
11	1395x(mm)(1))), a low volume hospital (as de-
12	fined in section 1886(d)(12)(C)(i) of such Act
13	(42 U.S.C. 1395ww(d)(12)(C)(i))), or a sole
14	community hospital (as defined in section
15	1886(d)(5)(D)(iii) of such Act (42 U.S.C
16	1395ww(d)(5)(D)(iii))).
17	(B) The eligible entity is located in a State
18	with an overdose mortality rate that is above
19	the national overdose mortality rate, as deter-
20	mined by the Director of the Centers for Dis-
21	ease Control and Prevention.
22	(C) The eligible entity demonstrates that
23	recovery coaches will be placed in both health

care settings and community settings.

1	(7) PERIOD OF GRANT.—A grant awarded to an
2	eligible entity under this section shall be for a period
3	of not more than 5 years.
4	(e) Definition.—In this section, the term "recovery
5	eoach'' means an individual—
6	(1) with knowledge of, or experience with, re-
7	covery from a substance use disorder; and
8	(2) who has completed training from, and is de-
9	termined to be in good standing by, a recovery serv-
10	ices organization capable of conducting such training
11	and making such determination.
12	(d) REPORTING REQUIREMENTS.—
13	(1) Reports by Grantees.—Each eligible en-
14	tity awarded a grant under this section shall submit
15	to the Secretary an annual report for each year for
16	which the entity has received such grant that in-
17	eludes information on—
18	(A) the number of individuals treated by
19	the entity for non-fatal overdoses, including the
20	number of non-fatal overdoses where overdose
21	reversal medication was administered;
22	(B) the number of individuals administered
23	medication-assisted treatment by the entity;
24	(C) the number of individuals referred by
25	the entity to other treatment facilities after a

non-fatal overdose, the types of such other facilities, and the number of such individuals admitted to such other facilities pursuant to such referrals; and

- (D) the frequency and number of patients with reoccurrences, including readmissions for non-fatal overdoses and evidence of relapse related to substance abuse disorder.
- (2) REPORT BY SECRETARY. Not later than 5 years after the date of enactment of this Act, the Secretary shall submit to Congress a report that includes an evaluation of the effectiveness of the grant program carried out under this section with respect to long term health outcomes of the population of individuals who have experienced a drug overdose, the percentage of patients treated or referred to treatment by grantees, and the frequency and number of patients who experienced relapse, were readmitted for treatment, or experienced another overdose.
- 20 (e) Privacy.—The requirements of this section, in-21 eluding with respect to data reporting and program over-22 sight, shall be subject to all applicable Federal and State 23 privacy laws.
- 24 (f) AUTHORIZATION OF APPROPRIATIONS.—There is 25 authorized to be appropriated to earry out this section

- 1 such sums as may be necessary for each of fiscal years
- 2 2019 through 2023.
- 3 SEC. 403. ALTERNATIVES TO OPIOIDS.

iting the use of opioids;

- 4 (a) In General.—The Secretary of Health and
- 5 Human Services shall, directly or through grants to, or
- 6 contracts with, public and private entities, provide tech-
- 7 nical assistance to hospitals and other acute care settings
- 8 on alternatives to opioids for pain management. The tech-
- 9 nical assistance provided shall be for the purpose of—
- 10 (1) utilizing information from acute care pro11 viders including emergency departments and other
 12 providers that have successfully implemented alter13 natives to opioids programs, promoting non-opioid
 14 protocols and medications while appropriately lim-
 - (2) identifying or facilitating the development of best practices on the use of alternatives to opioids, which may include pain-management strategies that involve non-addictive medical products, non-pharmacologie treatments, and technologies or techniques to identify patients at-risk for opioid use disorder;
 - (3) identifying or facilitating the development of best practices on the use of alternatives to opioids that target common painful conditions and include

15

16

17

18

19

20

21

22

23

1	certain patient populations, such as geriatric pa-
2	tients, pregnant women, and children;
3	(4) disseminating information on the use of al-
4	ternatives to opioids to providers in acute care set-
5	tings, which may include emergency departments,
6	outpatient clinics, critical access hospitals, and Fed-
7	erally qualified health centers; and
8	(5) collecting data and reporting on health out-
9	comes associated with the use of alternatives to
10	opioids.
11	(b) AUTHORIZATION OF APPROPRIATIONS.—There is
12	authorized to be appropriated to earry out this section
13	such sums as may be necessary for each of fiscal years
14	2019 through 2023.
15	SEC. 404. PEER SUPPORT TECHNICAL ASSISTANCE.
16	(a) Technical Assistance for Peer Support
17	SERVICES.—The Secretary of Health and Human Services
18	(referred to in this section as the "Secretary"), acting
19	through the Assistant Secretary for Mental Health and
20	Substance Abuse, shall provide technical assistance and
21	support to organizations providing peer support services
22	related to substance use disorder, including technical as-
23	sistance and support related to—
24	(1) training on identifying—
25	(A) signs of substance use disorder;

1	(B) resources to assist individuals with a
2	substance use disorder, or resources for families
3	of an individual with a substance use disorder;
4	and
5	(C) best practices for the delivery of recov-
6	ery support services;
7	(2) the provision of translation services, inter-
8	pretation, or other such services for clients with lim-
9	ited English speaking proficiency;
10	(3) capacity building; and
11	(4) evaluation and improvement, as necessary,
12	of the effectiveness of such peer support services.
13	(b) Best Practices.—The Secretary shall periodi-
14	eally issue best practices related to peer support services
15	for use by organizations that provide peer support serv-
16	i ces.
17	(e) Authorization of Appropriations.—There is
18	authorized to be appropriated to earry out this section
19	such sums as may be necessary for each of fiscal years
20	2019 through 2023.
21	SEC. 405. MEDICATION-ASSISTED TREATMENT FOR RECOV-
22	ERY FROM ADDICTION.
23	(a) Repeal of Requirement To Update Regula-
24	TIONS.—Section 303 of the Comprehensive Addiction and

- 1 Recovery Act of 2016 (Public Law 114-198; 130 Stat.
- 2 720) is amended by striking subsection (e).
- 3 (b) Codification of Expansion of Maximum
- 4 Number of Patients for Medication-Assisted
- 5 Treatment.—Section 303(g)(2)(B)(iii)(H) of the Con-
- 6 trolled Substances Act (21 U.S.C. (g)(2)(B)(iii)(II)) is
- 7 amended by striking "100" each place it appears and in-
- 8 serting "275".
- 9 SEC. 406. NATIONAL RECOVERY HOUSING BEST PRAC-
- 10 TICES.
- 11 (a) BEST PRACTICES.—The Secretary of Health and
- 12 Human Services (referred to in this section as the "Sec-
- 13 retary"), in consultation with the Secretary for Housing
- 14 and Urban Development, patients with a history of opioid
- 15 use disorder, and other stakeholders, which may include
- 16 State accrediting entities and reputable providers of, and
- 17 analysts of, recovery housing services, shall identify or fa-
- 18 cilitate the development of best practices, which may in-
- 19 clude model laws for implementing suggested minimum
- 20 standards, for operating recovery housing.
- 21 (b) DISSEMINATION.—The Secretary shall dissemi-
- 22 nate the best practices identified or developed under sub-
- 23 section (a) to—

1	(1) State agencies, which may include the provi-
2	sion of technical assistance to State agencies seeking
3	to adopt or implement such best practices;
4	(2) recovery housing entities; and
5	(3) the public, as appropriate.
6	(e) REQUIREMENTS.—In identifying or facilitating
7	the development of best practices under subsection (a), the
8	Secretary, in consultation with appropriate stakeholders,
9	shall consider how recovery housing is able to (including
10	by improving access and adherence to treatment) support
11	recovery and prevent relapse, recidivism, or overdose, in-
12	eluding overdose death.
13	(d) Rule of Construction.—Nothing in this sec-
14	tion shall be construed to provide the Secretary with the
15	ability to require States to adhere to minimum standards
16	in the State oversight of recovery housing.
17	(e) Definition.—In this section, the term "recovery
18	housing" means a shared living environment free from al-
19	cohol and illicit drug use and centered on peer support
20	and connection to services that promote sustained recovery
21	from substance use disorders.
22	SEC. 407. ADDRESSING ECONOMIC AND WORKFORCE IM-
23	PACTS OF THE OPIOID CRISIS.
24	(a) Definitions.—Except as otherwise expressly
25	provided in this section:

1	(1) Education Provider.—The term "edu-
2	eation provider" means—
3	(A) an institution of higher education, as
4	defined in section 101 of the Higher Education
5	Act of 1965 (20 U.S.C. 1001); or
6	(B) a postsecondary vocational institution,
7	as defined in section 102(e) of such Act (20
8	U.S.C. 1002(e)).
9	(2) ELIGIBLE ENTITY.—The term "eligible enti-
10	ty" means—
11	(A) a State workforce agency;
12	(B) a State board;
13	(C) an outlying area, as defined in section
14	3 of the Workforce Innovation and Opportunity
15	Act (29 U.S.C. 3102); or
16	(D) a Tribal entity.
17	(3) Local area; local board; one-stop op-
18	ERATOR.—The terms "local area", "local board",
19	and "one-stop operator" have the meanings given
20	such terms in section 3 of the Workforce Innovation
21	and Opportunity Act (29 U.S.C. 3102).
22	(4) Local entity.—The term "local entity"
23	means a local board or one-stop operator.
24	(5) Participating partnership.—The term
25	"participating partnership" means a partnership es-

1	tablished under subsection (e)(1) by a local entity
2	receiving a subgrant under subsection (d).
3	(6) Program Participant.—The term "pro-
4	gram participant' means an individual who—
5	(A) is a member of a population of workers
6	described in subsection (e)(2) that is served by
7	a participating partnership through the pilot
8	program under this section; and
9	(B) enrolls with the applicable partici-
10	pating partnership to receive any of the services
11	described in subsection $(e)(3)$.
12	(7) Secretary.—The term "Secretary" means
13	the Secretary of Labor.
14	(8) STATE BOARD.—The term "State board"
15	has the meaning given the term in section 3 of the
16	Workforce Innovation and Opportunity Act (29)
17	U.S.C. 3102).
18	(9) STATE WORKFORCE AGENCY.—The term
19	"State workforce agency" means the lead State
20	agency with responsibility for the administration of
21	a program under chapter 2 or 3 of subtitle B of title
22	I of the Workforce Innovation and Opportunity Act
23	(29 U.S.C. 3161 et seq., 3171 et seq.).
24	(10) Substance use disorder.—The term
25	"substance use disorder" means such a disorder

1	within the meaning of title V of the Public Health
2	Service Act (42 U.S.C. 290aa et seq.).
3	(11) Supportive services.—The term "sup-
4	portive services" has the meaning given such term in
5	section 3 of the Workforce Innovation and Oppor-
6	tunity Act (29 U.S.C. 3102).
7	(12) Treatment provider.—The term "treat-
8	ment provider''—
9	(A) means a health eare provider that of-
10	fers services for treating substance use dis-
11	orders and is licensed in accordance with appli-
12	eable State law to provide such services;
13	(B) accepts health insurance for such serv-
14	ices, including coverage under title XIX of the
15	Social Security Act (42 U.S.C. 1396 et seq.);
16	and
17	(C) may include—
18	(i) a nonprofit provider of peer recov-
19	ery support services, as defined by the
20	State involved in regulation or guidance;
21	(ii) a community health care provider;
22	01'
23	(iii) a Federally qualified health cen-
24	ter (as defined in section 1861(aa) of the
25	Social Security Act (42 U.S.C. 1395x)).

1 (13) Tribal enti2 ty" includes any Indian tribe, tribal organization,
3 Indian-controlled organization serving Indians, Na4 tive Hawaiian organization, or Alaska Native entity,
5 as such terms are defined or used in section 166 of
6 the Workforce Innovation and Opportunity Act (29)
7 U.S.C. 3221).

(b) PILOT PROGRAM AND GRANTS AUTHORIZED.—

(1) IN GENERAL.—The Secretary, in consultation with the Secretary of Health and Human Services, shall carry out a pilot program to address economic and workforce impacts associated with a high rate of a substance use disorder. In carrying out the pilot program, the Secretary shall make grants, on a competitive basis, to eligible entities to enable such entities to make subgrants to local boards and one-stop operators to address the economic and workforce impacts associated with a high rate of a substance use disorder.

(2) Grant amounts.—The Secretary shall make each such grant in an amount that is not less than \$500,000, and not more than \$5,000,000, for a fiscal year.

24 (c) Grant Applications.—

1	(1) In General.—An eligible entity applying
2	for a grant under this section shall submit an appli-
3	eation to the Secretary at such time and in such
4	form and manner as the Secretary may reasonably
5	require, including the information described in this
6	subsection.
7	(2) Significant impact on community by
8	OPIOID ABUSE AND SUBSTANCE USE DISORDER-RE-
9	LATED PROBLEMS.—
10	(A) DEMONSTRATION.—An eligible entity
11	shall include in the application information that
12	demonstrates significant impact on the commu-
13	nity by problems related to opioid abuse or an-
14	other substance use disorder, by—
15	(i) identifying the communities, re-
16	gions, or local areas that will be served
17	through the grant (each referred to in this
18	section as a "service area"); and
19	(ii) showing, for each such service
20	area, an increase equal to or greater than
21	the national increase in such problems, be-
22	tween
23	(I) 1999; and
24	(H) 2016 or the latest year for
25	which data are available

1	(B) INFORMATION.—In making the show-
2	ing described in subparagraph (A)(ii), the eligi-
3	ble entity may use information including data
4	on
5	(i) the incidence or prevalence of
6	opioid abuse and other substance use dis-
7	orders;
8	(ii) the per capita drug overdose mor-
9	tality rate, as determined by the Director
10	of the Centers for Disease Control and
11	Prevention;
12	(iii) the rate of non-fatal hospitaliza-
13	tions related to opioid abuse or another
14	substance use disorder; or
15	(iv) the number of arrests or convic-
16	tions, or a relevant law enforcement sta-
17	tistic, that reasonably shows an increase in
18	opioid abuse or another substance use dis-
19	order.
20	(C) Support for state strategy.—The
21	eligible entity shall also include in the applica-
22	tion information describing how the proposed
23	services and activities support the State's strat-
24	egy for addressing problems described in sub-

1	paragraph (A) in specific regions or across the
2	State, outlaying area, or Tribal entity.
3	(3) Economic and employment conditions
4	DEMONSTRATE ADDITIONAL FEDERAL SUPPORT
5	NEEDED.—
6	(A) DEMONSTRATION.—An eligible entity
7	shall include in the application information that
8	demonstrates that a high rate of a substance
9	use disorder has eaused, or is coincident to, an
10	economic or employment downturn in the serv-
11	ice area.
12	(B) Information.—In making the dem-
13	onstration described in subparagraph (A), the
14	eligible entity may use information including—
15	(i) documentation of any layoff, an-
16	nounced future layoff, legacy industry de-
17	cline, decrease in an employment or labor
18	market participation rate, or economic im-
19	pact, whether or not the result described in
20	this clause is overtly related to a high rate
21	of a substance use disorder;
22	(ii) documentation showing decreased
23	economic activity related to, caused by, or
24	contributing to a high rate of a substance
25	use disorder, including a description of

1	how the service area has been impacted, or
2	will be impacted, by such a decrease;
3	(iii) in particular, information on eco-
4	nomie indicators, labor market analyses
5	information from public announcements
6	and demographic and industry data;
7	(iv) information on rapid response ac-
8	tivities (as defined in section 3 of the
9	Workforce Innovation and Opportunity Act
10	(29 U.S.C. 3102)) that have been or wil
11	be conducted, including demographic data
12	gathered by employer or worker surveys or
13	through other methods;
14	(v) data or documentation, beyond an
15	eedotal evidence, showing that employers
16	face challenges filling job vacancies due to
17	a lack of skilled workers able to pass a
18	drug test; or
19	(vi) any additional relevant data or in-
20	formation on the economy, workforce, or
21	another aspect of the service area to sup-
22	port the application.
23	(4) Workforce shortage related to
24	TREATMENT WORKFORCE —

1	(A) In General.—An eligible entity may
2	include in the application a demonstration of
3	the workforce shortage in a professional area to
4	be addressed under the grant. Such professional
5	areas may include—
6	(i) substance use disorder treatment
7	and related services;
8	(ii) non-opioid pain therapy and pain
9	management services; or
10	(iii) mental health care treatment
11	services.
12	(B) Information to be included.—An
13	eligible entity demonstrating a workforce short-
14	age under subparagraph (A) shall demonstrate
15	the workforce shortage through information
16	that may include—
17	(i) the distance between—
18	(I) communities affected by
19	opioid abuse or another substance use
20	disorder; and
21	(II) facilities or professionals of-
22	fering services in the professional
23	area;
24	(ii) the maximum capacity of facilities
25	or professionals to serve individuals in an

1	affected community, or increases in arrests
2	related to opioid abuse or another sub-
3	stance use disorder, overdose deaths, or
4	nonfatal overdose emergencies in the com-
5	munity; or
6	(iii) other information that can dem-
7	onstrate such a shortage.
8	(d) Subgrant Authorization and Application
9	Process.—
10	(1) Subgrants authorized.—
11	(A) In General.—An eligible entity re-
12	eciving a grant under subsection (b)—
13	(i) may use not more than 5 percent
14	of the grant funds for the administrative
15	costs of carrying out the grant; and
16	(ii) shall use the remaining grant
17	funds to make subgrants to local entities
18	in the area served by the eligible entity to
19	earry out the services and activities de-
20	scribed in subsection (e).
21	(B) Geographic distribution.—In mak-
22	ing subgrants under this subsection, an eligible
23	entity shall ensure, to the extent practicable,
24	the equitable geographic distribution (such as

1 urban and rural distribution) of areas receiving 2 subgrant funds. 3 (2) Subgrant application.— 4 (A) IN GENERAL.—A local entity desiring to receive a subgrant under this subsection shall 6 submit an application at such time and in such 7 and manner as the eligible entity may reason-8 ably require, including the information de-9 scribed in this paragraph. (B) CONTENTS.—Each application 10 11 scribed in subparagraph (A) shall include an 12 analysis of the estimated performance of the 13 local entity in carrying out the proposed serv-14 ices and activities under the subgrant that— 15 (i) uses primary indicators of per-16 **formance** described section in 116(e)(1)(A)(i) of the Workforce Innova-17 tion and Opportunity Act (29 U.S.C. 18 19 3141(e)(1)(A)(i), to assess estimated ef-20 feetiveness of the proposed services and ac-21 tivities, including the estimated number of 22 individuals with a substance use disorder 23 who may be served by the proposed serv-

ices and activities;

1	(ii) analyzes the record of the local
2	entity in serving individuals with a barrier
3	to employment; and
4	(iii) analyzes the ability of the local
5	entity to establish the partnership de-
6	seribed in subsection $(e)(1)$.
7	(C) Analysis.—The analysis described in
8	subparagraph (B) may include or utilize—
9	(i) data from the National Center for
10	Health Statistics of the Centers for Dis-
11	ease Control and Prevention;
12	(ii) data from the Center for Behav-
13	ioral Health Statistics and Quality of the
14	Substance Abuse and Mental Health Serv-
15	ices Administration;
16	(iii) State vital statistics;
17	(iv) municipal police department
18	records;
19	(v) reports from local coroners; or
20	(vi) other relevant data.
21	(e) Subgrant Services and Activities.—
22	(1) Formation of Partnership.—
23	(A) In General.—Each local entity that
24	receives a subgrant under subsection (d) shall
25	form a partnership, established through a writ-

1	ten contract or other agreement, with members
2	described in subparagraph (B), and shall earry
3	out the services and activities described in this
4	subsection through the partnership.
5	(B) Members of the partnership.—A
6	partnership described in subparagraph (A) shall
7	include 1 or more of the following:
8	(i) The eligible entity.
9	(ii) A treatment provider.
10	(iii) An employer or industry organi-
11	zation.
12	(iv) An education provider.
13	(v) A justice or law enforcement orga-
14	nization.
15	(vi) A faith-based or community-based
16	organization.
17	(vii) Other State or local agencies.
18	(viii) Other organizations, as deter-
19	mined to be necessary by the local entity.
20	(2) SELECTION OF POPULATION TO BE
21	SERVED.—A participating partnership shall elect to
22	provide services and activities under the subgrant to
23	one or both of the following populations of workers:
24	(A) Workers, including dislocated workers,
25	new entrants in the workforce, or incumbent

1	workers (employed or underemployed), who are
2	directly or indirectly affected by a high rate of
3	a substance use disorder and each of whom is—
4	(i) an individual who voluntarily con-
5	firms that the individual, or a friend or
6	family member of the individual, has a his
7	tory of opioid abuse or another substance
8	use disorder; or
9	(ii) an individual who works or resides
10	in a community substantially impacted by
11	a high rate of a substance use disorder or
12	ean otherwise demonstrate job loss as a re-
13	sult of a high rate of a substance use dis-
14	order.
15	(B) Workers, including dislocated workers
16	new entrants in the workforce, or incumbent
17	workers (employed or underemployed), who—
18	(i) seek to transition to professions
19	that support individuals struggling with a
20	substance use disorder or at risk for devel-
21	oping such disorder, such as professions
22	that provide—
23	(I) substance use disorder treat
24	ment and related services;

1	(H) peer recovery support serv-
2	ices described in subsection
3	$\frac{(a)(12)(C)(i)}{(a)}$;
4	(III) non-opioid pain therapy and
5	pain management services; or
6	(IV) mental health care; and
7	(ii) need new or upgraded skills to
8	better serve such a population of strug-
9	gling or at-risk individuals.
10	(3) Services and activities.—Each partici-
11	pating partnership shall use funds available through
12	a subgrant under this subsection to carry out 1 or
13	more of the following:
14	(A) Engaging employers. Engaging
15	with employers to—
16	(i) learn about the skill and hiring re-
17	quirements of employers;
18	(ii) learn about the support needed by
19	employers to hire and retain program par-
20	ticipants, and other individuals with a sub-
21	stance use disorder, and the support need-
22	ed by such employers to obtain their com-
23	mitment to testing creative solutions to
24	employing program participants and such
25	individuals;

1	(iii) connect employers and workers to
2	on-the-job or customized training programs
3	before or after layoff to help facilitate re-
4	employment;
5	(iv) connect employers with an edu-
6	eation provider to develop elassroom in-
7	struction to complement on-the-job learn-
8	ing for program participants and such in-
9	dividuals;
10	(v) help employers develop the cur-
11	riculum design of a work-based learning
12	program for program participants and
13	such individuals; or
14	(vi) help employers employ program
15	participants or such individuals engaging
16	in a work-based learning program for a
17	transitional period before hiring such a
18	program participant or individual for full-
19	time employment of not less than 30 hours
20	a week.
21	(B) Screening services. Providing
22	screening services, which may include—
23	(i) using an evidence-based screening
24	method to screen each individual seeking
25	participation in the pilot program to deter-

1	mine whether the individual has a sub-
2	stance use disorder;
3	(ii) conducting an assessment of each
4	such individual to determine the services
5	needed for such individual to obtain or re-
6	tain employment, including an assessment
7	of strengths and general work readiness;
8	and
9	(iii) accepting walk-ins or referrals
10	from employers, labor organizations, or
11	other entities recommending individuals to
12	participate in such program.
13	(C) Individual treatment and em-
14	PLOYMENT PLAN.—Developing an individual
15	treatment and employment plan for each pro-
16	gram participant, which shall include providing
17	a case manager to work with each participant
18	to develop the plan, which may include—
19	(i) identifying employment and career
20	goals;
21	(ii) exploring career pathways that
22	lead to in-demand industries and sectors as
23	determined by the State board and the
24	head of the State workforce agency;

1	(iii) setting appropriate achievement
2	objectives to attain the employment and
3	career goals identified under clause (i); or
4	(iv) developing the appropriate com-
5	bination of services to enable the partici-
6	pant to achieve the employment and career
7	goals.
8	(D) OUTPATIENT TREATMENT AND RECOV-
9	ERY CARE. In the case of a participating part-
10	nership serving program participants described
11	in paragraph (2)(A)(i) with a substance use dis-
12	order, providing individualized and group out-
13	patient treatment and recovery services for such
14	program participants that are offered during
15	the day and evening, and on weekends. Such
16	treatment and recovery services—
17	(i) shall be based on a model that uti-
18	lizes combined behavioral interventions and
19	other evidence-based or evidence-informed
20	interventions; and
21	(ii) may include additional services
22	such as—
23	(I) health, mental health, addie-
24	tion, or other forms of outpatient
25	treatment that may impact a sub-

1	stance use disorder and co-occurring
2	conditions;
3	(II) drug testing for a current
4	substance use disorder prior to enroll-
5	ment in career or training services or
6	prior to employment;
7	(III) linkages to community serv-
8	ices, including services offered by
9	partner organizations designed to sup-
10	port program participants; and
11	(IV) referrals to health eare, in-
12	eluding referrals to substance use dis-
13	order treatment and mental health
14	services.
15	(E) Supportive services.—Providing
16	supportive services, which shall include services
17	such as—
18	(i) coordinated wraparound services to
19	provide maximum support for program
20	participants to ensure that the program
21	participants maintain employment and re-
22	covery for not less than 12 months, as ap-
23	propriate;
24	(ii) assistance in establishing eligi-
25	bility for assistance under Federal, State,

1	and local programs providing health serv-
2	ices, mental health services, housing serv-
3	ices, transportation services, or social serv-
4	ices;
5	(iii) peer recovery support services de-
6	scribed in subsection (a)(12)(C)(i);
7	(iv) networking and mentorship op-
8	portunities; or
9	(v) any supportive services determined
10	necessary by the local entity.
11	(F) CAREER AND JOB TRAINING SERV-
12	ICES. Offering career services and training
13	services, and related services, concurrently or
14	sequentially with the services provided under
15	subparagraphs (B) through (E). Such services
16	shall include the following:
17	(i) Services provided to program par-
18	ticipants who are in a pre-employment
19	stage of the program. Such services may
20	include
21	(I) initial education and skills as-
22	sessments;
23	(H) traditional classroom train-
24	ing funded through individual training
25	accounts under chapter 3 of subtitle B

1	of title I of the Workforce Innovation
2	and Opportunity Act (29 U.S.C. 3171
3	et seq.);
4	(III) services to promote employ-
5	ability skills such as punctuality, per-
6	sonal maintenance skills, and profes-
7	sional conduct;
8	(IV) in-depth interviewing and
9	evaluation to identify employment bar-
10	riers and to develop individual em-
11	ployment plans;
12	(V) career planning that in-
13	cludes—
14	(aa) career pathways leading
15	to in-demand, high-wage jobs;
16	and
17	(bb) job coaching, job
18	matching, and job placement
19	services;
20	(VI) provision of payments and
21	fees for employment and training-re-
22	lated applications, tests, and certifi-
23	eations; or
24	(VII) any other appropriate ca-
25	reer service or training service de-

1	scribed in section 134(e) of the Work-
2	force Innovation and Opportunity Act
3	(29 U.S.C. 3174(e)).
4	(ii) Services provided to program par-
5	ticipants during their first 6 months of
6	employment to ensure job retention, which
7	may include—
8	(I) case management and support
9	services, including a continuation of
10	the services described in clause (i);
11	(II) a continuation of skills train-
12	ing, and career and technical edu-
13	eation, described in clause (i) that is
14	conducted in collaboration with the
15	employers of such participants;
16	(III) mentorship services and job
17	retention support for such partici-
18	pants; or
19	(IV) targeted training for man-
20	agers and workers working with such
21	participants (such as mentors), and
22	human resource representatives in the
23	business in which such participants
24	are employed.

1	(iii) Services to assist program partici-
2	pants in maintaining employment for not
3	less than 12 months, as appropriate.
4	(G) PROVEN AND PROMISING PRAC-
5	TICES.—Leading efforts in the service area to
6	identify and promote proven and promising
7	strategies and initiatives for meeting the needs
8	of employers and program participants.
9	(4) Limitations.—A participating partnership
10	may not use—
11	(A) more than 5 percent of the funds re-
12	ceived under a subgrant under subsection (d)
13	for the administrative costs of the partnership;
14	(B) more than 10 percent of the funds re-
15	ceived under such subgrant for the provision of
16	treatment and recovery services, as described in
17	paragraph (3)(D); or
18	(C) more than 10 percent of the funds re-
19	ceived under such subgrant for the provision of
20	supportive services described in paragraph
21	(3)(E) to program participants.
22	(f) Performance Accountability.—
23	(1) REPORTS.—The Secretary shall establish
24	quarterly reporting requirements for recipients of
25	grants and subgrants under this section that, to the

extent practicable, are based on the performance accountability system under section 116 of the Workforce Innovation and Opportunity Act (29 U.S.C. 3141), including the indicators described in subsection (e)(1)(A)(i) of such section and the requirements for local area performance reports under subsection (d) of such section.

(2) EVALUATIONS.—

(A) AUTHORITY TO ENTER INTO AGREE-MENTS.—The Secretary shall ensure that an independent evaluation is conducted on the pilot program carried out under this section to determine the impact of the program on employment of individuals with substance use disorders. The Secretary shall enter into an agreement with eligible entities receiving grants under this section to pay for all or part of such evaluation.

(B) METHODOLOGIES TO BE USED.—The independent evaluation required under this paragraph shall use experimental designs using random assignment or, when random assignment is not feasible, other reliable, evidence-based research methodologies that allow for the strongest possible causal inferences.

(g) Funding.—

1	(1) COVERED FISCAL YEAR.—In this sub-
2	section, the term "covered fiscal year" means any of
3	fiscal years 2018 through 2023.
4	(2) Using funding for national dis-
5	LOCATED WORKER GRANTS.—Subject to paragraph
6	(4) and notwithstanding section 132(a)(2)(A) and
7	subtitle D of the Workforce Innovation and Oppor-
8	tunity Act (29 U.S.C. 3172(a)(2)(A), 3221 et seq.)
9	or any other provision of law, the Secretary may use
10	to carry out the pilot program under this section for
11	a covered fiscal year—
12	(A) funds made available to earry out see
13	tion 170 of such Act (29 U.S.C. 3225) for that
14	fiscal year;
15	(B) funds made available to earry out see
16	tion 170 of such Act that remain available for
17	that fiscal year; and
18	(C) funds that remain available under see
19	tion 172(f) of such Act (29 U.S.C. 3227(f)).
20	(3) Availability of funds.—Funds appro-
21	priated under section 136(e) of such Act (29 U.S.C
22	3181(e)) and made available to carry out section
23	170 of such Act for a fiscal year shall remain avail-
24	able for use under paragraph (2) for a subsequent

fiscal year until expended.

1	(4) Limitation.—The Secretary may not use
2	more than \$100,000,000 of the funds described in
3	paragraph (2) for any covered fiscal year under this
4	section.
5	SEC. 408. YOUTH PREVENTION AND RECOVERY.
6	(a) Substance Abuse Treatment Services for
7	CHILDREN, ADOLESCENTS, AND YOUNG ADULTS.—Sec-
8	tion 514 of the Public Health Service Act (42 U.S.C.
9	290bb-7) is amended—
10	(1) in the section heading, by striking "CHIL-
11	DREN AND ADOLESCENTS" and inserting "CHIL-
12	DREN, ADOLESCENTS, AND YOUNG ADULTS";
13	(2) in subsection (a)(2), by striking "children,
14	including" and inserting "children, adolescents, and
15	young adults, including"; and
16	(3) by striking "children and adolescents" each
17	place it appears and inserting "children, adolescents,
18	and young adults".
19	(b) Youth Prevention and Recovery Initia-
20	TIVE.—
21	(1) Definitions.—In this subsection:
22	(A) ELIGIBLE ENTITY.—The term "eligible
23	entity" means—
24	(i) a local educational agency that is
25	seeking to establish or expand substance

1	use prevention and recovery support serv-
2	ices at one or more high schools;
3	(ii) an institution of higher education;
4	(iii) a recovery program at an institu-
5	tion of higher education;
6	(iv) a local board or one-stop oper-
7	ator; or
8	(v) a nonprofit organization, excluding
9	a school.
10	(B) HIGH SCHOOL.—The term "high
11	school" has the meaning given such term in
12	section 8101 of the Elementary and Secondary
13	Education Act of 1965 (20 U.S.C. 7801).
14	(C) Institution of Higher Edu-
15	CATION.—The term "institution of higher edu-
16	eation" has the meaning given such term in
17	section 101 of the Higher Education Act of
18	1965 (20 U.S.C. 1001) and includes a "post-
19	secondary vocational institution" as defined in
20	section 102(e) of such Act (20 U.S.C. 1002(e)).
21	(D) LOCAL EDUCATION AGENCY.—The
22	term "local educational agency" has the mean-
23	ing given the term in section 8101 of the Ele-
24	mentary and Secondary Education Act of 1965.

1	(E) Local board; one-stop oper-
2	ATOR.—The terms "local board" and "one-stop
3	operator" have the meanings given such terms
4	in section 3 of the Workforce Innovation and
5	Opportunity Act (29 U.S.C. 3102).
6	(F) RECOVERY PROGRAM.—The term "re-
7	covery program" means a program—
8	(i) to help children, adolescents, or
9	young adults who are recovering from sub-
10	stance use disorders to initiate, stabilize,
11	and maintain healthy and productive lives
12	in the community; and
13	(ii) that includes peer-to-peer support
14	delivered by individuals with lived experi-
15	ence in recovery, and communal activities
16	to build recovery skills and supportive so-
17	cial networks.
18	(G) Secretary.—The term "Secretary"
19	means the Secretary of Health and Human
20	Services, except as otherwise specified.
21	(2) Best practices.—The Secretary, in con-
22	sultation with the Secretary of Education, shall—
23	(A) identify or facilitate the development of
24	evidence-based best practices for prevention of
25	substance misuse and abuse by children, adoles-

1	cents, and young adults, for appropriate recov-
2	ery support services, and for appropriate use of
3	medication-assisted treatment for such individ-
4	uals, if applicable;
5	(B) disseminate such best practices to local
6	educational agencies, institutions of higher edu-
7	cation, recovery programs at institutions of
8	higher education, local boards, one-stop opera-
9	tors, and nonprofit organizations, as appro-
10	priate;
11	(C) conduct a rigorous, independent eval-
12	uation of each grant funded under this sub-
13	section, particularly its impact on the indicators
14	described in paragraph (5)(B); and
15	(D) provide technical assistance for grant-
16	ees under this subsection.
17	(3) Grants authorized.—The Secretary, in
18	consultation with the Secretary of Education, shall
19	award 3-year grants, on a competitive basis, to eligi-
20	ble entities to enable such entities, in coordination
21	with State agencies responsible for carrying out sub-
22	stance use disorder prevention and treatment pro-
23	grams, to carry out evidence-based or promising pro-

grams for—

1	(A) prevention of substance abuse and mis-
2	use by children, adolescents, and young adults;
3	(B) recovery support services for children,
4	adolescents, and young adults, which may in-
5	elude counseling, job training, linkages to com-
6	munity-based services, family support groups,
7	and recovery coaching; and
8	(C) treatment or referrals for treatment of
9	substance use disorders, as appropriate.
10	(4) APPLICATION.—To be eligible for a grant
11	under this subsection, an entity shall submit to the
12	Secretary an application at such time, in such man-
13	ner, and containing such information as the Sec-
14	retary may require. Such application shall include—
15	(A) a description of the impact of sub-
16	stance use disorders on children, adolescents,
17	and young adults enrolled in the local edu-
18	cational agency, one-stop operator, local board,
19	or institution of higher education;
20	(B) a description of how the eligible entity
21	has solicited input from faculty, teachers, staff,
22	families, students, and experts in substance use
23	prevention and treatment in developing such
24	application;

1	(C) how the eligible entity plans to use
2	grant funds for evidence-based or promising ac-
3	tivities, in accordance with this subsection to
4	prevent, provide recovery support for, and treat
5	substance use disorders amongst such individ-
6	uals;
7	(D) an assurance that the eligible entity
8	will participate in the evaluation described in
9	paragraph (2)(C); and
10	(E) a description of how the eligible entity
11	will collaborate with local service providers, in-
12	eluding substance use disorder treatment pro-
13	grams, providers of mental health services, and
14	primary care providers, in carrying out the
15	grant program.
16	(5) REPORT.—Each eligible entity awarded a
17	grant under this section shall submit to the appro-
18	priate committees of Congress, a report at such time
19	and in such manner as the Secretary may require.
20	Such report shall include—
21	(A) a description of how the eligible entity
22	used grant funds, in accordance with this sub-
23	section, including the number of children, ado-
24	lescents, and young adults reached through pro-
25	gramming; and

1	(B) a description of how the grant pro-
2	gram has made an impact on—
3	(i) indicators of student success, in-
4	eluding student well-being and academic
5	achievement; and
6	(ii) substance use disorders amongst
7	children, adolescents, and young adults, in-
8	cluding the number of overdoses and
9	deaths amongst children, adolescents, and
10	young adults during the grant period.
11	(6) Authorization of Appropriations.
12	There is authorized to be appropriated, such sums
13	as may be necessary to carry out this subsection.
14	SEC. 409. PLANS OF SAFE CARE.
15	(a) In General.—Section 105(a) of the Child Abuse
16	Prevention and Treatment Act (42 U.S.C. 5106(a)) is
17	amended by adding at the end the following:
18	"(7) Grants to states to improve and co-
19	ORDINATE THEIR RESPONSE TO ENSURE THE SAFE-
20	TY, PERMANENCY, AND WELL-BEING OF INFANTS
21	AFFECTED BY SUBSTANCE USE.
22	"(A) Program Authorized.—The Sec-
23	retary shall make grants to States for the pur-
24	pose of assisting child welfare agencies, social
25	services agencies, substance use disorder treat-

1	ment agencies, public health and mental health
2	agencies, and maternal and child health agen-
3	cies to facilitate collaboration in developing, up-
4	dating, and implementing plans of safe care de-
5	scribed in section 106(b)(2)(B)(iii).
6	"(B) DISTRIBUTION OF FUNDS.—
7	"(i) Reservations.—Of the amounts
8	appropriated under subparagraph (H), the
9	Secretary shall reserve—
10	"(I) no more than 3 percent for
11	the purposes described in subpara-
12	graph (G); and
13	"(H) up to 3 percent for grants
14	to Indian Tribes and tribal organiza-
15	tions for purposes consistent with this
16	section, as the Secretary determines
17	appropriate.
18	"(ii) Allotments to states and
19	TERRITORIES.—The Secretary shall allot
20	the amount appropriated under subpara-
21	graph (H) that remains after application
22	of clause (i) on a competitive basis to
23	States that apply for such a grant.
24	"(iii) SELECTION CRITERIA.—The
25	Secretary shall allot funds to States that

1	demonstrate a strong need for such funds,
2	and a strong commitment to using such
3	funds, to meet the purposes described in
4	subparagraph (A) in accordance with sub-
5	paragraph (D).
6	"(C) Application.—A State desiring a
7	grant under this paragraph shall submit an ap-
8	plication to the Secretary at such time and in
9	such manner as the Secretary may require.
10	Such application shall include—
11	"(i) a description of—
12	"(I) the impact of substance use
13	disorder in such State, including with
14	respect to the substance or class of
15	substances with the highest incidence
16	of abuse in the previous year in such
17	State, including—
18	"(aa) the prevalence of sub-
19	stance use disorder in such State;
20	"(bb) the aggregate rate of
21	births in the State of infants af-
22	feeted by substance abuse or
23	withdrawal symptoms or a fetal
24	alcohol spectrum disorder (as de-
25	termined by hospitals, insurance

1 claims, claims submitted to the
2 State Medicaid program, or other
3 records), if available and to the
4 extent practicable; and
5 "(ee) the number of infant
6 identified, for whom a plan o
7 safe care was developed, and fo
8 whom a referral was made for
9 appropriate services, as reported
under section $106(d)(18)$;
"(H) the challenges the State
faces in developing and implementing
plans of safe care in accordance with
section $106(b)(2)(B)(iii)$;
15 "(III) the State's lead agency fo
the grant program and how that agen
ey will coordinate with relevant Stat
entities and programs, including the
child welfare agency, the substance
use disorder treatment agency, th
public health and mental health agen
cies, programs funded by the Residen
tial Treatment for Pregnant and
Postpartum Women grant program o
25 the Substance Abuse and Menta

1	Health Services Administration under
2	section 508 of the Public Health Serv-
3	ice Act (42 U.S.C. 290bb-1), the
4	State Medicaid program, the State
5	agency administering the block grant
6	program under title V of the Social
7	Security Act (42 U.S.C. 701 et seq.),
8	the State agency administering the
9	programs funded under part C of the
10	Individuals with Disabilities Edu-
11	eation Act (20 U.S.C. 1431 et seq.),
12	the maternal, infant, and early child-
13	hood home visiting program under
14	section 511 of the Social Security Act
15	(42 U.S.C. 711), the State judicial
16	system, and other agencies, as deter-
17	mined by the Secretary;
18	"(IV) how the State will monitor
19	local implementation of plans of safe
20	eare, in accordance with section
21	106(b)(2)(B)(iii)(II);
22	"(V) how the State meets the re-
23	quirements of section 1927 of the
24	Public Health Service Act (42 U.S.C.
25	300x-27);

1	"(VI) how the State plans to uti-
2	lize funding authorized under part E
3	of title IV of the Social Security Act
4	(42 U.S.C. 670 et seq.) to assist in
5	carrying out any plan of safe care, in-
6	eluding such funding authorized under
7	section 471(e) of such Act (as in ef-
8	feet on October 1, 2018) for mental
9	health and substance abuse prevention
10	and treatment services and in-home
11	parent skill-based programs and fund-
12	ing authorized under such section
13	472(j) (as in effect on October 1,
14	2018) for children with a parent in a
15	licensed residential family-based treat-
16	ment facility for substance abuse; and
17	"(VII) an assessment of the
18	treatment and other services and pro-
19	grams available in the State, to effec-
20	tively carry out any plan of safe care
21	developed, including identification of
22	needed treatment, and other services
23	and programs to ensure the wellbeing
24	of young children and their families
25	affected by substance use disorder

1	such as programs carried out under
2	part C of the Individuals with Disabil-
3	ities Education Act and comprehen-
4	sive early childhood development serv-
5	ices and programs such as Head Start
6	programs;
7	"(ii) a description of how the State
8	plans to use funds for activities described
9	in subparagraph (D) for the purposes of
10	ensuring State compliance with require-
11	ments under clauses (ii) and (iii) of section
12	106(b)(2)(B); and
13	"(iii) an assurance that the State
14	will—
15	"(I) comply with this Act and
16	parts B and E of title IV of the Social
17	Security Act (42 U.S.C. 621 et seq.,
18	670 et seq.); and
19	"(II) comply with requirements
20	to refer a child identified as sub-
21	stance-exposed to early intervention
22	services as required pursuant to a
23	grant under part C of the Individuals
24	with Disabilities Education Act (20
25	U.S.C. 1431 et seq.).

1 "(D) Uses of funds.—Funds awarded to
2 a State under this paragraph may be used for
3 the following activities, which may be carried
4 out by the State directly, or through grants or
5 subgrants, contracts, or cooperative agreements
6 "(i) Improving State and local sys-
7 tems with respect to the development and
8 implementation of plans of safe care
9 which—
0 "(I) shall include parent and
1 caregiver engagement, as required
2 under section 106(b)(2)(B)(iii)(I), re-
3 garding available treatment and serv-
4 ice options, which may include re-
5 sources available for pregnant
6 perinatal, and postnatal women; and
7 "(H) may include activities such
8 as-
9 <u>"(aa) developing policies</u>
oprocedures, or protocols for the
administration of evidence-based
2 and validated screening tools for
infants who may be affected by
4 substance use withdrawal symp
5 toms or a fetal alcohol spectrum

1	disorder and pregnant, perinatal,
2	and postnatal women whose in-
3	fants may be affected by sub-
4	stance use withdrawal symptoms
5	or a fetal alcohol spectrum dis-
6	order;
7	"(bb) improving assessments
8	used to determine the needs of
9	the infant and family;
10	"(ce) improving ongoing
11	ease management services; and
12	"(dd) improving access to
13	treatment services, which may be
14	prior to the pregnant woman's
15	delivery date.
16	"(ii) Developing policies, procedures,
17	or protocols in consultation and coordina-
18	tion with health professionals, public and
19	private health facilities, and substance use
20	disorder treatment agencies to ensure
21	that
22	"(I) appropriate notification to
23	child protective services is made in a
24	timely manner;

1 "(II) a plan of safe care is in	1
2 place, where needed, before the infant	2
is discharged from the birth or health	3
4 care facility; and	4
5 "(III) such health and related	5
6 agency professionals are trained on	6
7 how to follow such protocols and are	7
8 aware of the supports that may be	8
9 provided under a plan of safe care.	9
0 <u>"(iii) Training health professionals</u>	10
1 and health system leaders, child welfare	11
2 workers, substance use disorder treatment	12
3 agencies, and other related professionals	13
4 such as home visiting agency staff and law	14
5 enforcement in relevant topics including—	15
6 "(I) State mandatory reporting	16
7 laws and the referral and notification	17
8 process;	18
9 "(H) the co-occurrence of preg-	19
0 nancy and substance use disorder;	20
1 "(III) the clinical guidance about	21
2 treating substance use disorder in	22
3 pregnant and postpartum women;	23
4 "(IV) appropriate screening and	24
5 interventions for infants affected by	25

1	substance use disorder, withdrawal
2	symptoms, or a fetal alcohol spectrum
3	disorder and the requirements under
4	section 106(b)(2)(B)(iii); and
5	"(V) appropriate strategies to ad-
6	dress the mental health needs of the
7	parent and child together.
8	"(iv) Establishing partnerships, agree-
9	ments, or memoranda of understanding be-
10	tween the lead agency and health profes-
11	sionals, health facilities, child welfare pro-
12	fessionals, substance use disorder and
13	mental health disorder treatment pro-
14	grams, early childhood education pro-
15	grams, and maternal and child health and
16	early intervention professionals, including
17	home visiting providers, peer-to-peer recov-
18	ery programs such as parent mentoring
19	programs, and housing agencies to facili-
20	tate the implementation of, and compliance
21	with section 106(b)(2) and clause (ii) of
22	this subparagraph, in areas which may in-
23	clude
24	"(I) developing a comprehensive,
25	multi-disciplinary assessment and

1 intervention process for infants and 2 their families who are affected by sub-3 stance use disorder, withdrawal symp-4 toms, or a fetal alcohol spectrum dis-5 order, that includes meaningful en-6 gagement with and takes into account 7 the unique needs of each family and addresses differences between legal, 8 9 medically supervised substance use, 10 and substance use disorder; 11 "(II) ensuring that treatment ap-12 proaches for serving infants, pregnant 13 women, and perinatal and postnatal 14 women whose infants may be affected 15 by substance use, withdrawal symp-16 toms, or a fetal alcohol spectrum dis-17 order, are designed to, where appro-18 priate, keep infants with their moth-19 ers during both inpatient and out-20 patient treatment; and 21 "(III) increasing access to evi-22 dence-based medication-assisted treat-23 ment approved by the Food and Drug 24 Administration, behavioral therapy,

and counseling services for the treat-

1	ment of substance use disorders, as
2	appropriate.
3	"(v) Developing and updating systems
4	of technology for improved data collection
5	and monitoring under section
6	106(b)(2)(B)(iii), including existing elec-
7	tronic medical records, to measure the out-
8	comes achieved through the plans of safe
9	eare, including monitoring systems to meet
10	the requirements of this Act and submis-
11	sion of performance measures.
12	"(E) REPORTING.—Each State that re-
13	ceives funds under this paragraph, for each
14	year such funds are received, shall submit a re-
15	port to the Secretary, disaggregated by geo-
16	graphic location, economic status, and major
17	racial and ethnic groups, except that such
18	disaggregation shall not be required if the re-
19	sults would reveal personally identifiable infor-
20	mation, on the following:
21	"(i) The number of the infants identi-
22	fied under section 106(b)(2)(B)(ii) who ex-
23	perienced removal due to parental sub-
24	stance use concerns who are reunified with

1	parents,	and	the	length	of	time	between
2	such rem	oval	and	reunific	atic	n.	

"(ii) The number of the infants identified under section 106(b)(2)(B)(ii) who experienced substantiated reports of child abuse or neglect and received differential response while in the care of their birth parents or within 1 year after a reunification has occurred.

"(iii) The number of the infants identified under section 106(b)(2)(B)(ii) who experienced a return to out-of-home care within one year after reunification.

"(F) Secretary's Report to con-GRESS.—The Secretary shall submit an annual report to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Education and the Workforce and the Committee on Appropriations of the House of Representatives that includes the information described in subparagraph (E) and recommendations or observations on the challenges, successes, and lessons derived from implementation of the grant program.

1	"(G) RESERVATION OF FUNDS.—The Sec-
2	retary shall use the amount reserved under sub-
3	paragraph (B)(i)(I) for the purposes of—
4	"(i) providing technical assistance, in-
5	eluding programs of in-depth technical as-
6	sistance, to additional States, territories,
7	and Indian tribes in accordance with the
8	substance-exposed infant initiative devel-
9	oped by the National Center on Substance
10	Abuse and Child Welfare;
11	"(ii) issuing guidance on the require-
12	ments of this Act with respect to infants
13	born with and identified as being affected
14	by substance use or withdrawal symptoms
15	or fetal alcohol spectrum disorder, as de-
16	scribed in clauses (ii) and (iii) of section
17	106(b)(2)(B), including by—
18	"(I) clarifying key terms; and
19	"(II) disseminating best practices
20	on implementation of plans of safe
21	eare, on such topics as differential re-
22	sponse, collaboration and coordina-
23	tion, and identification and delivery of
24	services, for different populations;

1	"(iii) supporting State efforts to de-
2	velop information technology systems to
3	manage plans of safe care; and
4	"(iv) preparing the Secretary's report
5	to Congress described in subparagraph
6	(F).
7	"(H) AUTHORIZATION OF APPROPRIA-
8	TIONS.—To carry out the program under this
9	paragraph, there are authorized to be appro-
10	priated \$60,000,000 for each of fiscal years
11	2019 through 2023.".
12	(b) DEFINITION.—Section 3 of the Child Abuse Pre-
13	vention and Treatment Act (42 U.S.C. 5101 note) is
14	amended—
15	(1) in paragraph (7), by striking "; and" and
16	inserting a semicolon;
17	(2) by redesignating paragraph (8) as para-
18	graph (9); and
19	(3) by inserting after paragraph (7) the fol-
20	lowing:
21	"(8) the term 'substance use disorder' means
22	the abuse of alcohol or other drugs; and".

1	SEC. 410. REGULATIONS RELATING TO SPECIAL REGISTRA-
2	TION FOR TELEMEDICINE.
3	Section 311(h) of the Controlled Substances Act (21
4	U.S.C. 831(h)) is amended by striking paragraph (2) and
5	inserting the following:
6	"(2) Regulations.—
7	"(A) IN GENERAL.—Not later than 1 year
8	after the date of enactment of the Opioid Crisis
9	Response Act of 2018, in consultation with the
10	Secretary, and in accordance with the procedure
11	described in subparagraph (B), the Attorney
12	General shall promulgate final regulations
13	specifying—
14	"(i) the limited circumstances in
15	which a special registration under this sub-
16	section may be issued; and
17	"(ii) the procedure for obtaining a
18	special registration under this subsection.
19	"(B) Procedure.—In promulgating final
20	regulations under subparagraph (A), the Attor-
21	ney General shall—
22	"(i) issue a notice of proposed rule-
23	making that includes a copy of the pro-
24	posed regulations;

1	"(ii) provide a period of not less than
2	60 days for comments on the proposed reg-
3	ulations;
4	"(iii) finalize the proposed regulation
5	not later than 6 months after the close of
6	the comment period; and
7	"(iv) publish the final regulations not
8	later than 30 days before the effective date
9	of the final regulations.".
10	SEC. 411. NATIONAL HEALTH SERVICE CORPS BEHAVIORAL
11	AND MENTAL HEALTH PROFESSIONALS PRO-
12	VIDING OBLIGATED SERVICE IN SCHOOLS
13	AND OTHER COMMUNITY-BASED SETTINGS.
14	Subpart III of part D of title III of the Public Health
15	Service Act (42 U.S.C. 254l et seq.) is amended by adding
16	at the end the following:
17	"SEC. 338N. BEHAVIORAL AND MENTAL HEALTH PROFES-
18	SIONALS PROVIDING OBLIGATED SERVICE IN
19	SCHOOLS AND OTHER COMMUNITY-BASED
20	SETTINGS.
21	"(a) Schools and Community-Based Settings.—
22	An entity to which a Corps member is assigned under sec-
23	tion 333 may direct such Corps member to provide service
24	as a behavioral and mental health professional at a school

1	or other community-based setting located in a health pro-
2	fessional shortage area.
3	"(b) Obligated Service.—
4	"(1) In General.—Any service described in
5	subsection (a) that a Corps member provides may
6	count towards such Corps member's completion of
7	any obligated service requirements under the Schol-
8	arship Program or the Loan Repayment Program
9	subject to any limitation imposed under paragraph
10	$\frac{(2)}{}$.
11	"(2) Limitation.—The Secretary may impose
12	a limitation on the number of hours of service de-
13	scribed in subsection (a) that a Corps member may
14	eredit towards completing obligated service require-
15	ments, provided that the limitation allows a member
16	to credit service described in subsection (a) for not
17	less than 50 percent of the total hours required to
18	complete such obligated service requirements.
19	"(c) Rule of Construction.—The authorization
20	under subsection (a) shall be notwithstanding any other
21	provision of this subpart or subpart H.".
22	SEC. 412. LOAN REPAYMENT FOR SUBSTANCE USE DIS
23	ORDER TREATMENT PROVIDERS.
24	(a) Loan Repayment for Substance Use Treat-
25	MENT PROVIDERS.—The Secretary of Health and Human

- 1 Services (referred to in this section as the "Secretary")
- 2 shall enter into contracts under section 338B of the Public
- 3 Health Service Act (42 U.S.C. 2541-1) with eligible health
- 4 professionals providing substance use disorder treatment
- 5 services in substance use disorder treatment facilities, as
- 6 defined by the Secretary.
- 7 (b) Provision of Substance Use Disorder
- 8 Treatment.—In carrying out the activities described in
- 9 subsection (a)—
- 10 (1) such facilities shall be located in mental
- 11 health professional shortage areas designated under
- section 332 of the Public Health Service Act (42)
- 13 U.S.C. 254e);
- 14 (2) section 331(a)(3)(D) of such Act (42 U.S.C.
- 15 254d(a)(3)(D)) shall be applied as if the term "pri-
- 16 mary health services" includes health services re-
- 17 garding substance use disorder treatment;
- 18 $\frac{(3)}{\text{section}} \frac{331(a)(3)(E)(i)}{\text{of such Act}} \frac{Act}{(42)}$
- 19 U.S.C. 254d(a)(3)(E)(i) shall be applied as if the
- 20 term "behavioral and mental health professionals"
- 21 includes masters level, licensed substance use dis-
- 22 order treatment counselors; and
- 23 (4) such professionals and facilities shall pro-
- 24 <u>vide</u>

1	(A) counseling by a program counselor or
2	other certified professional who is licensed and
3	qualified by education, training, or experience
4	to assess the psychological and sociological
5	background of patients, to contribute to the ap-
6	propriate treatment plan for the patient, and to
7	monitor progress; and
8	(B) all drugs approved by the Food and
9	Drug Administration to treat substance use dis-
10	orders.
11	(e) Authorization of Appropriations.—There is
12	authorized to be appropriated to earry out this section,
13	\$25,000,000 for each of fiscal years 2019 through 2023.
14	SEC. 413. IMPROVING TREATMENT FOR PREGNANT AND
15	POSTPARTUM WOMEN.
16	(a) Report.—
17	(1) In General.—Not later than 60 days after
18	the date of enactment of this Act, the Secretary of
19	Health and Human Services (referred to in this sub-
20	section as the "Secretary") shall submit to the ap-
21	propriate committees of Congress and make avail-
22	able to the public on the internet website of the De-
23	partment of Health and Human Services a report

regarding the implementation of the recommenda-

tions in the strategy relating to prenatal opioid use,

24

1	including neonatal abstinence syndrome, developed
2	pursuant to section 2 of the Protecting Our Infants
3	Act of 2015 (Public Law 114-91). Such report shall
4	include
5	(A) an update on the implementation of
6	the recommendations in the strategy, including
7	information regarding the agencies involved in
8	the implementation; and
9	(B) information on additional funding or
10	authority the Secretary requires, if any, to im-
11	plement the strategy, which may include au-
12	thorities needed to coordinate implementation
13	of such strategy across the Department of
14	Health and Human Services.
15	(2) PERIODIC UPDATES.—The Secretary shall
16	periodically update the report under paragraph (1).
17	(b) RESIDENTIAL TREATMENT PROGRAMS FOR
18	PREGNANT AND POSTPARTUM WOMEN.—Section 508(s)
19	of the Public Health Service Act (42 U.S.C. 290bb-1(s))
20	is amended by striking "\$16,900,000 for each of fiscal
21	years 2017 through 2021" and inserting "\$29,931,000 for
22	each of fiscal years 2019 through 2023".

1	SEC. 414. EARLY INTERVENTIONS FOR PREGNANT WOMEN
2	AND INFANTS.
3	(a) DEVELOPMENT OF EDUCATIONAL MATERIALS BY
4	CENTER FOR SUBSTANCE ABUSE PREVENTION.—Section
5	515(b) of the Public Health Service Act (42 U.S.C.
6	290bb-21(b)) is amended—
7	(1) in paragraph (13), by striking "and" at the
8	end;
9	(2) in paragraph (14), by striking the period at
10	the end and inserting "; and"; and
11	(3) by adding at the end the following:
12	"(15) in cooperation with relevant stakeholders
13	and the Director of the Centers for Disease Control
14	and Prevention, develop educational materials for
15	elinicians to use with pregnant women for shared de-
16	cisionmaking regarding pain management during
17	pregnancy.".
18	(b) Guidelines and Recommendations by Cen-
19	TER FOR SUBSTANCE ABUSE TREATMENT.—Section
20	507(b) of the Public Health Service Act (42 U.S.C.
21	290bb(b)) is amended—
22	(1) in paragraph (13), by striking "and" at the
23	end;
24	(2) in paragraph (14), by striking the period at
25	the end and inserting a semicolon; and
26	(3) by adding at the end the following:

1	"(15) in cooperation with the Secretary, imple-
2	ment and disseminate, as appropriate, the rec-
3	ommendations in the report entitled 'Protecting Our
4	Infants Act: Final Strategy' issued by the Depart-
5	ment of Health and Human Services in 2017; and".
6	(e) Support of Partnerships by Center for
7	SUBSTANCE ABUSE TREATMENT.—Section 507(b) of the
8	Public Health Service Act (42 U.S.C. 290bb(b)), as
9	amended by subsection (b), is further amended by adding
10	at the end the following:
11	"(16) in cooperation with relevant stakeholders,
12	support public-private partnerships to assist with
13	education about, and support with respect to, sub-
14	stance use disorder for pregnant women and health
15	eare providers who treat pregnant women and ba-
16	bies.".
17	TITLE V—PREVENTION
18	SEC. 501. STUDY ON PRESCRIBING LIMITS.
19	Not later than 2 years after the date of enactment
20	of this Act, the Secretary of Health and Human Services,
21	in consultation with the Attorney General, shall submit to
22	the Committee on Health, Education, Labor, and Pen-

sions of the Senate and the Committee on Energy and

24 Commerce of the House of Representatives a report on

25 the impact of Federal and State laws and regulations that

1	limit the length, quantity, or dosage of opioid prescrip-
2	tions. Such report shall address—
3	(1) the impact of such limits on—
4	(A) the incidence and prevalence of over-
5	dose related to prescription opioids;
6	(B) the incidence and prevalence of over-
7	dose related to illicit opioids;
8	(C) the prevalence of opioid use disorders;
9	and
10	(D) medically appropriate use of, and ac-
11	cess to, opioids, including any impact on travel
12	expenses and pain management outcomes for
13	patients, whether such limits are associated
14	with significantly higher rates of negative
15	health outcomes, including suicide, and whether
16	the impact of such limits differs based on clin-
17	ical indication for which opioids are prescribed;
18	(2) whether such limits lead to a significant in-
19	crease in burden for prescribers of opioids or pre-
20	scribers of treatments for opioid use disorder, in-
21	eluding any impact on patient access to treatment,
22	and whether any such burden is mitigated by any
23	factors such as electronic prescribing; and
24	(3) the impact of such limits on diversion or
25	misuse of any controlled substance in schedule II,

1	III, or IV of section 202(c) of the Controlled Sub-
2	stances Act (21 U.S.C. 812(e)).
3	SEC. 502. PROGRAMS FOR HEALTH CARE WORKFORCE.
4	(a) Program for Education and Training in
5	PAIN CARE.—Section 759 of the Public Health Service
6	Act (42 U.S.C. 294i) is amended—
7	(1) in subsection (a), by inserting "nonprofit"
8	after "private";
9	(2) in subsection (b)—
10	(A) in the matter preceding paragraph (1),
11	by striking "award may be made under sub-
12	section (a) only if the applicant for the award
13	agrees that the program carried out with the
14	award will include" and inserting "entity receiv-
15	ing an award under this section shall develop a
16	comprehensive education and training plan that
17	includes";
18	(B) in paragraph (1)—
19	(i) by inserting "preventing," after
20	"diagnosing,"; and
21	(ii) by inserting "non-addictive med-
22	ical products and non-pharmacologic treat-
23	ments and" after "including";
24	(C) in paragraph (2)—

1	(i) by inserting "Federal, State, and
2	local" after "applicable"; and
3	(ii) by striking "the degree to which"
4	and all that follows through "effective pain
5	care" and inserting "opioids";
6	(D) in paragraph (3), by inserting "and,
7	as appropriate, non-pharmacotherapy" before
8	the semicolon;
9	(E) in paragraph (4)—
10	(i) by inserting "any" before "cul-
11	tural"; and
12	(ii) by striking "; and" and inserting
13	<u>««, , , , , , , , , , , , , , , , , , ,</u>
14	(F) in paragraph (5), by striking "provi-
15	sion of pain care." and inserting "scientific
16	basis of pain and the provision of pain care, in-
17	eluding through non-addictive medical products
18	and non-pharmacologie treatments; and"; and
19	(G) by adding at the end the following:
20	"(6) the dangers of opioid abuse, detection of
21	early warning signs of opioid use disorders, and safe
22	disposal options for prescription medications, includ-
23	ing such options provided by law enforcement, or
24	other innovative deactivation mechanisms.";

1	(3) in subsection (d), by inserting "prevention,"
2	after "diagnosis,"; and
3	(4) in subsection (e), by striking "2010 through
4	2012" and inserting "2019 through 2023".
5	(b) Mental and Behavioral Health Education
6	AND TRAINING PROGRAM.—Section 756(a) of the Public
7	Health Service Act (42 U.S.C. 294e-1(a)) is amended—
8	(1) in paragraph (1), by inserting ", trauma,"
9	after "focus on child and adolescent mental health";
10	and
11	(2) in paragraphs (2) and (3), by inserting
12	"trauma-informed care and" before "substance use
13	disorder prevention and treatment services".
14	SEC. 503. EDUCATION AND AWARENESS CAMPAIGNS.
15	Section 102 of the Comprehensive Addiction and Re-
16	covery Act of 2016 (Public Law 114–198) is amended—
17	(1) by amending subsection (a) to read as fol-
18	lows:
19	"(a) IN GENERAL.—The Secretary of Health and
20	Human Services, acting through the Director of the Cen-
21	ters for Disease Control and Prevention and in coordina-
22	tion with the heads of other departments and agencies,
23	shall advance education and awareness regarding the risks
24	related to misuse and abuse of opioids, as appropriate,
25	which may include developing or improving existing pro-

1	grams, conducting activities, and awarding grants that ad-
2	vance the education and awareness of—
3	"(1) the public, including patients and con-
4	sumers;
5	"(2) patients, consumers, and other appropriate
6	members of the public, regarding such risks related
7	to unused opioids and the dispensing options under
8	section 309(f) of the Controlled Substances Act, as
9	applicable;
10	"(3) providers, which may include—
11	"(A) providing for continuing education or
12	appropriate prescribing practices;
13	"(B) education related to applicable State
14	or local prescriber limit laws, information or
15	the use of non-addictive or non-opioid alter-
16	natives for pain management, and the use of
17	overdose reversal drugs, as appropriate;
18	"(C) disseminating and improving the use
19	of evidence-based opioid prescribing guidelines
20	across relevant health care settings, as appro-
21	priate, and updating guidelines as necessary;
22	"(D) implementing strategies, such as best
23	practices, to encourage and facilitate the use of
24	prescriber guidelines, in accordance with State
25	and local law and

1	"(E) disseminating information to pro-
2	viders about prescribing options for controlled
3	substances, including such options under sec-
4	tion 309(f) of the Controlled Substances Act, as
5	applicable; and
6	"(4) other appropriate entities."; and
7	(2) in subsection (b)—
8	(A) by striking "opioid abuse" each place
9	such term appears and inserting "opioid misuse
10	and abuse"; and
11	(B) in paragraph (2), by striking "safe dis-
12	posal of prescription medications and other"
13	and inserting "non-addictive or non-opioid
14	treatment options, safe disposal options for pre-
15	scription medications, and other applicable".
16	SEC. 504. ENHANCED CONTROLLED SUBSTANCE
17	OVERDOSES DATA COLLECTION, ANALYSIS,
18	AND DISSEMINATION.
19	Part J of title III of the Public Health Service Act
20	is amended by inserting after section 392 (42 U.S.C.
21	280b-1) the following:

1	"SEC. 392A. ENHANCED CONTROLLED SUBSTANCE
2	OVERDOSES DATA COLLECTION, ANALYSIS,
3	AND DISSEMINATION.
4	"(a) In General.—The Director of the Centers for
5	Disease Control and Prevention, using the authority pro-
6	vided to the Director under section 392, may—
7	"(1) to the extent practicable, earry out and ex-
8	pand any controlled substance overdose data collec-
9	tion, analysis, and dissemination activity described
10	in subsection (b);
11	"(2) provide training and technical assistance
12	to States, localities, and Indian tribes for the pur-
13	pose of earrying out any such activity; and
14	"(3) award grants to States, localities, and In-
15	dian tribes for the purpose of carrying out any such
16	activity.
17	"(b) Controlled Substance Overdose Data
18	COLLECTION AND ANALYSIS ACTIVITIES.—A controlled
19	substance overdose data collection, analysis, and dissemi-
20	nation activity described in this subsection is any of the
21	following activities:
22	"(1) Improving the timeliness of reporting ag-
23	gregate data to the public, including data on fatal
24	and nonfatal controlled substance overdoses.
25	"(2) Enhancing the comprehensiveness of con-
26	trolled substance overdose data by collecting infor-

1	mation on such overdoses from appropriate sources
2	such as toxicology reports, death scene investiga-
3	tions, and emergency department services.
4	"(3) Modernizing the system for coding causes
5	of death related to controlled substance overdoses to
6	use an electronic-based system.
7	"(4) Using data to help identify risk factors as
8	sociated with controlled substance overdoses, includ-
9	ing the delivery of certain health care services.
10	"(5) Supporting entities involved in reporting
11	information on controlled substance overdoses, such
12	as coroners and medical examiners, to improve accu-
13	rate testing and reporting of causes and contributing
14	factors of such overdoses, and analysis of various
15	opioid analogues to controlled substances overdoses
16	"(6) Working to enable and encourage the ac-
17	cess, exchange, and use of data regarding controlled
18	substances overdoses among data sources and enti-
19	ties.
20	"(e) Controlled Substance Defined.—In this
21	section, the term 'controlled substance' has the meaning
22	given that term in section 102 of the Controlled Sub-

23 stances Act.".

1	SEC. 505. PREVENTING OVERDOSES OF CONTROLLED SUB-
2	STANCES.
3	Part J of title III of the Public Health Service Act
4	(42 U.S.C. 280b et seq.), as amended by section 504, is
5	further amended by inserting after section 392A the fol-
6	lowing:
7	"SEC. 392B. PREVENTING OVERDOSES OF CONTROLLED
8	SUBSTANCES.
9	"(a) Prevention Activities.—
10	"(1) In GENERAL.—The Director of the Cen-
11	ters for Disease Control and Prevention (referred to
12	in this section as the 'Director'), using the authority
13	provided to the Director under section 392, may
14	"(A) to the extent practicable, earry out
15	and expand any prevention activity described in
16	$\frac{\text{paragraph}}{(2)}$;
17	"(B) provide training and technical assist-
18	ance to States, localities, and Indian tribes to
19	earrying out any such activity; and
20	"(C) award grants to States, localities, and
21	tribes for the purpose of carrying out any such
22	activity.
23	"(2) Prevention Activities.—A prevention
24	activity described in this paragraph is an activity to
25	improve the efficiency and use of a new or currently
26	operating prescription drug monitoring program—

1	"(A) encouraging all authorized users (as
2	specified by the State or other entity) to reg-
3	ister with and use the program;
4	"(B) enabling such users to access any
5	data updates in as close to real-time as prac-

"(C) providing for a mechanism for the program to notify authorized users of any potential misuse or abuse of controlled substances and any detection of inappropriate prescribing practices relating to such substances;

"(D) encouraging the analysis of prescription drug monitoring data for purposes of providing de-identified, aggregate reports based on such analysis to State public health agencies, State licensing boards, and other appropriate State agencies, as permitted under applicable Federal and State law and the policies of the prescription drug monitoring program and not containing any protected health information, to prevent inappropriate prescribing, drug diversion, or abuse and misuse of controlled substances, and to facilitate better coordination among agencies;

ticable;

1	"(E) enhancing interoperability between
2	the program and any health information tech-
3	nology (including certified health information
4	technology), including by integrating program
5	data into such technology;
6	"(F) updating program capabilities to re-
7	spond to technological innovation for purposes
8	of appropriately addressing the occurrence and
9	evolution of controlled substance overdoses; and
10	"(G) facilitating and encouraging data ex-
11	change between the program and the prescrip-
12	tion drug monitoring programs of other States.
13	"(b) Additional Grants.—The Director may
14	award grants to States, localities, and Indian tribes—
15	"(1) to carry out innovative projects for grant-
16	ees to rapidly respond to controlled substance mis-
17	use, abuse, and overdoses, including changes in pat-
18	terns of controlled substance use; and
19	"(2) for any other evidence-based activity for
20	preventing controlled substance misuse, abuse, and
21	overdoses as the Director determines appropriate.
22	"(e) Research.—The Director may conduct studies
23	and evaluations to address substance use disorders, in-
24	eluding preventing substance use disorders or other re-
25	lated topics the Director determines appropriate.

- 1 "(d) Public and Prescriber Education.—Pursu-
- 2 ant to section 102 of the Comprehensive Addiction and
- 3 Recovery Act of 2016, the Director may advance the edu-
- 4 cation and awareness of prescribers and the public regard-
- 5 ing the risk of abuse of prescription opioids.
- 6 "(e) Controlled Substance Defined.—In this
- 7 section, the term 'controlled substance' has the meaning
- 8 given that term in section 102 of the Controlled Sub-
- 9 stances Act.
- 10 "(f) Authorization of Appropriations.—For
- 11 purposes of carrying out this section, section 392A of this
- 12 Act, and section 102 of the Comprehensive Addiction and
- 13 Recovery Act of 2016, there is authorized to be appro-
- 14 priated \$486,000,000 for each of fiscal years 2019
- 15 through 2024.".
- 16 SEC. 506. CDC SURVEILLANCE AND DATA COLLECTION FOR
- 17 CHILD, YOUTH, AND ADULT TRAUMA.
- 18 (a) DATA COLLECTION.—The Director of the Centers
- 19 for Disease Control and Prevention (referred to in this
- 20 section as the "Director" may, in cooperation with the
- 21 States, collect and report data on adverse childhood expe-
- 22 riences through the Behavioral Risk Factor Surveillance
- 23 System, the Youth Risk Behavior Surveillance System,
- 24 and other relevant public health surveys or questionnaires.

1	(b) Timing.—The collection of data under subsection
2	(a) may occur in fiscal year 2019 and every 2 years there-
3	after.
4	(e) Data From Tribal and Rural Areas.—The
5	Director shall encourage each State that participates in
6	collecting and reporting data under subsection (a) to col-
7	lect and report data from tribal and rural areas within
8	such State, in order to generate a statistically reliable rep-
9	resentation of such areas.
10	(d) Authorization of Appropriations.—To carry
11	out this section, there are authorized to be appropriated
12	such sums as may be necessary for the period of fiscal
13	years 2019 through 2021.
14	SEC. 507. REAUTHORIZATION OF NASPER.
15	Section 3990 of the Public Health Service Act (42
16	U.S.C. 280g-3) is amended—
17	(1) in subsection (a)—
18	(A) in paragraph (1), in the matter pre-
19	ceding subparagraph (A), by striking "Adminis-
20	trator of the Substance Abuse and Mental
21	Health Services Administration and Director of
22	the Centers for Disease Control and Preven-
23	tion" and inserting "Director of the Centers for
24	Disease Control and Prevention and the Assist-

1	ant Secretary for Mental Health and Substance
2	Use Disorders'; and
3	(B) by adding at the end the following:
4	"(4) STATES AND LOCAL GOVERNMENTS.—
5	"(A) In GENERAL.—In the case of a State
6	that does not have a prescription drug moni-
7	toring program, a county or other unit of local
8	government within the State that has a pre-
9	scription drug monitoring program shall be
10	treated as a State for purposes of this section,
11	including for purposes of eligibility for grants
12	under paragraph (1).
13	"(B) Plan for interoperability.—For
14	purposes of meeting the interoperability re-
15	quirements under subsection (e)(3), a county or
16	other unit of local government shall submit a
17	plan outlining the methods such county or unit
18	of local government will use to ensure the capa-
19	bility of data sharing with other counties and
20	units of local government within the State and
21	with other States, as applicable.";
22	(2) in subsection (e)—
23	(A) in paragraph (1)(A)(iii)—

1	(i) by inserting "as such standards
2	become available," after "interoperability
3	standards,"; and
4	(ii) by striking "generated or identi-
5	fied by the Secretary or his or her des-
6	ignee" and inserting "recognized by the
7	Office of the National Coordinator for
8	Health Information Technology"; and
9	(B) in paragraph (3)(A), by inserting "in-
10	eluding electronic health records," after "tech-
11	nology systems,";
12	(3) in subsection (d)(1), by striking "not later
13	than 1 week after the date of such dispensing" and
14	inserting "in as close to real time as practicable";
15	(4) in subsection (f)(1)(D), by striking "med-
16	icaid" and inserting "Medicaid";
17	(5) in subsection (i), by inserting ", in collabo-
18	ration with the National Coordinator for Health In-
19	formation Technology and the Director of the Na-
20	tional Institute of Standards and Technology," after
21	"The Secretary"; and
22	(6) in subsection (n), by striking "2021" and
23	inserting "2026".
24	SEC. 508. JESSIE'S LAW.
25	(a) Best Practices.—

1	(1) In General.—Not later than 1 year after
2	the date of enactment of this Act, the Secretary of
3	Health and Human Services (referred to in this sec-
4	tion as the "Secretary"), in consultation with appro-
5	priate stakeholders, including a patient with a his-
6	tory of opioid use disorder, an expert in electronic
7	health records, an expert in the confidentiality of pa-
8	tient health information and records, and a health
9	care provider, shall identify or facilitate the develop-
10	ment of best practices regarding—
11	(A) the circumstances under which infor-
12	mation that a patient has provided to a health
13	care provider regarding such patient's history of
14	opioid use disorder should, only at the patient's
15	request, be prominently displayed in the med-
16	ical records (including electronic health records)
17	of such patient;
18	(B) what constitutes the patient's request
19	for the purpose described in subparagraph (A);
20	and
21	(C) the process and methods by which the
22	information should be so displayed.
23	(2) Dissemination.—The Secretary shall dis-
24	seminate the best practices developed under para-

1	graph (1) to health care providers and State agen-
2	cies.
3	(b) REQUIREMENTS.—In identifying or facilitating
4	the development of best practices under subsection (a), as
5	applicable, the Secretary, in consultation with appropriate
6	stakeholders, shall consider the following:
7	(1) The potential for addiction relapse or over-
8	dose, including overdose death, when opioid medica-
9	tions are prescribed to a patient recovering from
10	opioid use disorder.
11	(2) The benefits of displaying information
12	about a patient's opioid use disorder history in a
13	manner similar to other potentially lethal medical
14	concerns, including drug allergies and contraindica-
15	tions.
16	(3) The importance of prominently displaying
17	information about a patient's opioid use disorder
18	when a physician or medical professional is pre-
19	scribing medication, including methods for avoiding
20	alert fatigue in providers.
21	(4) The importance of a variety of appropriate
22	medical professionals, including physicians, nurses,
23	and pharmacists, having access to information de-

24 seribed in this section when prescribing or dis-

1	pensing opioid medication, consistent with Federal
2	and State laws and regulations.
3	(5) The importance of protecting patient pri-
4	vacy, including the requirements related to consent
5	for disclosure of substance use disorder information
6	under all applicable laws and regulations.
7	(6) All applicable Federal and State laws and
8	regulations.
9	SEC. 509. DEVELOPMENT AND DISSEMINATION OF MODEL
10	TRAINING PROGRAMS FOR SUBSTANCE USE
11	DISORDER PATIENT RECORDS.
12	(a) Initial Programs and Materials.—Not later
13	than 1 year after the date of the enactment of this Act,
14	the Secretary of Health and Human Services (referred to
15	in this section as the "Secretary"), in consultation with
16	appropriate experts, shall identify the following model pro-
17	grams and materials (or if no such programs or materials
18	exist, recognize private or public entities to develop and
19	disseminate such programs and materials):
20	(1) Model programs and materials for training
21	health care providers (including physicians, emer-
22	gency medical personnel, psychiatrists, psychologists,
23	counselors, therapists, nurse practitioners, physician
24	assistants, behavioral health facilities and clinics,
25	eare managers, and hospitals, including individuals

1 such as general counsels or regulatory compliance 2 staff who are responsible for establishing provider 3 privacy policies) concerning the permitted uses and 4 disclosures, consistent with the standards and regulations governing the privacy and security of sub-5 6 stance use disorder patient records promulgated by the Secretary under section 543 of the Public 7 8 Health Service Act (42 U.S.C. 290dd-2) for the 9 confidentiality of patient records.

- (2) Model programs and materials for training patients and their families regarding their rights to protect and obtain information under the standards and regulations described in paragraph (1).
- (b) REQUIREMENTS.—The model programs and ma-15 terials described in paragraphs (1) and (2) of subsection 16 (a) shall address circumstances under which disclosure of 17 substance use disorder patient records is needed to—
 - (1) facilitate communication between substance use disorder treatment providers and other health care providers to promote and provide the best possible integrated care;
- 22 (2) avoid inappropriate prescribing that can
 23 lead to dangerous drug interactions, overdose, or re24 lapse; and

10

11

12

13

18

19

20

21

1	(3) notify and involve families and caregivers
2	when individuals experience an overdose.
3	(e) Periodic Updates.—The Secretary shall—
4	(1) periodically review and update the model
5	program and materials identified or developed under
6	subsection (a); and
7	(2) disseminate such updated programs and
8	materials to the individuals described in subsection
9	(a)(1).
10	(d) INPUT OF CERTAIN ENTITIES.—In identifying,
11	reviewing, or updating the model programs and materials
12	under this section, the Secretary shall solicit the input of
13	relevant stakeholders.
14	(e) Authorization of Appropriations.—There is
15	authorized to be appropriated to earry out this section,
16	such sums as may be necessary for each of fiscal years
17	2019 through 2023.
18	SEC. 510. COMMUNICATION WITH FAMILIES DURING EMER-
19	GENCIES.
20	(a) Promoting Awareness of Authorized Dis-
21	CLOSURES DURING EMERGENCIES. The Secretary of
22	Health and Human Services shall annually notify health
23	care providers regarding permitted disclosures during
24	emergencies, including overdoses, of certain health infor-

1	mation to families and caregivers under Federal health
2	eare privacy laws and regulations.
3	(b) USE OF MATERIAL.—For the purposes of car-
4	rying out subsection (a), the Secretary of Health and
5	Human Services may use material produced under section
6	509 of this Act or under section 11004 of the 21st Cen-
7	tury Cures Act (42 U.S.C. 1320d-2 note).
8	SEC. 511. PRENATAL AND POSTNATAL HEALTH.
9	Section 317L of the Public Health Service Act (42
10	U.S.C. 247b–13) is amended—
11	(1) in subsection (a)—
12	(A) by amending paragraph (1) to read as
13	follows:
14	"(1) to collect, analyze, and make available data
15	on prenatal smoking, alcohol and substance abuse
16	and misuse, including—
17	"(A) data on—
18	"(i) the incidence, prevalence, and im-
19	plications of such activities; and
20	"(ii) the incidence and prevalence of
21	implications and outcomes, including neo-
22	natal abstinence syndrome and other out-
23	comes associated with such activities; and
24	"(B) to inform such analysis, additional in-
25	formation or data on family health history

1	medication exposures during pregnancy, demo-
2	graphic information, such as race, ethnicity, ge-
3	ographic location, and family history, and other
4	relevant information, as appropriate;";
5	(B) in paragraph (2)—
6	(i) by striking "prevention of" and in-
7	serting "prevention and long-term out-
8	comes associated with"; and
9	(ii) by striking "illegal drug use" and
10	inserting "substance abuse and misuse";
11	(C) in paragraph (3), by striking "and ces-
12	sation programs; and" and inserting ", treat-
13	ment, and cessation programs;";
14	(D) in paragraph (4), by striking "illegal
15	drug use." and inserting "substance abuse and
16	misuse; and"; and
17	(E) by adding at the end the following:
18	"(5) to issue public reports on the analysis of
19	data described in paragraph (1), including analysis
20	of
21	"(A) long-term outcomes of children af-
22	feeted by neonatal abstinence syndrome;
23	"(B) health outcomes associated with pre-
24	natal smoking, alcohol, and substance abuse
25	and misuse; and

1	"(C) relevant studies, evaluations, or infor-
2	mation the Secretary determines to be appro-
3	priate.";
4	(2) in subsection (b), by inserting "tribal enti-
5	ties," after "local governments,";
6	(3) by redesignating subsection (e) as sub-
7	section (d);
8	(4) by inserting after subsection (b) the fol-
9	lowing:
10	"(c) Coordinating Activities.—To carry out this
11	section, the Secretary may—
12	"(1) provide technical and consultative assist-
13	ance to entities receiving grants under subsection
14	(b);
15	"(2) ensure a pathway for data sharing between
16	States, tribal entities, and the Centers for Disease
17	Control and Prevention;
18	"(3) ensure data collection under this section is
19	consistent with applicable State, Federal, and Tribal
20	privacy laws; and
21	"(4) coordinate with the National Coordinator
22	for Health Information Technology, as appropriate,
23	to assist States and tribes in implementing systems
24	that use standards recognized by such National Co-
25	ordinator, as such recognized standards are avail-

1	able, in order to facilitate interoperability between
2	such systems and health information technology sys-
3	tems, including certified health information tech-
4	nology."; and
5	(5) in subsection (d), as so redesignated, by
6	striking "2001 through 2005" and inserting "2019
7	through 2023".
8	SEC. 512. SURVEILLANCE AND EDUCATION REGARDING IN-
9	FECTIONS ASSOCIATED WITH INJECTION
10	DRUG USE AND OTHER RISK FACTORS.
11	Section 317N of the Public Health Service Act (42
12	U.S.C. 247b–15) is amended—
13	(1) by amending the section heading to read as
14	follows: "SURVEILLANCE AND EDUCATION RE-
15	GARDING INFECTIONS ASSOCIATED WITH IN-
16	JECTION DRUG USE AND OTHER RISK FAC-
17	TORS'';
18	(2) in subsection (a)—
19	(A) in the matter preceding paragraph (1),
20	by inserting "activities" before the colon;
21	(B) in paragraph (1)—
22	(i) by inserting "or maintaining" after
23	"implementing";
24	(ii) by striking "hepatitis C virus in-
25	fection (in this section referred to as 'HCV

1	infection')" and inserting "infections com-
2	monly associated with injection drug use,
3	including viral hepatitis and human im-
4	munodeficiency virus,"; and
5	(iii) by striking "such infection" and
6	all that follows through the period at the
7	end and inserting "such infections, which
8	may include the reporting of cases of such
9	infections.";
10	(C) in paragraph (2), by striking "HCV
11	infection" and all that follows through the pe-
12	riod at the end and inserting "infections as a
13	result of injection drug use, receiving blood
14	transfusions prior to July 1992, or other risk
15	factors.";
16	(D) in paragraphs (4) and (5), by striking
17	"HCV infection" each place such term appears
18	and inserting "infections described in para-
19	graph (1)"; and
20	(E) in paragraph (5), by striking "pedia-
21	tricians and other primary care physicians, and
22	obstetricians and gynecologists" and inserting
23	"substance use disorder treatment providers,
24	pediatricians, other primary care providers, and
25	obstetrician-evnecologists":

1	(3) in subsection (b)—
2	(A) by striking "directly and" and insert-
3	ing "directly or"; and
4	(B) by striking "hepatitis C," and all that
5	follows through the period at the end and in-
6	serting "infections described in subsection
7	(a)(1).'';
8	(4) by redesignating subsection (e) as sub-
9	section (d);
10	(5) by inserting after subsection (b) the fol-
11	lowing:
12	"(c) DEFINITION.—In this section, the term "injec-
13	tion drug use' means—
14	"(1) intravenous administration of a substance
15	in schedule I of section 202(e) of the Controlled
16	Substances Act;
17	"(2) intravenous administration of a substance
18	in schedule II, III, IV, or V of section 202(c) of the
19	Controlled Substances Act that has not been ap-
20	proved for intravenous use under section 505 of the
21	Federal Food, Drug and Cosmetic Act or section
22	351 of the Public Health Service Act; or
23	"(3) intravenous administration of a substance
24	in schedule H, HI, IV, or V of section 202(c) of the

1	Controlled Substances Act that has not been pre-
2	scribed to the person using the substance."; and
3	(6) in subsection (d), as so redesignated, by
4	striking "such sums as may be necessary for each of
5	the fiscal years 2001 through 2005" and inserting
6	"\$40,000,000 for each of fiscal years 2019 through
7	2023".
8	SEC. 513. TASK FORCE TO DEVELOP BEST PRACTICES FOR
9	TRAUMA-INFORMED IDENTIFICATION, RE-
10	FERRAL, AND SUPPORT.
11	(a) ESTABLISHMENT.—There is established a task
12	force, to be known as the Interagency Task Force on
13	Trauma-Informed Care (in this section referred to as the
14	"task force") that shall identify, evaluate, and make rec-
15	ommendations regarding best practices with respect to
16	children and youth, and their families as appropriate, who
17	have experienced or are at risk of experiencing trauma.
18	(b) Membership.—
19	(1) Composition.—The task force shall be
20	composed of the heads of the following Federal de-
21	partments and agencies, or their designees:
22	(A) The Centers for Medicare & Medicaid
23	Services.
24	(B) The Substance Abuse and Mental
25	Health Services Administration.

1	(C) The Agency for Healthcare Research
2	and Quality.
3	(D) The Centers for Disease Control and
4	Prevention.
5	(E) The Indian Health Service.
6	(F) The Department of Veterans Affairs.
7	(G) The National Institutes of Health.
8	(H) The Food and Drug Administration.
9	(I) The Health Resources and Services Ad-
10	ministration.
11	(J) The Department of Defense.
12	(K) The Office of Minority Health.
13	(L) The Administration for Children and
14	Families.
15	(M) The Office of the Assistant Secretary
16	for Planning and Evaluation.
17	(N) The Office for Civil Rights at the De-
18	partment of Health and Human Services.
19	(O) The Office of Juvenile Justice and De-
20	linquency Prevention of the Department of Jus-
21	tice.
22	(P) The Office of Community Oriented Po-
23	licing Services of the Department of Justice.
24	(Q) The Office on Violence Against
25	Women of the Department of Justice.

1	(R) The National Center for Education
2	Evaluation and Regional Assistance of the De-
3	partment of Education.
4	(S) The National Center for Special Edu-
5	eation Research of the Institute of Education
6	Science.
7	(T) The Office of Elementary and Sec-
8	ondary Education of the Department of Edu-
9	eation.
10	(U) The Office for Civil Rights at the De-
11	partment of Education.
12	(V) The Office of Special Education and
13	the Rehabilitative Services of the Department
14	of Education.
15	(W) the Bureau of Indian Affairs of the
16	Department of the Interior.
17	(X) The Veterans Health Administration
18	of the Department of Veterans Affairs.
19	(Y) The Office of Special Needs Assistance
20	Programs of the Department of Housing and
21	Urban Development.
22	(Z) The Office of Head Start of the Ad-
23	ministration for Children and Families.
24	(AA) The Children's Bureau of the Admin-
25	istration for Children and Families.

1	(BB) The Bureau of Indian Education of
2	the Department of the Interior.
3	(CC) Such other Federal agencies as the
4	Secretaries determine to be appropriate.
5	(2) Date of appointments.—The heads of
6	Federal departments and agencies shall appoint the
7	corresponding members of the task force not later
8	than 6 months after the date of enactment of this
9	Act.
10	(3) CHAIRPERSON.—The task force shall be
11	chaired by the Assistant Secretary for Mental
12	Health and Substance Use.
13	(e) Task Force Duties.—The task force shall—
14	(1) solicit input from stakeholders, including
15	frontline service providers, educators, mental health
16	professionals, researchers, experts in infant, child,
17	and youth trauma, child welfare professionals, and
18	the public, in order to inform the activities under
19	paragraph (2); and
20	(2) identify, evaluate, make recommendations,
21	and update such recommendations not less than an-
22	nually, to the general public, the Secretary of Edu-
23	eation, the Secretary of Health and Human Services,
24	the Secretary of Labor, the Secretary of the Inte-

1	rior, the Attorney General, and other relevant cabi-
2	net Secretaries, and Congress regarding—
3	(A) a set of evidence-based, evidence-in-
4	formed, and promising best practices with re-
5	spect to—
6	(i) the identification of infants, chil-
7	dren and youth, and their families as ap-
8	propriate, who have experienced or are at
9	risk of experiencing trauma; and
10	(ii) the expeditious referral to and im-
11	plementation of trauma-informed practices
12	and supports that prevent and mitigate the
13	effects of trauma;
14	(B) a national strategy on how the task
15	force and member agencies will collaborate,
16	prioritize options for, and implement a coordi-
17	nated approach which may include data sharing
18	and the awarding of grants that support chil-
19	dren and their families as appropriate, who
20	have experienced or are at risk of experiencing
21	trauma; and
22	(C) existing Federal authorities at the De-
23	partment of Education, Department of Health
24	and Human Services, Department of Justice,
25	Department of Labor, Department of Interior,

1	and other relevant agencies, and specific Fed-
2	eral grant programs to disseminate best prac-
3	tices on, provide training in, or deliver services
4	through, trauma-informed practices, and dis-
5	seminate such information—
6	(i) in writing to relevant program of-
7	fices at such agencies to encourage grant
8	applicants in writing to use such funds,
9	where appropriate, for trauma-informed
10	practices; and
11	(ii) to the general public through the
12	internet website of the task force.
13	(d) Best Practices.—In identifying, evaluating,
14	and recommending the set of best practices under sub-
15	section (e), the task force shall—
16	(1) include guidelines for providing professional
17	development for front-line services providers, includ-
18	ing school personnel, providers from child- or youth-
19	serving organizations, primary and behavioral health
20	eare providers, child welfare and social services pro-
21	viders, family and juvenile court judges and attor-
22	neys, health care providers, individuals who are
23	mandatory reporters of child abuse or neglect,
24	trained nonclinical providers (including peer mentors
25	and elergy), and first responders, in—

1	(A) understanding and identifying early
2	signs and risk factors of trauma in children and
3	youth, and their families as appropriate, includ-
4	ing through screening processes;
5	(B) providing practices to prevent and
6	mitigate the impact of trauma, including by fos-
7	tering safe and stable environments and rela-
8	tionships; and
9	(C) developing and implementing proce-
10	dures or systems that—
11	(i) are designed to quickly refer in-
12	fants, children, youth, and their families as
13	appropriate, who have experienced or are
14	at risk of experiencing trauma to the ap-
15	propriate trauma-informed screening and
16	support, including treatment appropriate
17	to the age of the child, and to ensure such
18	infants, children, youth, and family mem-
19	bers receive such support;
20	(ii) utilize and develop partnerships
21	with local social services organizations,
22	such as organizations serving youth, and
23	elinical mental health or health care service
24	providers with expertise in providing sup-
25	port services (including trauma-informed

1	and evidence-based treatment appropriate
2	to the age of the child) aimed at pre-
3	venting or mitigating the effects of trau-
4	ma;
5	(iii) educate children and youth to—
6	(I) understand and identify the
7	signs, effects, or symptoms of trauma;
8	and
9	(II) build the resilience and cop-
10	ing skills to mitigate the effects of ex-
11	periencing trauma;
12	(iv) promote and support multi-
13	generational practices that assist parents,
14	foster parents, and kinship and other care-
15	givers in accessing resources related to,
16	and developing environments conducive to,
17	the prevention and mitigation of trauma;
18	and
19	(v) collect and utilize data from
20	screenings, referrals, or the provision of
21	services and supports, conducted in the
22	covered settings, to evaluate and improve
23	processes for trauma-informed support and
24	outcomes that are culturally sensitive, lin-

1	guistically appropriate, and specific to age
2	ranges and sex, as applicable; and
3	(2) recommend best practices that are designed
4	to avoid unwarranted custody loss or criminal pen-
5	alties for parents or guardians in connection with in-
6	fants, children, and youth who have experienced or
7	are at risk of experiencing trauma.
8	(e) OPERATING PLAN.—Not later than 1 year after
9	the date of enactment of this Act, the task force shall hold
10	the first meeting. Not later than 2 years after such date
11	of enactment, the task force shall submit to the Secretary
12	of Education, Secretary of Health and Human Services,
13	Secretary of Labor, Secretary of the Interior, the Attorney
14	General, and Congress an operating plan for carrying out
15	the activities of the task force described in paragraphs (2)
16	and (3) of subsection (e). Such operating plan shall in-
17	elude—
18	(1) a list of specific activities that the task
19	force plans to carry out for purposes of carrying out
20	duties described in subsection (e)(2), which may in-
21	elude public engagement;
22	(2) a plan for carrying out the activities under
23	paragraphs (2) and (3) of subsection (e);
24	(3) a list of members of the task force and
25	other individuals who are not members of the task

1	force that may be consulted to carry out such activi-
2	ies;

- 3 (4) an explanation of Federal agency involve-
- 4 ment and coordination needed to carry out such ac-
- 5 tivities, including any statutory or regulatory bar-
- 6 riers to such coordination;
- 7 (5) a budget for carrying out such activities;
- 8 and
- 9 (6) other information that the task force deter-
- 10 mines appropriate.
- 11 (f) Final Report.—Not later than 3 years after the
- 12 date of the first meeting of the task force, the task force
- 13 shall submit to the general public, Secretary of Education,
- 14 Secretary of Health and Human Services, Secretary of
- 15 Labor, Secretary of the Interior, the Attorney General,
- 16 and other relevant cabinet Secretaries, and Congress, a
- 17 final report containing all of the findings and rec-
- 18 ommendations required under this section.
- 19 (g) AUTHORIZATION OF APPROPRIATIONS.—To carry
- 20 out this section, there are authorized to be appropriated
- 21 such sums as may be necessary for each of fiscal years
- 22 2019 through 2022.
- 23 (h) Sunser.—The task force shall on the date that
- 24 is 60 days after the submission of the final report under
- 25 subsection (f), but not later than September 30, 2022.

1	SEC. 514. GRANTS TO IMPROVE TRAUMA SUPPORT SERV-
2	ICES AND MENTAL HEALTH CARE FOR CHIL-
3	DREN AND YOUTH IN EDUCATIONAL SET-
4	TINGS.
5	(a) Grants, Contracts, and Cooperative
6	AGREEMENTS AUTHORIZED.—The Secretary, in coordina-
7	tion with the Director of Substance Abuse and Mental
8	Health Services Administration, is authorized to award
9	grants to, or enter into contracts or cooperative agree-
10	ments with, State educational agencies, local educational
11	agencies, Head Start agencies (including Early Head
12	Start agencies), State or local agencies that administer
13	public preschool programs, Indian tribes or their tribal
14	educational agencies, a school operated by the Bureau of
15	Indian Education, a Regional Corporation (as defined in
16	section 3 of the Alaska Native Claims Settlement Act (43
17	U.S.C. 1602)), or a Native Hawaiian educational organi-
18	zation (as defined in section 6207 of the Elementary and
19	Secondary Education Act of 1965 (20 U.S.C. 7517)), for
20	the purpose of increasing student access to evidence-based
21	trauma support services and mental health care by devel-
22	oping innovative initiatives, activities, or programs to link
23	local school systems with local trauma-informed support
24	and mental health systems, including those under the In-
25	dian Health Service

	143
1	(b) DURATION.—With respect to a grant, contract,
2	or cooperative agreement awarded or entered into under
3	this section, the period during which payments under such
4	grant, contract or agreement are made to the recipient
5	may not exceed 4 years.
6	(e) Use of Funds.—An entity that receives a grant,
7	contract, or cooperative agreement under this section shall
8	use amounts made available through such grant, contract,
9	or cooperative agreement for evidence-based or promising
10	activities, which shall include any of the following:
11	(1) Collaborative efforts between school-based
12	service systems and trauma-informed support and
13	mental health service systems to provide, develop, or
14	improve prevention, screening, referral, and treat-

- ment services to students, such as by providing universal trauma screenings to identify students in need of specialized support.
- (2) To implement multi-tiered positive behavioral interventions and supports, or other trauma-informed models of support.
- (3) To provide professional development to teachers, teacher assistants, school leaders, specialized instructional support personnel, and mental health professionals that—

15

16

17

18

19

20

21

22

23

24

1	(A) fosters safe and stable learning envi-
2	ronments that prevent and mitigate the effects
3	of trauma, including through social and emo-
4	tional learning;
5	(B) improves school capacity to identify,
6	refer, and provide services to students in need
7	of trauma support or behavioral health services;
8	Or
9	(C) reflects the best practices developed by
10	the Interagency Task Force on Trauma-In-
11	formed Care established under section 513.
12	(4) Engaging families and communities in ef-
13	forts to increase awareness of child and youth trau-
14	ma, which may include sharing best practices with
15	law enforcement regarding trauma-informed care
16	and working with mental health professionals to pro-
17	vide interventions, as well as longer term coordi-
18	nated care within the community for children and
19	youth who have experienced trauma and their fami-
20	lies.
21	(5) To provide technical assistance to school
22	systems and mental health agencies.
23	(6) To evaluate the effectiveness of the program
24	carried out under this section in increasing student

1	access to evidence-based trauma support services
2	and mental health care.
3	(d) APPLICATIONS.—To be eligible to receive a grant
4	contract, or cooperative agreement under this section, ar
5	entity described in subsection (a) shall submit an applica-
6	tion to the Secretary at such time, in such manner, and
7	containing such information as the Secretary may reason-
8	ably require, which shall include the following:
9	(1) A description of the program to be funded
10	under the grant, contract, or cooperative agreement
11	including how such program will increase access to
12	evidence-based trauma support services and menta
13	health eare for students, and, as applicable, the fam-
14	ilies of the students.
15	(2) A description of how the program will pro-
16	vide linguistically appropriate and culturally com-
17	petent services.
18	(3) A description of how the program will sup-
19	port students and the school in improving the school
20	elimate in order to support an environment condu-
21	eive to learning.
22	(4) An assurance that—
23	(A) persons providing services under the
24	grant, contract, or cooperative agreement are
25	adequately trained to provide such services; and

(B) teachers, school leaders, administra-tors, specialized instructional support personnel, representatives of local Indian tribes as appro-priate, other school personnel, and parents or guardians of students participating in services under this section will be engaged and involved in the design and implementation of the serv-ices.

(5) A description of how the applicant will support and integrate existing school-based services with the program in order to provide mental health services for students, as appropriate.

(e) Interagency Agreements.—

- (1) DESIGNATION OF LEAD AGENCY.—A recipient of a grant, contract, or cooperative agreement under this section shall designate a lead agency to direct the establishment of an interagency agreement among local educational agencies, juvenile justice authorities, mental health agencies, child welfare agencies, and other relevant entities in the State, in collaboration with local entities, such as Indian tribes.
- (2) Contents.—The interagency agreement shall ensure the provision of the services described in subsection (e), specifying with respect to each agency, authority, or entity—

1	(A) the financial responsibility for the serv-
2	ices;
3	(B) the conditions and terms of responsi-
4	bility for the services, including quality, ac-
5	countability, and coordination of the services;
6	and
7	(C) the conditions and terms of reimburse-
8	ment among the agencies, authorities, or enti-
9	ties that are parties to the interagency agree-
10	ment, including procedures for dispute resolu-
11	tion.
12	(f) EVALUATION.—The Secretary shall reserve not to
13	exceed 3 percent of the funds made available under sub-
14	section (l) for each fiscal year to—
15	(1) conduct a rigorous, independent evaluation
16	of the activities funded under this section; and
17	(2) disseminate and promote the utilization of
18	evidence-based practices regarding trauma support
19	services and mental health care.
20	(g) Distribution of Awards.—The Secretary shall
21	ensure that grants, contracts, and cooperative agreements
22	awarded or entered into under this section are equitably
23	distributed among the geographical regions of the United
24	States and among tribal, urban, suburban, and rural pop-
25	ulations.

1	(h) Rule of Construction.—Nothing in this sec-
2	tion shall be construed—
3	(1) to prohibit an entity involved with a pro-
4	gram carried out under this section from reporting
5	a crime that is committed by a student to appro-
6	priate authorities; or
7	(2) to prevent Federal, State, and tribal law en-
8	forcement and judicial authorities from exercising
9	their responsibilities with regard to the application
10	of Federal, tribal, and State law to crimes com-
11	mitted by a student.
12	(i) Supplement, Not Supplant.—Any services
13	provided through programs carried out under this section
14	shall supplement, and not supplant, existing mental health
15	services, including any special education and related serv-
16	ices provided under the Individuals with Disabilities Edu-
17	eation Act.
18	(j) Consultation With Indian Tribes.—In car-
19	rying out subsection (a), the Secretary shall, in a timely
20	manner, meaningfully consult, engage, and cooperate with
21	Indian tribes and their representatives to ensure notice of
22	eligibility.
23	(k) DEFINITIONS.—In this section:
24	(1) Elementary or secondary school.—
25	The term "elementary or secondary school" means a

1	public elementary and secondary school as such term
2	is defined in section 8101 of the Elementary and
3	Secondary Education Act of 1965 (20 U.S.C. 7801).
4	(2) EVIDENCE-BASED.—The term "evidence-

- (2) EVIDENCE-BASED.—The term "evidence-based" has the meaning given such term in section 8101(21)(A)(i) of the Elementary and Secondary Education Act of 1965 (20 U.S.C. 7801(21)(A)(i)).
- 8 (3) SCHOOL LEADER.—The term "school lead-9 er" has the meaning given such term in section 10 8101 of the Elementary and Secondary Education 11 Act of 1965 (20 U.S.C. 7801).
- 12 (4) SECRETARY.—The term "Secretary" means 13 the Secretary of Education.
- 14 (5) SPECIALIZED INSTRUCTIONAL SUPPORT
 15 PERSONNEL.—The term "specialized instructional
 16 support personnel" has the meaning given such term
 17 in 8101 of the Elementary and Secondary Education
 18 Act of 1965 (20 U.S.C. 7801).
- (l) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to earry out this section, such sums as may be necessary for each of fiscal years 22 2019 through 2023.

5

6

1 SEC. 515. NATIONAL CHILD TRAUMATIC STRESS INITIA-

- 2 **TIVE.**
- 3 Section 582(j) of the Public Health Service Act (42)
- 4 U.S.C. 290hh-1(j)) is amended by striking "\$46,887,000
- 5 for each of fiscal years 2018 through 2022" and inserting
- 6 "\$53,887,000 for each of fiscal years 2019 through
- 7 2023".
- 8 SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
- 9 (a) Short Title.—This Act may be cited as the
- 10 "Opioid Crisis Response Act of 2018".
- 11 (b) Table of Contents of this
- 12 Act is as follows:
 - Sec. 1. Short title; table of contents.
 - Sec. 2. Definitions.

TITLE I—REAUTHORIZATION OF CURES FUNDING

Sec. 101. State response to the opioid abuse crisis.

TITLE II—RESEARCH AND INNOVATION

- Sec. 201. Advancing cutting-edge research.
- Sec. 202. Pain research.

TITLE III—MEDICAL PRODUCTS AND CONTROLLED SUBSTANCES SAFETY

- Sec. 301. Clarifying FDA regulation of non-addictive pain products.
- Sec. 302. Clarifying FDA packaging authorities.
- Sec. 303. Strengthening FDA and CBP coordination and capacity.
- Sec. 304. Clarifying FDA post-market authorities.
- Sec. 305. Restricting entrance of illicit drugs.
- Sec. 306. First responder training.
- Sec. 307. Disposal of controlled substances of hospice patients.
- Sec. 308. GAO study and report on hospice safe drug management.
- Sec. 309. Delivery of a controlled substance by a pharmacy to be administered by injection or implantation.

TITLE IV—TREATMENT AND RECOVERY

- Sec. 401. Comprehensive opioid recovery centers.
- Sec. 402. Program to support coordination and continuation of care for drug overdose patients.

- Sec. 403. Alternatives to opioids.
- Sec. 404. Building communities of recovery.
- Sec. 405. Peer support technical assistance center.
- Sec. 406. Medication-assisted treatment for recovery from addiction.
- Sec. 407. Grant program.
- Sec. 408. Allowing for more flexibility with respect to medication-assisted treatment for opioid use disorders.
- Sec. 409. National recovery housing best practices.
- Sec. 410. Addressing economic and workforce impacts of the opioid crisis.
- Sec. 411. Youth prevention and recovery.
- Sec. 412. Plans of safe care.
- Sec. 413. Regulations relating to special registration for telemedicine.
- Sec. 414. National Health Service Corps behavioral and mental health professionals providing obligated service in schools and other community-based settings.
- Sec. 415. Loan repayment for substance use disorder treatment providers.
- Sec. 416. Protecting moms and infants.
- Sec. 417. Early interventions for pregnant women and infants.
- Sec. 418. Report on investigations regarding parity in mental health and substance use disorder benefits.

TITLE V—PREVENTION

- Sec. 501. Study on prescribing limits.
- Sec. 502. Programs for health care workforce.
- Sec. 503. Education and awareness campaigns.
- Sec. 504. Enhanced controlled substance overdoses data collection, analysis, and dissemination.
- Sec. 505. Preventing overdoses of controlled substances.
- Sec. 506. CDC surveillance and data collection for child, youth, and adult trauma
- Sec. 507. Reauthorization of NASPER.
- Sec. 508. Jessie's law.
- Sec. 509. Development and dissemination of model training programs for substance use disorder patient records.
- Sec. 510. Communication with families during emergencies.
- Sec. 511. Prenatal and postnatal health.
- Sec. 512. Surveillance and education regarding infections associated with illicit drug use and other risk factors.
- Sec. 513. Task force to develop best practices for trauma-informed identification, referral, and support.
- Sec. 514. Grants to improve trauma support services and mental health care for children and youth in educational settings.
- Sec. 515. National Child Traumatic Stress Initiative.

1 SEC. 2. DEFINITIONS.

- 2 In this Act—
- 3 (1) the terms "Indian tribe" and "tribal organi-
- 4 zation" have the meanings given such terms in section

1	4 of the Indian Self-Determination and Education
2	Assistance Act (25 U.S.C. 5304); and
3	(2) the term "Secretary" means the Secretary of
4	Health and Human Services, unless otherwise speci-
5	fied.
6	TITLE I—REAUTHORIZATION OF
7	CURES FUNDING
8	SEC. 101. STATE RESPONSE TO THE OPIOID ABUSE CRISIS.
9	(a) In General.—Section 1003 of the 21st Century
10	Cures Act (Public Law 114–255) is amended—
11	(1) in subsection (a)—
12	(A) by striking "the authorization of appro-
13	priations under subsection (b) to carry out the
14	grant program described in subsection (c)" and
15	inserting "subsection (h) to carry out the grant
16	program described in subsection (b)"; and
17	(B) by inserting "and Indian tribes" after
18	"States"
19	(2) by striking subsection (b);
20	(3) by redesignating subsections (c) through (e)
21	as subsections (b) through (d), respectively;
22	(4) by redesignating subsection (f) as subsection
23	(j);
24	(5) in subsection (b), as so redesignated—
25	(A) in paragraph (1)—

1	(i) in the paragraph heading, by in-
2	serting "AND INDIAN TRIBE" after "STATE"
3	(ii) by striking "States for the purpose
4	of addressing the opioid abuse crisis within
5	such States" and inserting "States and In-
6	dian tribes for the purpose of addressing the
7	opioid abuse crisis within such States and
8	Indian tribes";
9	(iii) by inserting "or Indian tribes"
10	after "preference to States"; and
11	(iv) by inserting before the period of
12	the second sentence "or other Indian tribes,
13	as applicable";
14	(B) in paragraph (2)—
15	(i) in the matter preceding subpara-
16	graph (A), by striking "to a State";
17	(ii) in subparagraph (A), by striking
18	"State";
19	(iii) in subparagraph (C), by inserting
20	"preventing diversion of controlled sub-
21	stances," after "treatment programs,"; and
22	(iv) in subparagraph (E), by striking
23	"as the State determines appropriate, re-
24	lated to addressing the opioid abuse crisis
25	within the State" and inserting "as the

1	State or Indian tribe determines appro-
2	priate, related to addressing the opioid
3	abuse crisis within the State, including di-
4	recting resources in accordance with local
5	needs related to substance use disorders";
6	(6) in subsection (c), as so redesignated, by strik-
7	ing "subsection (c)" and inserting "subsection (b)";
8	(7) in subsection (d), as so redesignated—
9	(A) in the matter preceding paragraph (1),
10	by striking "the authorization of appropriations
11	under subsection (b)" and inserting "subsection
12	(h)"; and
13	(B) in paragraph (1), by striking "sub-
14	section (c)" and inserting "subsection (b)"; and
15	(8) by inserting after subsection (d), as so redes-
16	ignated, the following:
17	"(e) Indian Tribes.—
18	"(1) Definition.—For purposes of this section,
19	the term 'Indian tribe' has the meaning given such
20	term in section 4 of the Indian Self-Determination
21	and Education Assistance Act (25 U.S.C. 5304).
22	"(2) Appropriate mechanisms.—The Sec-
23	retary, in consultation with Indian tribes, shall iden-
24	tify and establish appropriate mechanisms for tribes

- 1 to demonstrate or report the information as required
- 2 under subsections (b), (c), and (d).
- 3 "(f) Report to Congress.—Not later than 1 year
- 4 after the date on which amounts are first awarded after
- 5 the date of enactment of the Opioid Crisis Response Act
- 6 of 2018, pursuant to subsection (b), and annually there-
- 7 after, the Secretary shall submit to the Committee on
- 8 Health, Education, Labor, and Pensions of the Senate and
- 9 the Committee on Energy and Commerce of the House of
- 10 Representatives a report summarizing the information pro-
- 11 vided to the Secretary in reports made pursuant to sub-
- 12 section (c), including the purposes for which grant funds
- 13 are awarded under this section and the activities of such
- 14 grant recipients.
- 15 "(g) Technical Assistance.—The Secretary, includ-
- 16 ing through the Tribal Training and Technical Assistance
- 17 Center of the Substance Abuse and Mental Health Services
- 18 Administration, shall provide State agencies and Indian
- 19 tribes, as applicable, with technical assistance concerning
- 20 grant application and submission procedures under this
- 21 section, award management activities, and enhancing out-
- 22 reach and direct support to rural and underserved commu-
- 23 nities and providers in addressing the opioid crisis.
- 24 "(h) Authorization of Appropriations.—For pur-
- 25 poses of carrying out the grant program under subsection

1	(b), there are authorized to be appropriated \$500,000,000
2	for each of fiscal years 2019 through 2021, to remain avail-
3	able until expended.
4	"(i) Set Aside.—Of the amounts made available for
5	each fiscal year to award grants under subsection (b) for
6	a fiscal year, 5 percent of such amount for such fiscal year
7	shall be made available to Indian tribes, and up to 15 per-
8	cent of such amount for such fiscal year may be set aside
9	for States with the highest age-adjusted rate of drug over-
10	dose death based on the ordinal ranking of States according
11	to the Director of the Centers for Disease Control and Pre-
12	vention.".
13	(b) Conforming Amendment.—Section 1004(c) of the
14	21st Century Cures Act (Public Law 114–255) is amended
15	by striking ", the FDA Innovation Account, or the Account
16	For the State Response to the Opioid Abuse Crisis" and
17	inserting "or the FDA Innovation Account".
18	TITLE II—RESEARCH AND
19	INNOVATION
20	SEC. 201. ADVANCING CUTTING-EDGE RESEARCH.
21	Section $402(n)(1)$ of the Public Health Service Act (42)
22	U.S.C. 282(n)(1)) is amended—
23	(1) in subparagraph (A), by striking "or";
24	(2) in subparagraph (B), by striking the period
25	and inserting "; or"; and

1	(3) by adding at the end the following:
2	"(C) high impact cutting-edge research that
3	fosters scientific creativity and increases funda-
4	mental biological understanding leading to the
5	prevention, diagnosis, or treatment of diseases
6	and disorders, or research urgently required to
7	respond to a public health threat.".
8	SEC. 202. PAIN RESEARCH.
9	Section 409 $J(b)$ of the Public Health Service Act (42)
10	U.S.C. 284q(b)) is amended—
11	(1) in paragraph (5)—
12	(A) in subparagraph (A), by striking "and
13	treatment of pain and diseases and disorders as-
14	sociated with pain" and inserting "treatment,
15	and management of pain and diseases and dis-
16	orders associated with pain, including informa-
17	tion on best practices for utilization of non-phar-
18	macologic treatments, non-addictive medical
19	products, and other drugs approved, or devices
20	approved or cleared, by the Food and Drug Ad-
21	ministration";
22	(B) in subparagraph (B), by striking "on
23	the symptoms and causes of pain;" and inserting
24	the following: "on—

1	"(i) the symptoms and causes of pain,
2	including the identification of relevant bio-
3	markers and screening models;
4	"(ii) the diagnosis, prevention, treat-
5	ment, and management of pain; and
6	"(iii) risk factors for, and early warn-
7	ing signs of, substance use disorders; and";
8	and
9	(C) by striking subparagraphs (C) through
10	(E) and inserting the following:
11	"(C) make recommendations to the Director
12	of NIH—
13	"(i) to ensure that the activities of the
14	National Institutes of Health and other
15	Federal agencies are free of unnecessary du-
16	plication of effort;
17	"(ii) on how best to disseminate infor-
18	mation on pain care; and
19	"(iii) on how to expand partnerships
20	between public entities and private entities
21	to expand collaborative, cross-cutting re-
22	search.";
23	(2) by redesignating paragraph (6) as para-
24	graph (7); and

1	(3) by inserting after paragraph (5) the fol-
2	lowing:
3	"(6) Report.—The Director of NIH shall ensure
4	that recommendations and actions taken by the Direc-
5	tor with respect to the topics discussed at the meetings
6	described in paragraph (4) are included in appro-
7	priate reports to Congress.".
8	TITLE III—MEDICAL PRODUCTS
9	AND CONTROLLED SUB-
10	STANCES SAFETY
11	SEC. 301. CLARIFYING FDA REGULATION OF NON-ADDICT-
12	IVE PAIN PRODUCTS.
13	(a) Public Meetings.—Not later than 1 year after
14	the date of enactment of this Act, the Secretary, acting
15	through the Commissioner of Food and Drugs, shall hold
16	not less than one public meeting to address the challenges
17	and barriers of developing non-addictive medical products
18	intended to treat pain or addiction, which may include—
19	(1) the manner by which the Secretary may in-
20	corporate the risks of misuse and abuse of a controlled
21	substance (as defined in section 102 of the Controlled
22	Substances Act (21 U.S.C. 802) into the risk benefit
23	assessments under subsections (d) and (e) of section
24	505 of the Federal Food, Drug, and Cosmetic Act (21
25	U.S.C. 355), section 510(k) of such Act (21 U.S.C.

- 360(k)), or section 515(c) of such Act (21 U.S.C.
 360e(c)), as applicable;
- (2) the application of novel clinical trial designs 3 4 (consistent with section 3021 of the 21st Century 5 Cures Act (Public Law 114–255)), use of real world 6 evidence (consistent with section 505F of the Federal 7 Food, Drug, and Cosmetic Act (21 U.S.C. 355g)), and 8 use of patient experience data (consistent with section 9 569C of the Federal Food, Drug, and Cosmetic Act 10 (21 U.S.C. 360bbb-8c)) for the development of non-11 addictive medical products intended to treat pain or 12 addiction:
 - (3) the evidentiary standards and the development of opioid sparing data for inclusion in the labeling of medical products; and
 - (4) the application of eligibility criteria under sections 506 and 515B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356, 360e-3) for non-addictive medical products intended to treat pain or addiction.
- 21 (b) GUIDANCE.—Not less than one year after the public 22 meetings are conducted under subsection (a) the Secretary 23 shall issue one or more final guidance documents, or update 24 existing guidance documents, to help address challenges to 25 developing non-addictive medical products to treat pain or

13

14

15

16

17

18

19

1	addiction. Such guidance documents shall include informa-
2	tion regarding—
3	(1) how the Food and Drug Administration may
4	apply sections 506 and 515B of the Federal Food,
5	Drug, and Cosmetic Act (21 U.S.C. 356, 360e-3) to
6	non-addictive medical products intended to treat pain
7	or addiction, including the circumstances under
8	which the Secretary—
9	(A) may apply the eligibility criteria under
10	such sections 506 and 515B to non-addictive
11	medical products intended to treat pain or ad-
12	diction;
13	(B) considers the risk of addiction of con-
14	trolled substances approved to treat pain when
15	establishing unmet medical need; and
16	(C) considers pain, pain control, or pain
17	management in assessing whether a disease or
18	condition is a serious or life-threatening disease
19	$or\ condition;$
20	(2) the methods by which sponsors may evaluate
21	acute and chronic pain, endpoints for non-addictive
22	medical products intended to treat pain, the manner
23	in which endpoints and evaluations of efficacy will be
24	applied across and within review divisions, taking
25	into consideration the etiology of the underlying dis-

1	ease, and the manner in which sponsors may use sur-
2	rogate endpoints, intermediate endpoints, and real
3	world evidence;
4	(3) the manner in which the Food and Drug Ad-
5	ministration will assess evidence to support the inclu-
6	sion of opioid sparing data in the labeling of non-ad-
7	dictive medical products intended to treat pain, in-
8	cluding—
9	(A) data collection methodologies, including
10	the use of novel clinical trial designs (consistent
11	with section 3021 of the 21st Century Cures Act
12	(Public Law 114–255)) and real world evidence
13	(consistent with section 505F of the Federal
14	Food, Drug, and Cosmetic Act (21 U.S.C. 355g)),
15	as appropriate, to support product labeling;
16	(B) ethical considerations of exposing sub-
17	jects to controlled substances in clinical trials to
18	develop opioid sparing data and considerations
19	on data collection methods that reduce harm,
20	which may include the reduction of opioid use as
21	a clinical benefit;
22	(C) endpoints, including primary, sec-
23	ondary, and surrogate endpoints, to evaluate the

reduction of opioid use;

1	(D) best practices for communication be-
2	tween sponsors and the agency on the develop-
3	ment of data collection methods, including the
4	initiation of data collection; and
5	(E) the appropriate format to submit such
6	data results to the Secretary; and
7	(4) the circumstances under which the Food and
8	Drug Administration considers misuse and abuse of a
9	controlled substance (as defined in section 102 of the
10	Controlled Substances Act (21 U.S.C. 802) in making
11	the risk benefit assessment under paragraphs (2) and
12	(4) of subsection (d) of section 505 of the Federal
13	Food, Drug, and Cosmetic Act (21 U.S.C. 355) and
14	in finding that a drug is unsafe under paragraph (1)
15	or (2) of subsection (e) of such section.
16	(c) Definitions.—In this section—
17	(1) the term "medical product" means a drug
18	(as defined in section $201(g)(1)$ of the Federal Food,
19	Drug, and Cosmetic Act (21 U.S.C. 321(g)(1))), bio-
20	logical product (as defined in section 351(i) of the
21	Public Health Service Act (42 U.S.C. 262(i))), or de-
22	vice (as defined in section 201(h) of the Federal Food,
23	Drug, and Cosmetic Act (21 U.S.C. 321(h))); and

1	(2) the term "opioid sparing" means reducing,
2	replacing, or avoiding the use of opioids or other con-
3	$trolled\ substances.$
4	SEC. 302. CLARIFYING FDA PACKAGING AUTHORITIES.
5	(a) Additional Potential Elements of Strat-
6	EGY.—Section 505–1(e) of the Federal Food, Drug, and
7	Cosmetic Act (21 U.S.C. 355-1(e)) is amended by adding
8	at the end the following:
9	"(4) Packaging and disposal.—The Secretary
10	may require a risk evaluation mitigation strategy for
11	a drug for which there is a serious risk of an adverse
12	drug experience described in subparagraph (B) or (C)
13	of subsection (b)(1), taking into consideration the fac-
14	tors described in subparagraphs (C) and (D) of sub-
15	section (f)(2) and in consultation with other relevant
16	Federal agencies with authorities over drug pack-
17	aging, which may include requiring that—
18	"(A) the drug be made available for dis-
19	pensing to certain patients in unit dose pack-
20	aging, packaging that provides a set duration, or
21	another packaging system that the Secretary de-
22	termines may mitigate such serious risk; or
23	"(B) the drug be dispensed to certain pa-
24	tients with a safe disposal packaging or safe dis-
25	posal system for purposes of rendering drugs

1	non-retrievable (as defined in section 1300.05 of
2	title 21, Code of Federal Regulations (or any
3	successor regulation)) if the Secretary has deter-
4	mines that such safe disposal packaging or sys-
5	tem may mitigate such serious risk and exists in
6	sufficient quantities.".
7	(b) Assuring Access and Minimizing Burden.—
8	Section 505–1(f)(2)(C) of the Federal Food, Drug, and Cos-
9	metic Act (21 U.S.C. 355–1(f)(2)(C)) is amended—
10	(1) in clause (i) by striking "and" at the end;
11	and
12	(2) by adding at the end the following:
13	"(iii) patients with functional needs;
14	and".
15	(c) Application to Abbreviated New Drug Appli-
16	CATIONS.—Section 505–1(i) of the Federal Food, Drug, and
17	Cosmetic Act (21 U.S.C. 355–1(i)) is amended—
18	(1) in paragraph (1)—
19	(A) by redesignating subparagraph (B) as
20	subparagraph (C); and
21	(B) inserting after subparagraph (A) the
22	following:
23	"(B) A packaging or disposal requirement,
24	if required under subsection (e)(4) for the appli-
25	cable listed drug."; and

1	(2) in paragraph (2)—
2	(A) in subparagraph (A), by striking "and"
3	at the end;
4	(B) by redesignating subparagraph (B) as
5	subparagraph (C); and
6	(C) by inserting after subparagraph (A) the
7	following:
8	"(B) shall permit packaging systems and
9	safe disposal packaging or safe disposal systems
10	that are different from those required for the ap-
11	$plicable \ \ listed \ \ drug \ \ under \ \ subsection \ \ (e)(4);$
12	and".
1 4	
	SEC. 303. STRENGTHENING FDA AND CBP COORDINATION
13 14	SEC. 303. STRENGTHENING FDA AND CBP COORDINATION AND CAPACITY.
13	
13 14	AND CAPACITY.
13 14 15	AND CAPACITY. (a) In General.—The Secretary, acting through the
13 14 15 16	AND CAPACITY. (a) In General.—The Secretary, acting through the Commissioner of Food and Drugs, shall coordinate with the
113 114 115 116 117	AND CAPACITY. (a) In General.—The Secretary, acting through the Commissioner of Food and Drugs, shall coordinate with the Secretary of Homeland Security to carry out activities re-
13 14 15 16 17 18	AND CAPACITY. (a) In General.—The Secretary, acting through the Commissioner of Food and Drugs, shall coordinate with the Secretary of Homeland Security to carry out activities related to customs and border protection and response to ille-
13 14 15 16 17 18 19 20	AND CAPACITY. (a) In General.—The Secretary, acting through the Commissioner of Food and Drugs, shall coordinate with the Secretary of Homeland Security to carry out activities related to customs and border protection and response to illegal controlled substances and drug imports, including at
13 14 15 16 17 18 19 20 21	AND CAPACITY. (a) In General.—The Secretary, acting through the Commissioner of Food and Drugs, shall coordinate with the Secretary of Homeland Security to carry out activities related to customs and border protection and response to illegal controlled substances and drug imports, including at sites of import (such as international mail facilities). Such
13 14 15 16 17 18 19 20 21	AND CAPACITY. (a) IN GENERAL.—The Secretary, acting through the Commissioner of Food and Drugs, shall coordinate with the Secretary of Homeland Security to carry out activities related to customs and border protection and response to illegal controlled substances and drug imports, including at sites of import (such as international mail facilities). Such Secretaries may carry out such activities through a memo-

1	(b) FDA IMPORT FACILITIES AND INSPECTION CAPAC-
2	ITY.—
3	(1) In general.—In carrying out this section,
4	the Secretary shall, in collaboration with the Sec-
5	retary of Homeland Security and the Postmaster
6	General of the United States Postal Service, provide
7	that import facilities in which the Food and Drug
8	Administration operates or carries out activities re-
9	lated to drug imports within the international mail
10	facilities include—
11	(A) facility upgrades and improved capac-
12	ity in order to increase and improve inspection
13	and detection capabilities, which may include, as
14	the Secretary determines appropriate—
15	(i) improvements to facilities, such as
16	upgrades or renovations, and support for
17	the maintenance of existing import facilities
18	and sites to improve coordination between
19	$Federal\ agencies;$
20	(ii) the construction of, or upgrades to,
21	laboratory capacity for purposes of detec-
22	tion and testing of imported goods;
23	(iii) upgrades to the security of import
24	facilities; and

1	(iv) innovative technology and equip-
2	ment to facilitate improved and near-real-
3	time information sharing between the Food
4	and Drug Administration, the Department
5	of Homeland Security, and the United
6	States Postal Service; and
7	(B) innovative technology, including con-
8	trolled substance detection and testing equipment
9	and other applicable technology, in order to col-
10	laborate with United States Customs and Border
11	Protection to share near-real-time information,
12	including information about test results, as ap-
13	propriate.
14	(2) Innovative technology.—Any technology
15	used in accordance with paragraph (1)(B) shall be
16	interoperable with technology used by other relevant
17	Federal agencies, including the United States Cus-
18	toms and Border Protection, as the Secretary deter-
19	mines appropriate.
20	(c) Report.—Not later than 6 months after the date
21	of enactment of this Act, the Secretary, in consultation with
22	the Secretary of Homeland Security and the Postmaster
23	General of the United States Postal Service, shall report
24	to the relevant committees of Congress on the implementa-
25	tion of this section, including a summary of progress made

- 1 towards near-real-time information sharing and the inter-
- 2 operability of such technologies.
- 3 (d) Authorization of Appropriations.—Out of
- 4 amounts otherwise available to the Secretary, the Secretary
- 5 may allocate such sums as may be necessary for purposes
- 6 of carrying out this section.

7 SEC. 304. CLARIFYING FDA POST-MARKET AUTHORITIES.

- 8 Section 505-1(b)(1)(E) of the Federal Food, Drug, and
- 9 Cosmetic Act (21 U.S.C. 355-1(b)(1)(E)) is amended by
- 10 striking "of the drug" and inserting "of the drug, which
- 11 may include reduced effectiveness under the conditions of
- 12 use prescribed in the labeling of such drug, but which may
- 13 not include reduced effectiveness that is in accordance with
- 14 such labeling".

15 SEC. 305. RESTRICTING ENTRANCE OF ILLICIT DRUGS.

- 16 (a) In General.—The Secretary, acting through the
- 17 Commissioner of Food and Drugs, upon discovering or re-
- 18 ceiving, in a package being offered for import, a controlled
- 19 substance that is offered for import in violation of any re-
- 20 quirement of the Controlled Substances Act (21 U.S.C. 801
- 21 et seq.), the Controlled Substances Import and Export Act
- 22 (21 U.S.C. 951 et seq.), the Federal Food, Drug, and Cos-
- 23 metic Act (21 U.S.C. 301 et seq.), or any other applicable
- 24 law, shall transfer such package to the U.S. Customs and
- 25 Border Protection. If the Secretary identifies additional

1	packages that appear to be the same as such package con-
2	taining a controlled substance, such additional packages
3	may also be transferred to U.S. Customs and Border Protec-
4	tion. The U.S. Customs and Border Protection shall receive
5	such packages consistent with the requirements of the Con-
6	trolled Substances Act (21 U.S.C. 801 et seq.).
7	(b) Debarment, Temporary Denial of Approval,
8	and Suspension.—
9	(1) In general.—Section 306(b) of the Federal
10	Food, Drug, and Cosmetic Act (21 U.S.C. 335a(b)) is
11	amended—
12	(A) in paragraph (1)—
13	(i) in the matter preceding subpara-
14	graph (A), by inserting "or (3)" after
15	"paragraph (2)";
16	(ii) in subparagraph (A), by striking
17	the comma at the end and inserting a semi-
18	colon;
19	(iii) in subparagraph (B), by striking
20	", or" and inserting a semicolon;
21	(iv) in subparagraph (C), by striking
22	the period and inserting "; or"; and
23	(v) by adding at the end the following:
24	"(D) a person from importing or offering
25	for import into the United States a drug."; and

1	(B) in paragraph (3)—
2	(i) in the heading, by striking "FOOD";
3	(ii) in subparagraph (A), by striking
4	"; or" and inserting a semicolon;
5	(iii) in subparagraph (B), by striking
6	the period and inserting "; or"; and
7	(iv) and by adding at the end the fol-
8	lowing:
9	"(C) the person has been convicted of a fel-
10	ony for conduct relating to the importation into
11	the United States of any drug or controlled sub-
12	stance (as defined in section 102 of the Con-
13	trolled Substances Act).".
14	(2) Prohibited act.—Section 301(cc) of the
15	Federal Food, Drug, and Cosmetic Act (21 U.S.C.
16	331(cc)) is amended by inserting "or a drug" after
17	"food".
18	(c) Imports and Exports.—Section 801(a) of the
19	Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381(a))
20	is amended—
21	(1) by striking the second sentence;
22	(2) by striking "If it appears" and inserting
23	"Subject to subsection (b), if it appears";
24	(3) by striking "regarding such article, then such
25	article shall be refused" and inserting the following:

1	"regarding such article, or (5) such article is being
2	imported or offered for import in violation of section
3	301(cc), then any such article described in any of
4	clauses (1) through (5) may be refused admission. If
5	it appears from the examination of such samples or
6	otherwise that the article is a counterfeit drug, such
7	article shall be refused admission.";
8	(4) by striking "this Act, then such article shall
9	be refused admission" and inserting "this Act, then
10	such article may be refused admission"; and
11	(5) by striking "Clause (2) of the third sentence"
12	and all that follows through the period at the end and
13	inserting the following: "Neither clause (2) nor clause
14	(5) of the second sentence of this subsection shall be
15	construed to prohibit the admission of narcotic drugs,
16	the importation of which is permitted under the Con-
17	trolled Substances Import and Export Act.".
18	SEC. 306. FIRST RESPONDER TRAINING.
19	Section 546 of the Public Health Service Act (42
20	U.S.C. 290ee–1) is amended—
21	(1) in subsection (c)—
22	(A) in paragraph (2), by striking "and" at
23	$the\ end;$
24	(B) in paragraph (3), by striking the period
25	and insertina ": and": and

1	(C) by adding at the end the following:
2	"(4) train and provide resources for first re-
3	sponders and members of other key community sectors
4	on safety around fentanyl, carfentanil, and other dan-
5	gerous licit and illicit drugs to protect themselves
6	from exposure to such drugs and respond appro-
7	priately when exposure occurs.";
8	(2) in subsection (d), by striking "and mecha-
9	nisms for referral to appropriate treatment for an en-
10	tity receiving a grant under this section" and insert-
11	ing "mechanisms for referral to appropriate treat-
12	ment, and safety around fentanyl, carfentanil, and
13	other dangerous licit and illicit drugs";
14	(3) in subsection (f)—
15	(A) in paragraph (3), by striking "and" at
16	$the\ end;$
17	(B) in paragraph (4), by striking the period
18	and inserting "; and"; and
19	(C) by adding at the end the following:
20	"(5) the number of first responders and members
21	of other key community sectors trained on safety
22	around fentanyl, carfentanil, and other dangerous
23	licit and illicit drugs."; and
24	(4) in subsection (g), by striking "\$12,000,000
25	for each of fiscal years 2017 through 2021" and in-

1	serting "\$36,000,000 for each of fiscal years 2019
2	through 2023".
3	SEC. 307. DISPOSAL OF CONTROLLED SUBSTANCES OF HOS-
4	PICE PATIENTS.
5	(a) In General.—Section 302(g) of the Controlled
6	Substances Act (21 U.S.C. 822(g)) is amended by adding
7	at the end the following:
8	"(5)(A) An employee of a qualified hospice program
9	acting within the scope of employment may handle, in the
10	place of residence of a hospice patient, any controlled sub-
11	stance that was lawfully dispensed to the hospice patient,
12	for the purpose of assisting in the disposal of the controlled
13	substance—
14	"(i) after the hospice patient's death;
15	"(ii) if the controlled substance is expired; or
16	"(iii) if—
17	"(I) the employee is—
18	"(aa) the physician of the hospice pa-
19	tient; and
20	"(bb) registered under section 303(f);
21	and
22	"(II) the hospice patient no longer requires
23	the controlled substance because the plan of care
24	of the hospice patient has been modified.
25	"(B) In this paragraph:

1	"(i) The term 'employee of a qualified hospice
2	program' means a physician, physician assistant,
3	registered nurse, or nurse practitioner who—
4	"(I) is employed by, or is acting pursuant
5	to arrangements made with, a qualified hospice
6	program; and
7	"(II) is licensed or certified to perform such
8	employment, or such activities arranged by the
9	qualified hospice program, in accordance with
10	applicable State law.
11	"(ii) The terms 'hospice care' and 'hospice pro-
12	gram' have the meanings given those terms in section
13	1861(dd) of the Social Security Act (42 U.S.C.
14	1395x(dd)).
15	"(iii) The term 'hospice patient' means an indi-
16	vidual receiving hospice care.
17	"(iv) The term 'qualified hospice program'
18	means a hospice program that—
19	"(I) has written policies and procedures for
20	employees of the hospice program to use when as-
21	sisting in the disposal of the controlled sub-
22	stances of a hospice patient in a circumstance
23	described in clause (i), (ii), or (iii) of subpara-
24	graph(A);

1	"(II) at the time when the controlled sub-
2	stances are first ordered—
3	"(aa) provides a copy of the written
4	policies and procedures to the hospice pa-
5	tient or hospice patient representative and
6	the family of the hospice patient;
7	"(bb) discusses the policies and proce-
8	dures with the hospice patient or hospice
9	patient's representative and the hospice pa-
10	tient's family in a language and manner
11	that such individuals understand to ensure
12	that such individuals are informed regard-
13	ing the safe disposal of controlled sub-
14	stances; and
15	"(cc) documents in the clinical record
16	of the hospice patient that the written poli-
17	cies and procedures were provided and dis-
18	cussed with the hospice patient or hospice
19	patient's representative; and
20	"(III) at the time when an employee of the
21	hospice program assists in the disposal of con-
22	trolled substances of a hospice patient, documents
23	in the clinical record of the hospice patient a list
24	of all controlled substances disposed of.

- 1 "(C) The Attorney General may, by regulation, include
- 2 additional types of licensed medical professionals in the def-
- 3 inition of the term 'employee of a qualified hospice pro-
- 4 gram' under subparagraph (B).".
- 5 (b) No Registration Required.—Section 302(c) of
- 6 the Controlled Substances Act (21 U.S.C. 822(c)) is amend-
- 7 ed by adding at the end the following:
- 8 "(4) An employee of a qualified hospice program
- 9 for the purpose of assisting in the disposal of a con-
- $trolled\ substance\ in\ accordance\ with\ subsection\ (g)(5),$
- 11 except as provided in subparagraph (A)(iii) of that
- 12 subsection.".
- 13 (c) Guidance.—The Attorney General may issue
- 14 guidance to qualified hospice programs to assist the pro-
- 15 grams in satisfying the requirements under paragraph (5)
- 16 of section 302(g) of the Controlled Substances Act (21
- 17 U.S.C. 822(g)), as added by subsection (a).
- 18 (d) State and Local Authority.—Nothing in this
- 19 section or the amendments made by this section shall be
- 20 construed to prevent a State or local government from im-
- 21 posing additional controls or restrictions relating to the reg-
- 22 ulation of the disposal of controlled substances in hospice
- 23 care or hospice programs.

1	SEC. 308. GAO STUDY AND REPORT ON HOSPICE SAFE DRUG
2	MANAGEMENT.
3	(a) Study.—
4	(1) In general.—The Comptroller General of
5	the United States (in this section referred to as the
6	"Comptroller General") shall conduct a study on the
7	requirements applicable to and challenges of hospice
8	programs with regard to the management and dis-
9	posal of controlled substances in the home of an indi-
10	vidual.
11	(2) Contents.—In conducting the study under
12	paragraph (1), the Comptroller General shall in-
13	clude—
14	(A) an overview of challenges encountered
15	by hospice programs regarding the disposal of
16	controlled substances, such as opioids, in a home
17	setting, including any key changes in policies,
18	procedures, or best practices for the disposal of
19	controlled substances over time; and
20	(B) a description of Federal requirements,
21	including requirements under the Medicare pro-
22	gram, for hospice programs regarding the dis-
23	posal of controlled substances in a home setting,
24	and oversight of compliance with those require-

ments.

1	(b) Report.—Not later than 18 months after the date
2	of enactment of this Act, the Comptroller General shall sub-
3	mit to Congress a report containing the results of the study
4	conducted under subsection (a), together with recommenda-
5	tions, if any, for such legislation and administrative action
6	as the Comptroller General determines appropriate.
7	SEC. 309. DELIVERY OF A CONTROLLED SUBSTANCE BY A
8	PHARMACY TO BE ADMINISTERED BY INJEC-
9	TION OR IMPLANTATION.
10	(a) In General.—The Controlled Substances Act is
11	amended by inserting after section 309 (21 U.S.C. 829) the
12	following:
13	"DELIVERY OF A CONTROLLED SUBSTANCE BY A PHARMACY
14	TO AN ADMINISTERING PRACTITIONER
15	"Sec. 309A. (a) In General.—Notwithstanding sec-
16	tion 102(10), a pharmacy may deliver a controlled sub-
17	stance to a practitioner in accordance with a prescription
18	that meets the requirements of this title and the regulations
19	issued by the Attorney General under this title, for the pur-
20	pose of administering of the controlled substance by the
21	practitioner if—
22	"(1) the controlled substance is delivered by the
23	pharmacy to the prescribing practitioner or the prac-
24	titioner administering the controlled substance, as ap-
25	plicable, at the location listed on the practitioner's
26	certificate of registration issued under this title;

1	"(2) in the case of administering of the con-
2	trolled substance for the purpose of maintenance or
3	$detoxification\ treatment\ under\ section\ 303(g)(2)$ —
4	"(A) the practitioner who issued the pre-
5	scription is a qualifying practitioner authorized
6	under, and acting within the scope of that sec-
7	tion; and
8	"(B) the controlled substance is to be ad-
9	ministered by injection or implantation;
10	"(3) the pharmacy and the practitioner are au-
11	thorized to conduct the activities specified in this sec-
12	tion under the law of the State in which such activi-
13	ties take place;
14	"(4) the prescription is not issued to supply any
15	practitioner with a stock of controlled substances for
16	the purpose of general dispensing to patients;
17	"(5) except as provided in subsection (b), the
18	controlled substance is to be administered only to the
19	patient named on the prescription not later than 14
20	days after the date of receipt of the controlled sub-
21	stance by the practitioner; and
22	"(6) notwithstanding any exceptions under sec-
23	tion 307, the prescribing practitioner, and the practi-
24	tioner administering the controlled substance, as ap-
25	plicable, maintain complete and accurate records of

1	all controlled substances delivered, received, adminis-
2	tered, or otherwise disposed of under this section, in-
3	cluding the persons to whom controlled substances
4	were delivered and such other information as may be
5	required by regulations of the Attorney General.
6	"(b) Modification of Number of Days Before
7	Which Controlled Substance Shall Be Adminis-
8	TERED.—
9	"(1) Initial 2-year period.—During the 2-
10	year period beginning on the date of enactment of this
11	section, the Attorney General, in coordination with
12	the Secretary, may reduce the number of days de-
13	scribed in subsection (a)(5) if the Attorney General
14	determines that such reduction will—
15	"(A) reduce the risk of diversion; or
16	"(B) protect the public health.
17	"(2) Modifications after submission of re-
18	PORT.—After the date on which the report described
19	in subsection (c) is submitted, the Attorney General,
20	in coordination with the Secretary, may modify the
21	number of days described in subsection $(a)(5)$.
22	"(3) Minimum number of days.—Any modi-
23	fication under this subsection shall be for a period of
24	not less than 7 days.".

1	(b) Study and Report.—Not later than 2 years after
2	the date of enactment of this section, the Comptroller Gen-
3	eral of the United States shall conduct a study and submit
4	to Congress a report on access to and potential diversion
5	of controlled substances administered by injection or im-
6	plantation.
7	(c) Technical and Conforming Amendment.—The
8	table of contents for the Comprehensive Drug Abuse Preven-
9	tion and Control Act of 1970 is amended by inserting after
10	the item relating to section 309 the following:
	"Sec. 309A. Delivery of a controlled substance by a pharmacy to an administering practitioner.".
11	TITLE IV—TREATMENT AND
12	RECOVERY
13	SEC. 401. COMPREHENSIVE OPIOID RECOVERY CENTERS.
14	(a) In General.—The Secretary shall award grants
15	on a competitive basis to eligible entities to establish or op-
16	erate a comprehensive opioid recovery center (referred to in
17	this section as a "Center"). A Center may be a single entity
18	or an integrated delivery network.
19	(b) Grant Period.—
20	(1) In General.—A grant awarded under sub-
21	section (a) shall be for a period not more than 5
22	years.
23	(2) Renewal.—A grant awarded under sub-
24	section (a) may be renewed, on a competitive basis,

1	for additional periods of time, as determined by the
2	Secretary. In determining whether to renew a grant
3	under this paragraph, the Secretary shall consider the
4	data submitted under subsection (h).
5	(c) Minimum Number of Grants.—The Secretary
6	shall allocate the amounts made available under subsection
7	(j) such that not fewer than 10 grants may be awarded.
8	Not more than one grant shall be made to entities in a sin-
9	gle State for any one period.
10	(d) Application.—
11	(1) Eligible entity.—An entity is eligible for
12	a grant under this section if the entity offers treat-
13	ment and other services for individuals with a sub-
14	stance use disorder.
15	(2) Submission of application.—In order to
16	be eligible for a grant under subsection (a), an entity
17	shall submit an application to the Secretary at such
18	time and in such manner as the Secretary may re-
19	quire. Such application shall include—
20	(A) evidence that such entity carries out, or
21	is capable of coordinating with other entities to
22	carry out, the activities described in subsection
23	(g); and
24	(B) such other information as the Secretary
25	may require.

1	(e) Priority.—In awarding grants under subsection
2	(a), the Secretary shall give priority to eligible entities lo-
3	cated in a State with an age-adjusted rate of drug overdose
4	deaths that is above the national overdose mortality rate,
5	as determined by the Director of the Centers for Disease
6	Control and Prevention.
7	(f) Preference.—In awarding grants under sub-
8	section (a), the Secretary may give preference to eligible en-
9	tities utilizing technology-enabled collaborative learning
10	and capacity building models, including such models as de-
11	fined in section 2 of the Expanding Capacity for Health
12	Outcomes Act (Public Law 114-270; 130 Stat. 1395), to
13	conduct the activities described in this section.
14	(g) Center Activities.—Each Center shall, at a
15	minimum, carry out the following activities directly,
16	through referral, or through contractual arrangements,
17	which may include carrying out such activities through
18	technology-enabled collaborative learning and capacity
19	building models described in subsection (f):
20	(1) Treatment and recovery services.—
21	Each Center shall—
22	(A) ensure that intake and evaluations meet
23	the individualized clinical needs of patients, in-
24	cluding by offering assessments for services and
25	care recommendations through independent evi-

1	dence-based verification processes for reviewing
2	patient placement in treatment settings;
3	(B) provide the full continuum of treatment
4	services, including—
5	(i) all drugs approved by the Food and
6	Drug Administration to treat substance use
7	disorders, pursuant to Federal and State
8	law;
9	(ii) medically supervised withdrawal
10	management that includes patient evalua-
11	tion, stabilization, and readiness for and
12	entry into treatment;
13	(iii) counseling provided by a program
14	counselor or other certified professional who
15	is licensed and qualified by education,
16	training, or experience to assess the psycho-
17	logical and sociological background of pa-
18	tients, to contribute to the appropriate
19	treatment plan for the patient, and to mon-
20	itor patient progress;
21	(iv) treatment, as appropriate, for pa-
22	tients with co-occurring substance use and
23	$mental\ disorders;$

1	(v) testing, as appropriate, for infec-
2	tions commonly associated with illicit drug
3	use;
4	(vi) residential rehabilitation, and out-
5	patient and intensive outpatient programs;
6	(vii) recovery housing;
7	(viii) community-based and peer recov-
8	ery support services;
9	(ix) job training, job placement assist-
10	ance, and continuing education assistance
11	to support reintegration into the workforce;
12	and
13	(x) other best practices to provide the
14	full continuum of treatment and services, as
15	determined by the Secretary;
16	(C) ensure that all programs covered by the
17	Center include medication-assisted treatment, as
18	appropriate, and do not exclude individuals re-
19	ceiving medication-assisted treatment from any
20	service;
21	(D) periodically conduct patient assess-
22	ments to support sustained and clinically sig-
23	nificant recovery, as defined by the Assistant
24	Secretary for Mental Health and Substance Use;

1	(E) administer an onsite pharmacy and
2	provide toxicology services, for purposes of car-
3	rying out this section; and
4	(F) operate a secure, confidential, and
5	interoperable electronic health information sys-
6	tem.
7	(2) Outreach.—Each Center shall carry out
8	outreach activities to publicize the services offered
9	through the Centers, which may include—
10	(A) training and supervising outreach staff,
11	as appropriate, to work with State and local
12	health departments, health care providers, the
13	Indian Health Service, State and local edu-
14	cational agencies, schools funded by the Indian
15	Bureau of Education, institutions of higher edu-
16	cation, State and local workforce development
17	boards, State and local community action agen-
18	cies, public safety officials, first responders, In-
19	dian tribes, child welfare agencies, as appro-
20	priate, and other community partners and the
21	public, including patients, to identify and re-
22	spond to community needs;
23	(B) ensuring that the entities described in
24	subparagraph (A) are aware of the services of the
25	Center; and

1	(C) disseminating and making publicly
2	available, including through the internet, evi-
3	dence-based resources that educate professionals
4	and the public on opioid use disorder and other
5	substance use disorders, including co-occurring
6	substance use and mental disorders.
7	(h) Data Reporting and Program Oversight.—
8	With respect to a grant awarded under subsection (a), not
9	later than 90 days after the end of the first year of the grant
10	period, and annually thereafter for the duration of the
11	grant period (including the duration of any renewal period
12	for such grant), the entity shall submit data, as appro-
13	priate, to the Secretary regarding—
14	(1) the programs and activities funded by the
15	grant;
16	(2) health outcomes of the population of individ-
17	uals with a substance use disorder who received serv-
18	ices from the Center, evaluated by an independent
19	program evaluator through the use of outcomes meas-
20	ures, as determined by the Secretary;
21	(3) the retention rate of program participants;
22	and
23	(4) any other information that the Secretary
24	may require for the purpose of ensuring that the Cen-
25	ter is complying with all the requirements of the

1	grant, including providing the full continuum of serv-
2	ices described in subsection $(g)(1)(B)$.
3	(i) Privacy.—The provisions of this section, including
4	with respect to data reporting and program oversight, shall
5	be subject to all applicable Federal and State privacy laws.
6	(j) Authorization of Appropriations.—There is
7	authorized to be appropriated \$10,000,000 for each of fiscal
8	years 2019 through 2023 for purposes of carrying out this
9	section.
10	(k) Reports to Congress.—
11	(1) Preliminary report.—Not later than 3
12	years after the date of the enactment of this Act, the
13	Secretary shall submit to Congress a preliminary re-
14	port that analyzes data submitted under subsection
15	(h).
16	(2) Final report.—Not later than 2 year after
17	submitting the preliminary report required under
18	paragraph (1), the Secretary shall submit to Congress
19	a final report that includes—
20	(A) an evaluation of the effectiveness of the
21	comprehensive services provided by the Centers
22	established or operated pursuant to this section
23	on health outcomes of the population of individ-
24	uals with substance use disorder who receive
25	services from the Center, which shall include an

1	evaluation of the effectiveness of services for
2	treatment and recovery support and to reduce re-
3	lapse, recidivism, and overdose; and
4	(B) recommendations, as appropriate, re-
5	garding ways to improve Federal programs re-
6	lated to substance use disorders, which may in-
7	clude dissemination of best practices for the
8	treatment of substance use disorders to health
9	care professionals.
10	SEC. 402. PROGRAM TO SUPPORT COORDINATION AND CON-
11	TINUATION OF CARE FOR DRUG OVERDOSE
12	PATIENTS.
13	(a) In General.—The Secretary shall identify or fa-
14	cilitate the development of best practices for—
15	(1) emergency treatment of known or suspected
16	drug overdose;
17	(2) the use of recovery coaches, as appropriate,
18	to encourage individuals who experience a non-fatal
19	overdose to seek treatment for substance use disorder
20	and to support coordination and continuation of care;
21	(3) coordination and continuation of care and
22	treatment, including, as appropriate, through refer-
23	rals, of individuals after an opioid overdose; and
24	(4) the provision of overdose reversal medication,
25	as appropriate.

1	(b) Grant Establishment and Participation.—
2	(1) In general.—The Secretary shall award
3	grants on a competitive basis to eligible entities to
4	support implementation of voluntary programs for
5	care and treatment of individuals after an opioid
6	overdose, as appropriate, which may include imple-
7	mentation of the best practices described in subsection
8	(a).
9	(2) Eligible entity.—In this section, the term
10	"eligible entity" means—
11	(A) a State alcohol or drug agency; or
12	(B) an entity that offers treatment or other
13	services for individuals in response to, or fol-
14	lowing, drug overdoses or a drug overdose, in
15	consultation with a State alcohol and drug agen-
16	cy.
17	(3) APPLICATION.—An eligible entity desiring a
18	grant under this section shall submit an application
19	to the Secretary, at such time and in such manner as
20	the Secretary may require, that includes—
21	(A) evidence that such eligible entity carries
22	out, or is capable of contracting and coordi-
23	nating with other community entities to carry
24	out, the activities described in paragraph (4);

1	(B) evidence that such eligible entity will
2	work with a recovery community organization to
3	recruit, train, hire, mentor, and supervise recov-
4	ery coaches and fulfill the requirements described
5	in paragraph (4)(A); and
6	(C) such additional information as the Sec-
7	retary may require.
8	(4) Use of grant funds.—An eligible entity
9	awarded a grant under this section shall use such
10	grant funds to—
11	(A) hire or utilize recovery coaches to help
12	support recovery, including by—
13	(i) connecting patients to a continuum
14	of care services, such as—
15	(I) treatment and recovery sup-
16	$port\ programs;$
17	(II) programs that provide non-
18	clinical recovery support services;
19	(III) peer support networks;
20	(IV) recovery community organi-
21	zations;
22	(V) health care providers, includ-
23	ing physicians and other providers of
24	behavioral health and primary care;

1	(VI) educational and vocational
2	schools;
3	(VII) employers;
4	(VIII) housing services; and
5	(IX) child welfare agencies;
6	(ii) providing education on overdose
7	prevention and overdose reversal to patients
8	and families, as appropriate;
9	(iii) providing follow-up services for
10	patients after an overdose to ensure contin-
11	ued recovery and connection to support
12	services;
13	(iv) collecting and evaluating outcome
14	data for patients receiving recovery coach-
15	ing services; and
16	(v) providing other services the Sec-
17	retary determines necessary to help ensure
18	continued connection with recovery support
19	services;
20	(B) establish policies and procedures that
21	address the provision of overdose reversal medi-
22	cation, the administration of all drugs approved
23	by the Food and Drug Administration to treat
24	substance use disorder, and subsequent continu-
25	ation of, or referral to, evidence-based treatment

1	for patients with a substance use disorder who
2	have experienced a non-fatal drug overdose, in
3	order to support long-term treatment, prevent re-
4	lapse, and reduce recidivism and future overdose;
5	and
6	(C) establish integrated models of care for
7	individuals who have experienced a non-fatal
8	drug overdose which may include patient assess-
9	ment, follow up, and transportation to and from
10	$treatment\ facilities.$
11	(5) Additional Permissible Uses.—In addi-
12	tion to the uses described in paragraph (4), a grant
13	awarded under this section may be used, directly or
14	through contractual arrangements, to provide—
15	(A) all drugs approved by the Food and
16	Drug Administration to treat substance use dis-
17	orders, pursuant to Federal and State law;
18	(B) withdrawal and detoxification services
19	that include patient evaluation, stabilization,
20	and preparation for treatment of substance use
21	disorder, including treatment described in sub-
22	paragraph (A), as appropriate; or
23	(C) mental health services provided by a
24	program counselor, social worker, therapist, or
25	other certified professional who is licensed and

- 1 qualified by education, training, or experience to 2 assess the psychosocial background of patients, to contribute to the appropriate treatment plan for 3 4 patients with substance use disorder, and to 5 monitor patient progress. 6 (6) Preference.—In awarding grants under 7 this section, the Secretary shall give preference to eli-8 gible entities that meet any or all of the following cri-
 - (A) The eligible entity is a critical access hospital (as defined in section 1861(mm)(1) of (42 theSocial Security ActU.S.C.1395x(mm)(1)), a low volume hospital (as defined in section 1886(d)(12)(C)(i) of such Act $(42\ U.S.C.\ 1395ww(d)(12)(C)(i))), or a sole com$ munity hospital defined insection (as 1886(d)(5)(D)(iii) of such Act U.S.C.(42)1395ww(d)(5)(D)(iii)).
 - (B) The eligible entity is located in a State with an age-adjusted rate of drug overdose deaths that is above the national overdose mortality rate, as determined by the Director of the Centers for Disease Control and Prevention.

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

teria:

1	(C) The eligible entity demonstrates that re-
2	covery coaches will be placed in both health care
3	settings and community settings.
4	(7) Period of grant.—A grant awarded to an
5	eligible entity under this section shall be for a period
6	of not more than 5 years.
7	(c) Definitions.—In this section:
8	(1) Recovery coach.—the term "recovery
9	coach" means an individual—
10	(A) with knowledge of, or experience with,
11	recovery from a substance use disorder; and
12	(B) who has completed training from, and
13	is determined to be in good standing by, a recov-
14	ery services organization capable of conducting
15	such training and making such determination.
16	(2) Recovery community organization.—The
17	term "recovery community organization" has the
18	meaning given such term in section 547(a) of the
19	Public Health Service Act (42 U.S.C. 290ee–2(a)).
20	(3) State alcohol and drug agency.—The
21	term "State alcohol and drug agency" means the
22	principal agency of a State that is responsible for
23	carrying out the block grant for prevention and treat-
24	ment of substance abuse under subpart II of part B

1	of title XIX of the Public Health Service Act (42
2	U.S.C. 300x-21 et seq.)
3	(d) Reporting Requirements.—
4	(1) Reports by grantees.—Each eligible enti-
5	ty awarded a grant under this section shall submit to
6	the Secretary an annual report for each year for
7	which the entity has received such grant that includes
8	information on—
9	(A) the number of individuals treated by the
10	entity for non-fatal overdoses, including the
11	number of non-fatal overdoses where overdose re-
12	versal medication was administered;
13	(B) the number of individuals administered
14	medication-assisted treatment by the entity;
15	(C) the number of individuals referred by
16	the entity to other treatment facilities after a
17	non-fatal overdose, the types of such other facili-
18	ties, and the number of such individuals admit-
19	ted to such other facilities pursuant to such refer-
20	rals; and
21	(D) the frequency and number of patients
22	with reoccurrences, including readmissions for
23	non-fatal overdoses and evidence of relapse re-
24	lated to substance use disorder.

- 1 (2) Report by Secretary.—Not later than 5 2 years after the date of enactment of this Act, the Sec-3 retary shall submit to Congress a report that includes 4 an evaluation of the effectiveness of the grant program 5 carried out under this section with respect to long 6 term health outcomes of the population of individuals 7 who have experienced a drug overdose, the percentage 8 of patients treated or referred to treatment by grant-9 ees, and the frequency and number of patients who ex-10 perienced relapse, were readmitted for treatment, or 11 experienced another overdose.
- 12 (e) PRIVACY.—The requirements of this section, includ-13 ing with respect to data reporting and program oversight, 14 shall be subject to all applicable Federal and State privacy 15 laws.
- 16 (f) AUTHORIZATION OF APPROPRIATIONS.—There is 17 authorized to be appropriated to carry out this section such 18 sums as may be necessary for each of fiscal years 2019 19 through 2023.
- 20 SEC. 403. ALTERNATIVES TO OPIOIDS.
- 21 (a) In General.—The Secretary shall, directly or 22 through grants to, or contracts with, public and private en-23 tities, provide technical assistance to hospitals and other 24 acute care settings on alternatives to opioids for pain man-

- 1 agement. The technical assistance provided shall be for the
 2 purpose of—
 - (1) utilizing information from acute care providers including emergency departments and other providers that have successfully implemented alternatives to opioids programs, promoting non-addictive protocols and medications while appropriately limiting the use of opioids;
 - (2) identifying or facilitating the development of best practices on the use of alternatives to opioids, which may include pain-management strategies that involve non-addictive medical products, non-pharmacologic treatments, and technologies or techniques to identify patients at-risk for opioid use disorder;
 - (3) identifying or facilitating the development of best practices on the use of alternatives to opioids that target common painful conditions and include certain patient populations, such as geriatric patients, pregnant women, and children;
 - (4) disseminating information on the use of alternatives to opioids to providers in acute care settings, which may include emergency departments, outpatient clinics, critical access hospitals, and Federally qualified health centers; and

1	(5) collecting data and reporting on health out-
2	comes associated with the use of alternatives to
3	opioids.
4	(b) Pain Management and Funding.—
5	(1) In general.—The Secretary shall award
6	grants to hospitals and other acute care settings relat-
7	ing to alternatives to opioids for pain management.
8	(2) Authorization of appropriations.—
9	There is authorized to be appropriated \$5,000,000 for
10	each of fiscal years 2019 through 2023 for purposes
11	of carrying out this section.
12	SEC. 404. BUILDING COMMUNITIES OF RECOVERY.
13	Section 547 of the Public Health Service Act (42
14	U.S.C. 290ee-2) is amended to read as follows:
15	"SEC. 547. BUILDING COMMUNITIES OF RECOVERY.
16	"(a) Definition.—In this section, the term 'recovery
17	community organization' means an independent nonprofit
18	organization that—
19	"(1) mobilizes resources within and outside of
20	the recovery community, which may include through
21	a peer support network, to increase the prevalence
22	and quality of long-term recovery from substance use
23	disorders; and

1	"(2) is wholly or principally governed by people
2	in recovery for substance use disorders who reflect the
3	community served.
4	"(b) Grants Authorized.—The Secretary shall
5	award grants to recovery community organizations to en-
6	able such organizations to develop, expand, and enhance re-
7	covery services.
8	"(c) Federal Share of the costs
9	of a program funded by a grant under this section may
10	not exceed 85 percent.
11	"(d) USE OF FUNDS.—Grants awarded under sub-
12	section (b)—
13	"(1) shall be used to develop, expand, and en-
14	hance community and statewide recovery support
15	services; and
16	"(2) may be used to—
17	"(A) build connections between recovery net-
18	works, including between recovery community
19	organizations and peer support networks, and
20	with other recovery support services, including—
21	"(i) behavioral health providers;
22	"(ii) primary care providers and phy-
23	sicians;
24	"(iii) educational and vocational
25	schools;

1	"(iv) employers;
2	"(v) housing services;
3	"(vi) child welfare agencies; and
4	"(vii) other recovery support services
5	that facilitate recovery from substance use
6	disorders, including non-clinical commu-
7	nity services;
8	"(B) reduce the stigma associated with sub-
9	stance use disorders; and
10	"(C) conduct outreach on issues relating to
11	substance use disorders and recovery, includ-
12	ing—
13	"(i) identifying the signs of substance
14	use disorder;
15	"(ii) the resources available to individ-
16	uals with substance use disorder and to
17	families of an individual with a substance
18	use disorder, including programs that men-
19	tor and provide support services to children;
20	"(iii) the resources available to help
21	support individuals in recovery; and
22	"(iv) related medical outcomes of sub-
23	stance use disorders, the potential of acquir-
24	ing an infection commonly associated with
25	illicit drug use, and neonatal abstinence

1	syndrome among infants exposed to opioids
2	during pregnancy.
3	"(e) Special Consideration.—In carrying out this
4	section, the Secretary shall give special consideration to the
5	unique needs of rural areas, including areas with an age-
6	adjusted rate of drug overdose deaths that is above the na-
7	tional average and areas with a shortage of prevention and
8	treatment services.
9	"(f) AUTHORIZATION OF APPROPRIATIONS.—There are
10	authorized to be appropriated to carry out this section
11	\$5,000,000 for each of fiscal years 2019 through 2023.".
12	SEC. 405. PEER SUPPORT TECHNICAL ASSISTANCE CENTER.
13	(a) Establishment.—The Secretary, acting through
14	the Assistant Secretary for Mental Health and Substance
15	Abuse, shall establish or operate a National Peer-Run
16	Training and Technical Assistance Center for Addiction
17	Recovery Support (referred to in this subsection as the
18	"Center").
19	(b) Functions.—The Center established under sub-
20	section (a) shall provide technical assistance and support
21	to recovery community organizations and peer support net-
22	works, including such assistance and support related to—
23	(1) training on identifying—
24	(A) signs of substance use disorder;

1	(B) resources to assist individuals with a
2	substance use disorder, or resources for families
3	of an individual with a substance use disorder;
4	and
5	(C) best practices for the delivery of recov-
6	ery support services;
7	(2) the provision of translation services, inter-
8	pretation, or other such services for clients with lim-
9	ited English speaking proficiency;
10	(3) data collection to support research, including
11	for translational research;
12	(4) capacity building; and
13	(5) evaluation and improvement, as necessary, of
14	the effectiveness of such services provided by recovery
15	community organizations (as defined in section 547
16	of the Public Health Service Act).
17	(c) Best Practices.—The Center established under
18	subsection (a) shall periodically issue best practices for use
19	by recovery community organizations and peer support net-
20	works.
21	(d) Recovery Community Organization.—In this
22	section, the term "recovery community organization" has
23	the meaning given such term in section 547 of the Public
24	Health Service Act.

1	(e) Authorization of Appropriations.—There is
2	authorized to be appropriated to carry out this section such
3	sums as may be necessary for each of fiscal years 2019
4	through 2023.
5	SEC. 406. MEDICATION-ASSISTED TREATMENT FOR RECOV-
6	ERY FROM ADDICTION.
7	(a) Waivers for Maintenance or Detoxification
8	Treatment.—Section $303(g)(2)(G)(ii)$ of the Controlled
9	Substances Act (21 U.S.C. $823(g)(2)(G)(ii)$) is amended by
10	adding at the end the following:
11	"(VIII) The physician graduated in good
12	standing from an accredited school of allopathic
13	medicine or osteopathic medicine in the United
14	States during the 5-year period immediately pre-
15	ceding the date on which the physician submits
16	to the Secretary a written notification under
17	subparagraph (B) and successfully completed a
18	$comprehensive\ allopathic\ or\ osteopathic\ medicine$
19	curriculum or accredited medical residency
20	that—
21	"(aa) included not less than 24 hours
22	of training on treating and managing opi-
23	ate-dependent patients; and
24	"(bb) included, at a minimum—

1	"(AA) the training described in
2	items (aa) through (gg) of subclause
3	(IV); and
4	"(BB) training with respect to
5	any other best practice the Secretary
6	determines should be included in the
7	curriculum, which may include train-
8	ing on pain management, including
9	assessment and appropriate use of
10	opioid and non-opioid alternatives.".
11	(b) Treatment for Children.—The Secretary shall
12	consider ways to ensure that an adequate number of physi-
13	cians who meet the requirements under the amendment
14	made by subsection (a) and have a specialty in pediatrics,
15	or the treatment of children or of adolescents, are granted
16	a waiver under section $303(g)(2)$ of the Controlled Sub-
17	stances Act (21 U.S.C. 823(g)(2)) to treat children and ado-
18	lescents with substance use disorders.
19	(c) Technical Amendment.—Section 102(24) of the
20	Controlled Substances Act (21 U.S.C. 802(24)) is amended
21	by striking "Health, Education, and Welfare" and insert-
22	ing "Health and Human Services".
23	SEC. 407. GRANT PROGRAM.
24	(a) In General.—The Secretary shall establish a
25	grant program under which the Secretary may make grants

1	to accredited schools of allopathic medicine or osteopathic
2	medicine and teaching hospitals located in the United
3	States to support the development of curricula that meet
4	the requirements under subclause (VIII) of section
5	303(g)(2)(G)(ii) of the Controlled Substances Act, as added
6	by section 406(a) of this Act.
7	(b) AUTHORIZATION OF APPROPRIATIONS.—There are
8	authorized to be appropriated for grants under subsection
9	(a), \$4,000,000 for each of fiscal years 2019 through 2023.
10	SEC. 408. ALLOWING FOR MORE FLEXIBILITY WITH RE-
11	SPECT TO MEDICATION-ASSISTED TREAT-
12	MENT FOR OPIOID USE DISORDERS.
13	Subclause (II) of section $303(g)(2)(B)(iii)$ of the Con-
14	trolled Substances Act (21 U.S.C. 823(g)(2)(B)(iii)) is
15	amended to read as follows:
16	"(II) The applicable number is—
17	"(aa) 100 if, not sooner than 1 year after
18	the date on which the practitioner submitted the
19	initial notification, the practitioner submits a
20	second notification to the Secretary of the need
21	and intent of the practitioner to treat up to 100
22	patients; or
23	"(bb) 275 if the practitioner meets the re-
24	auirements specified in section 8.610 of title 42.

1	Code of Federal Regulations (or successor regula-
2	tions).".
3	SEC. 409. NATIONAL RECOVERY HOUSING BEST PRACTICES.
4	(a) Best Practices.—The Secretary, in consultation
5	with the Secretary for Housing and Urban Development,
6	patients with a history of opioid use disorder, and other
7	stakeholders, which may include State accrediting entities
8	and reputable providers of, and analysts of, recovery hous-
9	ing services, shall identify or facilitate the development of
10	best practices, which may include model laws for imple-
11	menting suggested minimum standards, for operating re-
12	covery housing.
13	(b) Dissemination.—The Secretary shall disseminate
14	the best practices identified or developed under subsection
15	(a) to—
16	(1) State agencies, which may include the provi-
17	sion of technical assistance to State agencies seeking
18	to adopt or implement such best practices;
19	(2) Indian tribes and tribally designated housing
20	entities;
21	(3) recovery housing entities; and
22	(4) the public, as appropriate.
23	(c) Requirements.—In identifying or facilitating the
24	development of best practices under subsection (a), the Sec-
25	retary, in consultation with appropriate stakeholders, shall

1	consider how recovery housing is able to support recovery
2	and prevent relapse, recidivism, or overdose (including
3	overdose death), including by improving access and adher-
4	ence to treatment, including medication-assisted treatment.
5	(d) Rule of Construction.—Nothing in this section
6	shall be construed to provide the Secretary with the author-
7	ity to require States to adhere to minimum standards in
8	the State oversight of recovery housing.
9	(e) Definitions.—In this section—
10	(1) the term "recovery housing" means a shared
11	living environment free from alcohol and illicit drug
12	use and centered on peer support and connection to
13	services that promote sustained recovery from sub-
14	stance use disorders; and
15	(2) the term "tribally designated housing entity"
16	has the meaning given such term in the section 4 of
17	the Native American Housing Assistance and Self-De-
18	termination Act of 1996 (25 U.S.C. 4103).
19	SEC. 410. ADDRESSING ECONOMIC AND WORKFORCE IM-
20	PACTS OF THE OPIOID CRISIS.
21	(a) Definitions.—Except as otherwise expressly pro-
22	vided, in this section:
23	(1) WIOA DEFINITIONS.—The terms "core pro-
24	gram", "individual with a barrier to employment",
25	"local area", "local board", "one-stop operator", "out-

1	lying area", "State", "State board", and "supportive
2	services" have the meanings given the terms in section
3	3 of the Workforce Innovation and Opportunity Act
4	(29 U.S.C. 3102).
5	(2) Education provider.—The term "edu-
6	cation provider" means—
7	(A) an institution of higher education, as
8	defined in section 101 of the Higher Education
9	Act of 1965 (20 U.S.C. 1001); or
10	(B) a postsecondary vocational institution,
11	as defined in section $102(c)$ of such Act (20
12	$U.S.C.\ 1002(c)$).
13	(3) Eligible enti-The term "eligible enti-
14	ty" means—
15	(A) a State workforce agency;
16	(B) an outlying area; or
17	(C) a Tribal entity.
18	(4) Participating partnership.—The term
19	"participating partnership" means a partnership—
20	(A) evidenced by a written contract or
21	agreement; and
22	(B) including, as members of the partner-
23	ship, a local board receiving a subgrant under
24	subsection (d) and 1 or more of the following:
25	(i) The eligible entity.

1	(ii) A treatment provider.
2	(iii) An employer or industry organi-
3	zation.
4	(iv) An education provider.
5	(v) A legal service or law enforcement
6	organization.
7	(vi) A faith-based or community-based
8	organization.
9	(vii) Other State or local agencies, in-
10	cluding counties or local government.
11	(viii) Other organizations, as deter-
12	mined to be necessary by the local board.
13	(5) Program Participant.—The term "pro-
14	gram participant" means an individual who—
15	(A) is a member of a population of workers
16	described in subsection (e)(2) that is served by a
17	participating partnership through the pilot pro-
18	gram under this section; and
19	(B) enrolls with the applicable partici-
20	pating partnership to receive any of the services
21	described in subsection $(e)(3)$.
22	(6) Provider of Peer Recovery support
23	SERVICES.—The term "provider of peer recovery sup-
24	port services" means a provider that delivers peer re-
25	covery support services through an organization de-

1	scribed in section 547(a) of the Public Health Service
2	Act (42 U.S.C. 290ee–2(a)).
3	(7) Secretary.—The term "Secretary" means
4	the Secretary of Labor.
5	(8) State workforce agency.—The term
6	"State workforce agency" means the lead State agency
7	with responsibility for the administration of a pro-
8	gram under chapter 2 or 3 of subtitle B of title I of
9	the Workforce Innovation and Opportunity Act (29
10	U.S.C. 3161 et seq., 3171 et seq.).
11	(9) Substance use disorder.—The term "sub-
12	stance use disorder" has the meaning given such term
13	by the Assistant Secretary for Mental Health and
14	Substance Use.
15	(10) Treatment provider.—The term "treat-
16	ment provider"—
17	(A) means a health care provider that—
18	(i) offers services for treating substance
19	use disorders and is licensed in accordance
20	with applicable State law to provide such
21	services; and
22	(ii) accepts health insurance for such
23	services, including coverage under title XIX
24	of the Social Security Act (42 U.S.C. 1396
25	et seq.); and

1	(B) may include—
2	(i) a nonprofit provider of peer recov-
3	ery support services;
4	(ii) a community health care provider;
5	(iii) a Federally qualified health center
6	(as defined in section 1861(aa) of the Social
7	Security Act (42 U.S.C. 1395x));
8	(iv) an Indian health program (as de-
9	fined in section 3 of the Indian Health Care
10	Improvement Act (25 U.S.C. 1603)), includ-
11	ing an Indian health program that serves
12	an urban center (as defined in such sec-
13	tion); and
14	(v) a Native Hawaiian health center
15	(as defined in section 12 of the Native Ha-
16	waiian Health Care Improvement Act (42
17	U.S.C. 11711)).
18	(11) Tribal entity.—The term "Tribal entity"
19	includes any Indian tribe, tribal organization, In-
20	dian-controlled organization serving Indians, Native
21	Hawaiian organization, or Alaska Native entity, as
22	such terms are defined or used in section 166 of the
23	Workforce Innovation and Opportunity Act (29
24	U.S.C. 3221).
25	(b) Pilot Program and Grants Authorized.—

- (1) In General.—The Secretary, in consultation with the Secretary of Health and Human Services, shall carry out a pilot program to address economic and workforce impacts associated with a high rate of a substance use disorder. In carrying out the pilot program, the Secretary shall make grants, on a competitive basis, to eligible entities to enable such entities to make subgrants to local boards to address the economic and workforce impacts associated with a high rate of a substance use disorder.
 - (2) Grant amounts.—The Secretary shall make each such grant in an amount that is not less than \$500,000, and not more than \$5,000,000, for a fiscal year.

(c) Grant Applications.—

- (1) In General.—An eligible entity applying for a grant under this section shall submit an application to the Secretary at such time and in such form and manner as the Secretary may reasonably require, including the information described in this subsection.
- (2) Significant impact on community by Opioid and substance use disorder-related problems.—

1	(A) Demonstration.—An eligible entity
2	shall include in the application—
3	(i) information that demonstrates sig-
4	nificant impact on the community by prob-
5	lems related to opioid abuse or another sub-
6	stance use disorder, by—
7	(I) identifying the counties, com-
8	munities, regions, or local areas that
9	have been significantly impacted and
10	will be served through the grant (each
11	referred to in this section as a "service
12	area"); and
13	(II) demonstrating for each such
14	service area, an increase equal to or
15	greater than the national increase in
16	such problems, between—
17	(aa) 1999; and
18	(bb) 2016 or the latest year
19	for which data are available; and
20	(ii) a description of how the eligible
21	entity will prioritize support for signifi-
22	cantly impacted service areas described in
23	$clause\ (i)(I).$
24	(B) Information.—To meet the require-
25	ments described in subparagraph (A)(i)(II), the

1	eligible entity may use information including
2	data on—
3	(i) the incidence or prevalence of
4	opioid abuse and other substance use dis-
5	orders;
6	(ii) the age-adjusted rate of drug over-
7	dose deaths, as determined by the Director
8	of the Centers for Disease Control and Pre-
9	vention;
10	(iii) the rate of non-fatal hospitaliza-
11	tions related to opioid abuse or another sub-
12	stance use disorder;
13	(iv) the number of arrests or convic-
14	tions, or a relevant law enforcement sta-
15	tistic, that reasonably shows an increase in
16	opioid abuse or another substance use dis-
17	order; or
18	(v) in the case of an eligible entity de-
19	scribed in subsection $(a)(3)(C)$, other alter-
20	native relevant data as determined appro-
21	priate by the Secretary.
22	(C) Support for state strategy.—The
23	eligible entity may include in the application in-
24	formation describing how the proposed services
25	and activities are aligned with the State, out-

1	lying area, or Tribal strategy, as applicable, for
2	addressing problems described in subparagraph
3	(A) in specific service areas or across the State,
4	outlying area, or Tribal land.
5	(3) Economic and employment conditions
6	DEMONSTRATE ADDITIONAL FEDERAL SUPPORT NEED-
7	ED.—
8	(A) Demonstration.—An eligible entity
9	shall include in the application information that
10	demonstrates that a high rate of a substance use
11	disorder has caused, or is coincident to—
12	(i) an economic or employment down-
13	turn in the service area; or
14	(ii) persistent economically depressed
15	conditions in such service area.
16	(B) Information.—To meet the require-
17	ments of subparagraph (A), an eligible entity
18	may use information including—
19	(i) documentation of any layoff, an-
20	nounced future layoff, legacy industry de-
21	cline, decrease in an employment or labor
22	market participation rate, or economic im-
23	pact, whether or not the result described in
24	this clause is overtly related to a high rate
25	of a substance use disorder;

1	(ii) documentation showing decreased
2	economic activity related to, caused by, or
3	contributing to a high rate of a substance
4	use disorder, including a description of how
5	the service area has been impacted, or will
6	be impacted, by such a decrease;
7	(iii) information on economic indica-
8	tors, labor market analyses, information
9	from public announcements, and demo-
10	graphic and industry data;
11	(iv) information on rapid response ac-
12	tivities (as defined in section 3 of the Work-
13	force Innovation and Opportunity Act (29
14	U.S.C. 3102)) that have been or will be con-
15	ducted, including demographic data gath-
16	ered by employer or worker surveys or
17	$through\ other\ methods;$
18	(v) data or documentation, beyond an-
19	ecdotal evidence, showing that employers
20	face challenges filling job vacancies due to a
21	lack of skilled workers able to pass a drug
22	test; or
23	(vi) any additional relevant data or
24	information on the economy, workforce, or

1	another aspect of the service area to support
2	$the \ application.$
3	(d) Subgrant Authorization and Application
4	Process.—
5	(1) Subgrants authorized.—
6	(A) In General.—An eligible entity receiv-
7	ing a grant under subsection (b)—
8	(i) may use not more than 5 percent of
9	the grant funds for the administrative costs
10	of carrying out the grant;
11	(ii) in the case of an eligible entity de-
12	scribed in subparagraph (A) or (B) of sub-
13	section (a)(3), shall use the remaining grant
14	funds to make subgrants to local entities in
15	the service area to carry out the services
16	and activities described in subsection (e);
17	and
18	(iii) in the case of an eligible entity
19	described in subsection $(a)(3)(C)$, shall use
20	the remaining grant funds to carry out the
21	services and activities described in sub-
22	section (e).
23	(B) Equitable distribution.—In making
24	subgrants under this subsection, an eligible enti-

1	ty shall ensure, to the extent practicable, the eq-
2	uitable distribution of subgrants, based on—
3	(i) geography (such as urban and rural
4	distribution); and
5	(ii) significantly impacted service
6	areas as described in subsection $(c)(2)$.
7	(C) Timing of subgrant funds distribu-
8	TION.—An eligible entity making subgrants
9	under this subsection shall disburse subgrant
10	funds to a local board receiving a subgrant from
11	the eligible entity by the later of—
12	(i) the date that is 90 days after the
13	date on which the Secretary makes the
14	funds available to the eligible entity; or
15	(ii) the date that is 15 days after the
16	date that the eligible entity makes the
17	$subgrant\ under\ subparagraph\ (A)(ii).$
18	(2) Subgrant application.—
19	(A) In general.—A local board desiring to
20	receive a subgrant under this subsection from an
21	eligible entity shall submit an application at
22	such time and in such and manner as the eligi-
23	ble entity may reasonably require, including the
24	information described in this paragraph.

1	(B) Contents.—Each application de-
2	scribed in subparagraph (A) shall include—
3	(i) an analysis of the estimated per-
4	formance of the local board in carrying out
5	the proposed services and activities under
6	the subgrant—
7	(I) based on—
8	(aa) primary indicators of
9	performance described in section
10	116(c)(1)(A)(i) of the Workforce
11	Innovation and Opportunity Act
12	(29 U.S.C. 3141(c)(1)(A)(i), to as-
13	sess estimated effectiveness of the
14	proposed services and activities,
15	including the estimated number of
16	individuals with a substance use
17	disorder who may be served by the
18	proposed services and activities;
19	(bb) the record of the local
20	board in serving individuals with
21	a barrier to employment; and
22	(cc) the ability of the local
23	board to establish a participating
24	partnership; and

1	(II) which may include or uti-
2	lize—
3	(aa) data from the National
4	Center for Health Statistics of the
5	Centers for Disease Control and
6	Prevention;
7	(bb) data from the Center for
8	Behavioral Health Statistics and
9	Quality of the Substance Abuse
10	and Mental Health Services Ad-
11	ministration;
12	(cc) State vital statistics;
13	(dd) municipal police de-
14	$partment\ records;$
15	(ee) reports from local coro-
16	ners; or
17	(ff) other relevant data; and
18	(ii) in the case of a local board pro-
19	posing to serve a population described in
20	subsection $(e)(2)(B)$, a demonstration of the
21	workforce shortage in the professional area
22	to be addressed under the subgrant (which
23	may include substance use disorder treat-
24	ment and related services, non-addictive
25	pain therapy and pain management serv-

1	ices, mental health care treatment services,
2	emergency response services, or mental
3	health care), which shall include informa-
4	tion that can demonstrate such a shortage,
5	such as—
6	(I) the distance between—
7	(aa) communities affected by
8	opioid abuse or another substance
9	use disorder; and
10	(bb) facilities or professionals
11	offering services in the profes-
12	sional area; or
13	(II) the maximum capacity of fa-
14	cilities or professionals to serve indi-
15	viduals in an affected community, or
16	increases in arrests related to opioid or
17	another substance use disorder, over-
18	dose deaths, or nonfatal overdose emer-
19	gencies in the community.
20	(e) Subgrant Services and Activities.—
21	(1) In general.—Each local board that receives
22	a subgrant under subsection (d) shall carry out the
23	services and activities described in this subsection
24	through a participating partnership.

1	(2) Selection of population to be
2	SERVED.—A participating partnership shall elect to
3	provide services and activities under the subgrant to
4	one or both of the following populations of workers:
5	(A) Workers, including dislocated workers,
6	individuals with barriers to employment, new
7	entrants in the workforce, or incumbent workers
8	(employed or underemployed), each of whom—
9	(i) are directly or indirectly affected by
10	a high rate of a substance use disorder; and
11	(ii) voluntarily confirms that the work-
12	er, or a friend or family member of the
13	worker, has a history of opioid abuse or an-
14	other substance use disorder.
15	(B) Workers, including dislocated workers,
16	individuals with barriers to employment, new
17	entrants in the workforce, or incumbent workers
18	(employed or underemployed), who—
19	(i) seek to transition to professions that
20	support individuals with a substance use
21	disorder or at risk for developing such dis-
22	order, such as professions that provide—
23	(I) substance use disorder treat-
24	ment and related services;

1	(II) services offered through pro-
2	viders of peer recovery support services;
3	(III) non-addictive pain therapy
4	and pain management services;
5	(IV) emergency response services;
6	or
7	(V) mental health care; and
8	(ii) need new or upgraded skills to bet-
9	ter serve such a population of struggling or
10	at-risk individuals.
11	(3) Services and activities.—Each partici-
12	pating partnership shall use funds available through
13	a subgrant under this subsection to carry out 1 or
14	more of the following:
15	(A) Engaging employers.—Engaging
16	with employers to—
17	(i) learn about the skill and hiring re-
18	quirements of employers;
19	(ii) learn about the support needed by
20	employers to hire and retain program par-
21	ticipants, and other individuals with a sub-
22	stance use disorder, and the support needed
23	by such employers to obtain their commit-
24	ment to testing creative solutions to employ-

1	ing program participants and such individ-
2	uals;
3	(iii) connect employers and workers to
4	on-the-job or customized training programs
5	before or after layoff to help facilitate reem-
6	ployment;
7	(iv) connect employers with an edu-
8	cation provider to develop classroom in-
9	struction to complement on-the-job learning
10	for program participants and such individ-
11	uals;
12	(v) help employers develop the cur-
13	riculum design of a work-based learning
14	program for program participants and such
15	individuals;
16	(vi) help employers employ program
17	participants or such individuals engaging
18	in a work-based learning program for a
19	transitional period before hiring such a pro-
20	gram participant or individual for full-time
21	employment of not less than 30 hours a
22	week; or
23	(vii) connect employers to program
24	participants receiving concurrent outpatient
25	treatment and job training services.

1	(B) Screening Services.—Providing
2	screening services, which may include—
3	(i) using an evidence-based screening
4	method to screen each individual seeking
5	participation in the pilot program to deter-
6	mine whether the individual has a sub-
7	stance use disorder;
8	(ii) conducting an assessment of each
9	such individual to determine the services
10	needed for such individual to obtain or re-
11	tain employment, including an assessment
12	of strengths and general work readiness; or
13	(iii) accepting walk-ins or referrals
14	from employers, labor organizations, or
15	other entities recommending individuals to
16	participate in such program.
17	(C) Individual treatment and employ-
18	MENT PLAN.—Developing an individual treat-
19	ment and employment plan for each program
20	participant—
21	(i) in coordination, as appropriate,
22	with other programs serving the participant
23	such as the core programs within the work-
24	force development system under the Work-

1	force Innovation and Opportunity Act (29
2	U.S.C. 3101 et seq.); and
3	(ii) which shall include providing a
4	case manager to work with each participant
5	to develop the plan, which may include—
6	(I) identifying employment and
7	$career\ goals;$
8	(II) exploring career pathways
9	that lead to in-demand industries and
10	sectors, as determined by the State
11	board and the head of the State work-
12	force agency or, as applicable, the
13	$Tribal\ entity;$
14	(III) setting appropriate achieve-
15	ment objectives to attain the employ-
16	ment and career goals identified under
17	subclause (I); or
18	(IV) developing the appropriate
19	combination of services to enable the
20	participant to achieve the employment
21	and career goals identified under sub-
22	clause (I) .
23	(D) Outpatient treatment and recov-
24	ERY CARE.—In the case of a participating part-
25	nership serving program participants described

1	in paragraph (2)(A) with a substance use dis-
2	order, providing individualized and group out-
3	patient treatment and recovery services for such
4	program participants that are offered during the
5	day and evening, and on weekends. Such treat-
6	ment and recovery services—
7	(i) shall be based on a model that uti-
8	lizes combined behavioral interventions and
9	other evidence-based or evidence-informed
10	interventions; and
11	(ii) may include additional services
12	such as—
13	(I) health, mental health, addic-
14	tion, or other forms of outpatient treat-
15	ment that may impact a substance use
16	disorder and co-occurring conditions;
17	(II) drug testing for a current
18	substance use disorder prior to enroll-
19	ment in career or training services or
20	prior to employment;
21	(III) linkages to community serv-
22	ices, including services offered by part-
23	ner organizations designed to support
24	program participants; or

1	(IV) referrals to health care, in-
2	cluding referrals to substance use dis-
3	order treatment and mental health
4	services.
5	(E) Supportive services.—Providing
6	supportive services, which shall include services
7	such as—
8	(i) coordinated wraparound services to
9	provide maximum support for program
10	participants to assist the program partici-
11	pants in maintaining employment and re-
12	covery for not less than 12 months, as ap-
13	propriate;
14	(ii) assistance in establishing eligi-
15	bility for assistance under Federal, State,
16	Tribal, and local programs providing health
17	services, mental health services, vocational
18	services, housing services, transportation
19	services, social services, or services through
20	early childhood education programs (as de-
21	fined in section 103 of the Higher Edu-
22	cation Act of 1965 (20 U.S.C. 1003));
23	(iii) services offered through providers
24	of peer recovery support services;

1	(iv) networking and mentorship oppor-
2	tunities; or
3	(v) any supportive services determined
4	necessary by the local board.
5	(F) Career and job training serv-
6	ICES.—Offering career services and training
7	services, and related services, concurrently or se-
8	quentially with the services provided under sub-
9	paragraphs (B) through (E). Such services shall
10	include the following:
11	(i) Services provided to program par-
12	ticipants who are in a pre-employment
13	stage of the program, which may include—
14	(I) initial education and skills as-
15	sessments;
16	(II) traditional classroom train-
17	ing funded through individual training
18	accounts under chapter 3 of subtitle B
19	of title I of the Workforce Innovation
20	and Opportunity Act (29 U.S.C. 3171
21	et seq.);
22	(III) services to promote employ-
23	ability skills such as punctuality, per-
24	sonal maintenance skills, and profes-
25	$sional\ conduct;$

1	(IV) in-depth interviewing and
2	evaluation to identify employment bar-
3	riers and to develop individual em-
4	ployment plans;
5	(V) career planning that in-
6	cludes—
7	(aa) career pathways leading
8	to in-demand, high-wage jobs; and
9	(bb) job coaching, job match-
10	ing, and job placement services;
11	(VI) provision of payments and
12	fees for employment and training-re-
13	lated applications, tests, and certifi-
14	cations; or
15	(VII) any other appropriate ca-
16	reer service or training service de-
17	scribed in section 134(c) of the Work-
18	force Innovation and Opportunity Act
19	$(29\ U.S.C.\ 3174(c)).$
20	(ii) Services provided to program par-
21	ticipants during their first 6 months of em-
22	ployment to ensure job retention, which
23	may include—

1	(I) case management and support
2	services, including a continuation of
3	the services described in clause (i);
4	(II) a continuation of skills train-
5	ing, and career and technical edu-
6	cation, described in clause (i) that is
7	conducted in collaboration with the
8	employers of such participants;
9	(III) mentorship services and job
10	retention support for such partici-
11	pants; or
12	(IV) targeted training for man-
13	agers and workers working with such
14	participants (such as mentors), and
15	human resource representatives in the
16	business in which such participants
17	$are\ employed.$
18	(iii) Services to assist program partici-
19	pants in maintaining employment for not
20	less than 12 months, as appropriate.
21	(G) Proven and promising practices.—
22	Leading efforts in the service area to identify
23	and promote proven and promising strategies
24	and initiatives for meeting the needs of employ-
25	ers and program participants.

1	(4) Limitations.—A participating partnership
2	may not use—
3	(A) more than 10 percent of the funds re-
4	ceived under a subgrant under subsection (d) for
5	the administrative costs of the partnership;
6	(B) more than 10 percent of the funds re-
7	ceived under such subgrant for the provision of
8	treatment and recovery services, as described in
9	paragraph (3)(D); and
10	(C) more than 10 percent of the funds re-
11	ceived under such subgrant for the provision of
12	supportive services described in paragraph
13	(3)(E) to program participants.
14	(f) Performance Accountability.—
15	(1) Reports.—The Secretary shall establish
16	quarterly reporting requirements for recipients of
17	grants and subgrants under this section that, to the
18	extent practicable, are based on the performance ac-
19	countability system under section 116 of the Work-
20	force Innovation and Opportunity Act (29 U.S.C.
21	3141) and, in the case of a grant awarded to an eligi-
22	ble entity described in subsection $(a)(3)(C)$, section
23	166(h) of such Act (29 U.S.C. 3221(h)), including the
24	indicators described in subsection $(c)(1)(A)(i)$ of such
25	section 116 and the requirements for local area per-

1	formance reports under subsection (d) of such section
2	116.
3	(2) Evaluations.—
4	(A) AUTHORITY TO ENTER INTO AGREE-
5	MENTS.—The Secretary shall ensure that an
6	independent evaluation is conducted on the pilot
7	program carried out under this section to deter-
8	mine the impact of the program on employment
9	of individuals with substance use disorders. The
10	Secretary shall enter into an agreement with eli-
11	gible entities receiving grants under this section
12	to pay for all or part of such evaluation.
13	(B) Methodologies to be used.—The
14	independent evaluation required under this
15	paragraph shall use experimental designs using
16	random assignment or, when random assignment
17	is not feasible, other reliable, evidence-based re-
18	search methodologies that allow for the strongest
19	possible causal inferences.
20	(g) Funding.—
21	(1) Covered fiscal year.—In this subsection,
22	the term "covered fiscal year" means any of fisca
23	years 2018 through 2023.
24	(2) Using funding for national dislocated
25	WORKER GRANTS.—Subject to paragraph (4) and not

1	withstanding section $132(a)(2)(A)$ and subtitle D of
2	the Workforce Innovation and Opportunity Act (29
3	$U.S.C.\ 3172(a)(2)(A),\ 3221\ et\ seq.),\ the\ Secretary$
4	may use, to carry out the pilot program under this
5	section for a covered fiscal year—
6	(A) funds made available to carry out sec-
7	tion 170 of such Act (29 U.S.C. 3225) for that
8	fiscal year;
9	(B) funds made available to carry out sec-
10	tion 170 of such Act that remain available for
11	that fiscal year; and
12	(C) funds that remain available under sec-
13	tion 172(f) of such Act (29 U.S.C. 3227(f)).
14	(3) Availability of funds.—Funds appro-
15	priated under section 136(c) of such Act (29 U.S.C.
16	3181(c)) and made available to carry out section 170
17	of such Act for a fiscal year shall remain available
18	for use under paragraph (2) for a subsequent fiscal
19	year until expended.
20	(4) Limitation.—The Secretary may not use
21	more than \$100,000,000 of the funds described in
22	paragraph (2) for any covered fiscal year under this
23	section.

1	SEC. 411. YOUTH PREVENTION AND RECOVERY.
2	(a) Substance Abuse Treatment Services for
3	CHILDREN, ADOLESCENTS, AND YOUNG ADULTS.—Section
4	514 of the Public Health Service Act (42 U.S.C. 290bb-
5	7) is amended—
6	(1) in the section heading, by striking "CHIL-
7	DREN AND ADOLESCENTS" and inserting "CHIL-
8	DREN, ADOLESCENTS, AND YOUNG ADULTS";
9	(2) in subsection (a)(2), by striking "children,
10	including" and inserting "children, adolescents, and
11	young adults, including"; and
12	(3) by striking "children and adolescents" each
13	place it appears and inserting "children, adolescents,
14	and young adults".
15	(b) Youth Prevention and Recovery Initiative.—
16	(1) In General.—The Secretary, in consultation
17	with Secretary of Education, shall administer a pro-
18	gram to provide support for communities to support
19	the prevention, treatment, and recovery of substance
20	use disorders for children, adolescents, and young
21	adults.
22	(2) Definitions.—In this subsection:
23	(A) Eligible entity.—The term "eligible
24	entity" means—
25	(i) a local educational agency that is
26	seeking to establish or expand substance use

1	prevention or recovery support services at
2	one or more high schools;
3	(ii) a State educational agency;
4	(iii) an institution of higher education
5	(or consortia of such institutions), which
6	may include a recovery program at an in-
7	stitution of higher education;
8	(iv) a local board or one-stop operator;
9	(v) a nonprofit organization with ap-
10	propriate expertise in providing services or
11	programs for children, adolescents, or young
12	adults, excluding a school;
13	(vi) a State, political subdivision of a
14	State, Indian Tribe, or tribal organization;
15	or
16	(vii) a high school or dormitory serv-
17	ing high school students that receives fund-
18	ing from the Bureau of Indian Education.
19	(B) EVIDENCE-BASED.—The term "evi-
20	dence-based" has the meaning given such term in
21	section 8101 of the Elementary and Secondary
22	Education Act (20 U.S.C. 7801).
23	(C) Foster care.—The term "foster care"
24	has the meaning given such term in section

1	1355.20(a) of title 45, Code of Federal Regula-
2	tions (or any successor regulations).
3	(D) High school.—The term "high
4	school" has the meaning given such term in sec-
5	tion 8101 of the Elementary and Secondary
6	Education Act of 1965 (20 U.S.C. 7801).
7	(E) Homeless youth.—The term 'home-
8	less youth" has the meaning given the term
9	"homeless children or youths" in section 725 of
10	the McKinney-Vento Homeless Assistance Act (42
11	$U.S.C.\ 11434a);$
12	(F) Institution of higher education.—
13	The term "institution of higher education" has
14	the meaning given such term in section 101 of
15	the Higher Education Act of 1965 (20 U.S.C.
16	1001) and includes a "postsecondary vocational
17	institution" as defined in section 102(c) of such
18	Act (20 U.S.C. 1002(c)).
19	(G) Local Educational agency.—The
20	term 'local educational agency' has the meaning
21	given the term in section 8101 of the Elementary
22	and Secondary Education Act of 1965 (20
23	U.S.C. 7801).
24	(H) Local board; one-stop operator.—
25	The terms "local board" and "one-stop operator"

1	have the meanings given such terms in section 3
2	of the Workforce Innovation and Opportunity
3	Act (29 U.S.C. 3102).
4	(I) Out of school youth.—The term
5	"out-of-school youth" has the meaning given such
6	term in section 129(a)(1)(B) of the Workforce In-
7	novation and Opportunity Act (29 U.S.C.
8	3164(a)(1)(B)).
9	(J) Recovery program.—The term "recov-
10	ery program" means a program—
11	(i) to help children, adolescents, or
12	young adults who are recovering from sub-
13	stance use disorders to initiate, stabilize,
14	and maintain healthy and productive lives
15	in the community; and
16	(ii) that includes peer-to-peer support
17	delivered by individuals with lived experi-
18	ence in recovery, and communal activities
19	to build recovery skills and supportive so-
20	cial networks.
21	(K) State educational agency.—The
22	term "State educational agency" has the mean-
23	ing given the term in section 8101 of the Ele-
24	mentary and Secondary Education Act (20
25	U.S.C. 7801).

1	(3) Best practices.—The Secretary, in con-
2	sultation with the Secretary of Education, shall—
3	(A) identify or facilitate the development of
4	evidence-based best practices for prevention of
5	substance misuse and abuse by children, adoles-
6	cents, and young adults, including for specific
7	populations such as youth in foster care, home-
8	less youth, out-of-school youth, and youth who
9	are at risk of or have experienced trafficking that
10	address—
11	(i) primary prevention;
12	(ii) appropriate recovery support serv-
13	ices;
14	(iii) appropriate use of medication-as-
15	sisted treatment for such individuals, if ap-
16	plicable, and ways of overcoming barriers to
17	the use of medication-assisted treatment in
18	such population; and
19	(iv) efficient and effective communica-
20	tion, which may include the use of social
21	media, to maximize outreach efforts;
22	(B) disseminate such best practices to State
23	educational agencies, local educational agencies,
24	schools and dormitories funded by the Bureau of
25	Indian Education, institutions of higher edu-

1	cation, recovery programs at institutions of high-
2	er education, local boards, one-stop operators,
3	family and youth homeless providers, and non-
4	profit organizations, as appropriate;
5	(C) conduct a rigorous evaluation of each
6	grant funded under this subsection, particularly
7	its impact on the indicators described in para-
8	graph $(8)(B)$; and
9	(D) provide technical assistance for grantees
10	under this subsection.
11	(4) Grants authorized.—The Secretary, in
12	consultation with the Secretary of Education, shall
13	award 3-year grants, on a competitive basis, to eligi-
14	ble entities to enable such entities, in coordination
15	with Indian tribes, if applicable, and State agencies
16	responsible for carrying out substance use disorder
17	prevention and treatment programs, to carry out evi-
18	dence-based programs for—
19	(A) prevention of substance misuse and
20	abuse by children, adolescents, and young adults,
21	which may include primary prevention;
22	(B) recovery support services for children,
23	adolescents, and young adults, which may in-
24	clude counselina job trainina linkages to com-

1	munity-based services, family support groups,
2	peer mentoring, and recovery coaching; or
3	(C) treatment or referrals for treatment of
4	substance use disorders, which may include the
5	use of medication-assisted treatment, as appro-
6	priate.
7	(5) Special consideration.—In awarding
8	grants under this subsection, the Secretary shall give
9	special consideration to the unique needs of tribal,
10	urban, suburban, and rural populations.
11	(6) Application.—To be eligible for a grant
12	under this subsection, an entity shall submit to the
13	Secretary an application at such time, in such man-
14	ner, and containing such information as the Sec-
15	retary may require. Such application shall include—
16	(A) a description of—
17	(i) the impact of substance use dis-
18	orders in the population that will be served
19	by the grant program;
20	(ii) how the eligible entity has solicited
21	input from relevant stakeholders, which
22	may include faculty, teachers, staff, fami-
23	lies, students, and experts in substance use
24	prevention and treatment in developing
25	such application;

1	(iii) the goals of the proposed project,
2	including the intended outcomes;
3	(iv) how the eligible entity plans to use
4	grant funds for evidence-based activities, in
5	accordance with this subsection to prevent,
6	provide recovery support for, or treat sub-
7	stance use disorders amongst such individ-
8	uals, or a combination of such activities;
9	and
10	(v) how the eligible entity will collabo-
11	rate with relevant partners, which may in-
12	clude State educational agencies, local edu-
13	cational agencies, institutions of higher edu-
14	cation, juvenile justice agencies, prevention
15	and recovery support providers, local service
16	providers, including substance use disorder
17	treatment programs, providers of mental
18	health services, youth serving organizations,
19	family and youth homeless providers, child
20	welfare agencies, and primary care pro-
21	viders, in carrying out the grant program;
22	and
23	(B) an assurance that the eligible entity
24	will participate in the evaluation described in
25	paragraph (3)(C).

1	(7) Priority.—In awarding grants under this
2	subsection, the Secretary shall give priority to eligible
3	entities that propose to use grant funds for activities
4	that meet the criteria described in subclauses (I) and
5	(II) of section 8101(21)(A)(i) of the Elementary and
6	Secondary Education Act (20 U.S.C. $7801(21)(A)(i)$).
7	(8) Reports to the secretary.—Each eligible
8	entity awarded a grant under this subsection shall
9	submit to the Secretary, a report at such time and in
10	such manner as the Secretary may require. Such re-
11	port shall include—
12	(A) a description of how the eligible entity
13	used grant funds, in accordance with this sub-
14	section, including the number of children, adoles-
15	cents, and young adults reached through pro-
16	gramming; and
17	(B) a description, including relevant data,
18	of how the grant program has made an impact
19	on the intended outcomes described in paragraph
20	(6)(A)(iii), including—
21	(i) indicators of student success, which,
22	if the eligible entity is an educational insti-
23	tution, shall include student well-being and
24	academic achievement;

1	(ii) substance use disorders amongst
2	children, adolescents, and young adults, in-
3	cluding the number of overdoses and deaths
4	amongst children, adolescents, and young
5	adults during the grant period; and
6	(iii) other indicators, as the Secretary
7	determines appropriate.
8	(9) Report to congress.—The Secretary shall,
9	not later than October 1, 2022, submit a report to the
10	Committee on Health, Education, Labor, and Pen-
11	sions of the Senate, and the Committee on Energy
12	and Commerce and the Committee on Education and
13	the Workforce of the House of Representatives, a re-
14	port summarizing the effectiveness of the grant pro-
15	gram under this subsection, based on the information
16	submitted in reports required under paragraph (8).
17	(10) Authorization of Appropriations.—
18	There is authorized to be appropriated, such sums as
19	may be necessary to carry out this subsection for each
20	of fiscal years 2019 through 2023.
21	SEC. 412. PLANS OF SAFE CARE.
22	Section 105(a) of the Child Abuse Prevention and
23	Treatment Act (42 U.S.C. 5106(a)) is amended by adding
24	at the end the following:

1	"(7) Grants to states to improve and co-
2	ORDINATE THEIR RESPONSE TO ENSURE THE SAFETY,
3	PERMANENCY, AND WELL-BEING OF INFANTS AF-
4	FECTED BY SUBSTANCE USE.—
5	"(A) Program authorized.—The Sec-
6	retary shall make grants to States for the pur-
7	pose of assisting child welfare agencies, social
8	services agencies, substance use disorder treat-
9	ment agencies, hospitals with labor and delivery
10	units, medical staff, public health and mental
11	health agencies, and maternal and child health
12	agencies to facilitate collaboration in developing,
13	updating, implementing, and monitoring plans
14	of safe care described in section
15	106(b)(2)(B)(iii).
16	"(B) Distribution of funds.—
17	"(i) Reservations.—Of the amounts
18	appropriated under subparagraph (H), the
19	Secretary shall reserve—
20	"(I) no more than 3 percent for
21	the purposes described in subparagraph
22	(G); and
23	"(II) up to 3 percent for grants to
24	Indian tribes and tribal organizations
25	to address the needs of infants born

1	with, and identified as being affected
2	by, substance abuse or withdrawal
3	symptoms resulting from prenatal drug
4	exposure or a fetal alcohol spectrum
5	disorder and their families or care-
6	givers, which to the extent practicable,
7	shall be consistent with the uses of
8	funds described under subparagraph
9	(D).
10	"(ii) Allotments to states and
11	Territories.—The Secretary shall allot
12	the amount appropriated under subpara-
13	graph (H) that remains after application of
14	clause (i) to each States that applies for
15	such a grant, in an amount equal to the
16	sum of—
17	"(I) \$500,000; and
18	"(II) an amount that bears the
19	same relationship to any funds appro-
20	priated under subparagraph (H) and
21	remaining after application of clause
22	(i), as the number of live births in the
23	State in the previous calendar year
24	bears to the number of live births in all
25	States in such year.

1	"(iii) Ratable reduction.—If the
2	amount appropriated under subparagraph
3	(H) is insufficient to satisfy the require-
4	ments of clause (ii), the Secretary shall rat-
5	ably reduce each allotment to a State.
6	"(C) Application.—A State desiring a
7	grant under this paragraph shall submit an ap-
8	plication to the Secretary at such time and in
9	such manner as the Secretary may require. Such
10	application shall include—
11	"(i) a description of—
12	"(I) the impact of substance use
13	disorder in such State, including with
14	respect to the substance or class of sub-
15	stances with the highest incidence of
16	abuse in the previous year in such
17	State, including—
18	"(aa) the prevalence of sub-
19	stance use disorder in such State;
20	"(bb) the aggregate rate of
21	births in the State of infants af-
22	fected by substance abuse or with-
23	drawal symptoms or a fetal alco-
24	hol spectrum disorder (as deter-
25	mined by hospitals insurance

1	claims, claims submitted to the
2	State Medicaid program, or other
3	records), if available and to the
4	extent practicable; and
5	"(cc) the number of infants
6	identified, for whom a plan of safe
7	care was developed, and for whom
8	a referral was made for appro-
9	priate services, as reported under
10	$section \ 106(d)(18);$
11	"(II) the challenges the State faces
12	in developing, implementing, and mon-
13	itoring plans of safe care in accordance
14	with section $106(b)(2)(B)(iii)$;
15	"(III) the State's lead agency for
16	the grant program and how that agen-
17	cy will coordinate with relevant State
18	entities and programs, including the
19	child welfare agency, the substance use
20	disorder treatment agency, hospitals
21	with labor and delivery units, health
22	care providers, the public health and
23	mental health agencies, programs fund-
24	ed by the Substance Abuse and Mental
25	Health Services Administration that

1 provide substance use disorder treat-2 ment for women, the State Medicaid 3 program, the State agency admin-4 istering the block grant program under 5 title V of the Social Security Act (42 6 U.S.C. 701 et seg.), the State agency 7 administering the programs funded 8 under part C of the Individuals with 9 Disabilities Education Act (20 U.S.C. 10 1431 et seg.), the maternal, infant, and 11 early childhood home visiting program 12 under section 511 of the Social Secu-13 rity Act (42 U.S.C. 711), the State ju-14 dicial system, and other agencies, as 15 determined by the Secretary, and In-16 dian tribes and tribal organizations, as 17 appropriate; 18 "(IV) how the State will monitor 19 local development and implementation 20 of plans of safe care, in accordance 21 with section 106(b)(2)(B)(iii)(II), in-22 cluding how the State will monitor to 23 ensure plans of safe care address dif-24 ferences between substance use disorder 25 and medically supervised substance

1	use, including for the treatment of a
2	substance use disorder;
3	"(V) how the State meets the re-
4	quirements of section 1927 of the Pub-
5	lic Health Service Act (42 U.S.C.
6	300x-27);
7	"(VI) how the State plans to uti-
8	lize funding authorized under part E
9	of title IV of the Social Security Act
10	(42 U.S.C. 670 et seq.) to assist in car-
11	rying out any plan of safe care, in-
12	cluding such funding authorized under
13	section 471(e) of such Act (as in effect
14	on October 1, 2018) for mental health
15	and substance abuse prevention and
16	treatment services and in-home parent
17	skill-based programs and funding au-
18	thorized under such section 472(j) (as
19	in effect on October 1, 2018) for chil-
20	dren with a parent in a licensed resi-
21	dential family-based treatment facility
22	for substance abuse; and
23	"(VII) an assessment of the treat-
24	ment and other services and programs
25	available in the State, to effectively

1	carry out any plan of safe care devel-
2	oped, including identification of needed
3	treatment, and other services and pro-
4	grams to ensure the wellbeing of young
5	children and their families affected by
6	substance use disorder, such as pro-
7	grams carried out under part C of the
8	Individuals with Disabilities Edu-
9	cation Act and comprehensive early
10	childhood development services and
11	programs such as Head Start pro-
12	grams;
13	"(ii) a description of how the State
14	plans to use funds for activities described in
15	subparagraph (D) for the purposes of ensur-
16	ing State compliance with requirements
17	under clauses (ii) and (iii) of section
18	$106(b)(2)(B); \ and$
19	"(iii) an assurance that the State
20	will—
21	"(I) comply with this Act and
22	parts B and E of title IV of the Social
23	Security Act (42 U.S.C. 621 et seq.,
24	670 et seq.); and

1	"(II) comply with requirements to
2	refer a child identified as substance-ex-
3	posed to early intervention services as
4	required pursuant to a grant under
5	part C of the Individuals with Disabil-
6	ities Education Act (20 U.S.C. 1431 et
7	seq.).
8	"(D) Uses of funds.—Funds awarded to
9	a State under this paragraph may be used for
10	the following activities, which may be carried
11	out by the State directly, or through grants or
12	subgrants, contracts, or cooperative agreements:
13	"(i) Improving State and local systems
14	with respect to the development and imple-
15	mentation of plans of safe care, which—
16	"(I) shall include parent and
17	caregiver engagement, as required
18	$under\ section\ 106(b)(2)(B)(iii)(I),\ re-$
19	garding available treatment and serv-
20	ice options, which may include re-
21	sources available for pregnant,
22	perinatal, and postnatal women; and
23	"(II) may include activities such
24	as—

1	"(aa) developing policies,
2	procedures, or protocols for the
3	administration or development of
4	evidence-based and validated
5	screening tools for infants who
6	may be affected by substance use
7	withdrawal symptoms or a fetal
8	alcohol spectrum disorder and
9	pregnant, perinatal, and post-
10	natal women whose infants may
11	be affected by substance use with-
12	drawal symptoms or a fetal alco-
13	$hol\ spectrum\ disorder;$
14	"(bb) improving assessments
15	used to determine the needs of the
16	infant and family;
17	"(cc) improving ongoing case
18	management services; and
19	"(dd) improving access to
20	treatment services, which may be
21	prior to the pregnant woman's de-
22	livery date.
23	"(ii) Developing policies, procedures,
24	or protocols in consultation and coordina-
25	tion with health professionals, public and

1	private health facilities, and substance use
2	disorder treatment agencies to ensure that—
3	``(I) appropriate notification to
4	child protective services is made in a
5	timely manner;
6	"(II) a plan of safe care is in
7	place, in accordance with section
8	106(b)(2)(B)(iii), before the infant is
9	discharged from the birth or health
10	care facility; and
11	"(III) such health and related
12	agency professionals are trained on
13	how to follow such protocols and are
14	aware of the supports that may be pro-
15	vided under a plan of safe care.
16	"(iii) Training health professionals
17	and health system leaders, child welfare
18	workers, substance use disorder treatment
19	agencies, and other related professionals
20	such as home visiting agency staff and law
21	enforcement in relevant topics including—
22	"(I) State mandatory reporting
23	laws and the referral and process and
24	requirements for notification to child

1	protective services when child abuse or
2	neglect reporting is not mandated;
3	"(II) the co-occurrence of preg-
4	nancy and substance use disorder, and
5	implications of prenatal exposure;
6	"(III) the clinical guidance about
7	treating substance use disorder in
8	pregnant and postpartum women;
9	"(IV) appropriate screening and
10	interventions for infants affected by
11	substance use disorder, withdrawal
12	symptoms, or a fetal alcohol spectrum
13	disorder and the requirements under
14	section $106(b)(2)(B)(iii)$; and
15	"(V) appropriate
16	multigenerational strategies to address
17	the mental health needs of the parent
18	and child together.
19	"(iv) Establishing partnerships, agree-
20	ments, or memoranda of understanding be-
21	tween the lead agency and health profes-
22	sionals, health facilities, child welfare pro-
23	fessionals, juvenile and family court judges,
24	substance use and mental disorder treat-
25	ment programs, early childhood education

1	programs, and maternal and child health
2	and early intervention professionals, includ-
3	ing home visiting providers, peer-to-peer re-
4	covery programs such as parent mentoring
5	programs, and housing agencies to facilitate
6	the implementation of, and compliance with
7	section 106(b)(2) and clause (ii) of this sub-
8	paragraph, in areas which may include—
9	"(I) developing a comprehensive,
10	multi-disciplinary assessment and
11	intervention process for infants, preg-
12	nant women, and their families who
13	are affected by substance use disorder,
14	withdrawal symptoms, or a fetal alco-
15	hol spectrum disorder, that includes
16	meaningful engagement with and takes
17	into account the unique needs of each
18	family and addresses differences be-
19	tween medically supervised substance
20	use, including for the treatment of sub-
21	stance use disorder, and substance use
22	disorder;
23	"(II) ensuring that treatment ap-
24	proaches for serving infants, pregnant
25	women, and perinatal and postnatal

1	women whose infants may be affected
2	by substance use, withdrawal symp-
3	toms, or a fetal alcohol spectrum dis-
4	order, are designed to, where appro-
5	priate, keep infants with their mothers
6	during both inpatient and outpatient
7	treatment; and
8	"(III) increasing access to all evi-
9	dence-based medication-assisted treat-
10	ment approved by the Food and Drug
11	Administration, behavioral the rapy,
12	and counseling services for the treat-
13	ment of substance use disorders, as ap-
14	propriate.
15	"(v) Developing and updating systems
16	of technology for improved data collection
17	and monitoring under section
18	106(b)(2)(B)(iii), including existing elec-
19	tronic medical records, to measure the out-
20	comes achieved through the plans of safe
21	care, including monitoring systems to meet
22	the requirements of this Act and submission
23	of performance measures.
24	"(E) Reporting.—Each State that receives
25	funds under this paragraph, for each year such

1	funds are received, shall submit a report to the
2	Secretary, disaggregated by geographic location,
3	economic status, and major racial and ethnic
4	groups, except that such disaggregation shall not
5	be required if the results would reveal personally
6	identifiable information, on, with respect to in-
7	fants identified under section 106(b)(2)(B)(ii)—
8	"(i) the number who experienced re-
9	moval associated with parental substance
10	use;
11	"(ii) the number who experienced re-
12	moval and are subsequently are reunified
13	with parents, and the length of time between
14	such removal and reunification;
15	"(iii) the number who are referred to
16	community providers without a child pro-
17	$tection\ case;$
18	"(iv) the number who received services
19	while in the care of their birth parents;
20	"(v) the number who receive post-re-
21	unification services within 1 year after a
22	reunification has occurred; and
23	"(vi) the number who experienced a re-
24	turn to out-of-home care within 1 year after
25	reunification.

1	"(F) Secretary's report to con-
2	GRESS.—The Secretary shall submit an annual
3	report to the Committee on Health, Education,
4	Labor, and Pensions and the Committee on Ap-
5	propriations of the Senate and the Committee on
6	Education and the Workforce and the Committee
7	on Appropriations of the House of Representa-
8	tives that includes the information described in
9	subparagraph (E) and recommendations or ob-
10	servations on the challenges, successes, and les-
11	sons derived from implementation of the grant
12	program.
13	"(G) Reservation of funds.—The Sec-
14	retary shall use the amount reserved under sub-
15	paragraph $(B)(i)(I)$ for the purposes of—
16	"(i) providing technical assistance, in-
17	cluding programs of in-depth technical as-
18	sistance, to additional States, territories,
19	and Indian tribes and tribal organizations
20	in accordance with the substance-exposed
21	infant initiative developed by the National
22	Center on Substance Abuse and Child Wel-
23	fare;
24	"(ii) issuing guidance on the require-
25	ments of this Act with respect to infants

1	born with and identified as being affected
2	by substance use or withdrawal symptoms
3	or fetal alcohol spectrum disorder, as de-
4	scribed in clauses (ii) and (iii) of section
5	106(b)(2)(B), including by—
6	"(I) clarifying key terms; and
7	"(II) disseminating best practices
8	on implementation of plans of safe
9	care, on such topics as differential re-
10	sponse, collaboration and coordination,
11	and identification and delivery of serv-
12	ices for different populations;
13	"(iii) supporting State efforts to de-
14	velop information technology systems to
15	manage plans of safe care; and
16	"(iv) preparing the Secretary's report
17	to Congress described in subparagraph (F).
18	"(H) Authorization of Appropria-
19	TIONS.—To carry out the program under this
20	paragraph, there are authorized to be appro-
21	priated \$60,000,000 for each of fiscal years 2019
22	through 2023.".

1	SEC. 413. REGULATIONS RELATING TO SPECIAL REGISTRA-
2	TION FOR TELEMEDICINE.
3	Section 311(h) of the Controlled Substances Act (21
4	U.S.C. 831(h)) is amended by striking paragraph (2) and
5	inserting the following:
6	"(2) Regulations.—
7	"(A) In general.—Not later than 1 year
8	after the date of enactment of the Opioid Crisis
9	Response Act of 2018, in consultation with the
10	Secretary, and in accordance with the procedure
11	described in subparagraph (B), the Attorney
12	General shall promulgate final regulations speci-
13	fying—
14	"(i) the limited circumstances in which
15	a special registration under this subsection
16	may be issued; and
17	"(ii) the procedure for obtaining a spe-
18	cial registration under this subsection.
19	"(B) Procedure.—In promulgating final
20	regulations under subparagraph (A), the Attor-
21	ney General shall—
22	"(i) issue a notice of proposed rule-
23	making that includes a copy of the proposed
24	regulations:

1	"(ii) provide a period of not less than
2	60 days for comments on the proposed regu-
3	lations;
4	"(iii) finalize the proposed regulation
5	not later than 6 months after the close of the
6	comment period; and
7	"(iv) publish the final regulations not
8	later than 30 days before the effective date
9	of the final regulations.".
10	SEC. 414. NATIONAL HEALTH SERVICE CORPS BEHAVIORAL
11	AND MENTAL HEALTH PROFESSIONALS PRO-
12	VIDING OBLIGATED SERVICE IN SCHOOLS
13	AND OTHER COMMUNITY-BASED SETTINGS.
14	Subpart III of part D of title III of the Public Health
15	Service Act (42 U.S.C. 254l et seq.) is amended by adding
16	at the end the following:
17	"SEC. 338N. BEHAVIORAL AND MENTAL HEALTH PROFES-
18	SIONALS PROVIDING OBLIGATED SERVICE IN
19	SCHOOLS AND OTHER COMMUNITY-BASED
20	SETTINGS.
21	"(a) Schools and Community-based Settings.—
22	An entity to which a participant in the Scholarship Pro-
23	gram or the Loan Repayment Program (referred to in this
24	section as a 'participant') is assigned under section 333
25	may direct such participant to provide service as a behav-

- ioral or mental health professional at a school or other community-based setting located in a health professional short-3 age area. 4 "(b) Obligated Service.— "(1) In General.—Any service described in sub-5 6 section (a) that a participant provides may count to-7 wards such participant's completion of any obligated 8 service requirements under the Scholarship Program 9 or the Loan Repayment Program, subject to any limi-10 tation imposed under paragraph (2). 11 "(2) Limitation.—The Secretary may impose a 12 limitation on the number of hours of service described 13 in subsection (a) that a participant may credit to-14 wards completing obligated service requirements, pro-15 vided that the limitation allows a member to credit 16 service described in subsection (a) for not less than 50 17 percent of the total hours required to complete such 18 obligated service requirements. 19 "(c) Rule of Construction.—The authorization under subsection (a) shall be notwithstanding any other 20 21 provision of this subpart or subpart II.". 22 SEC. 415. LOAN REPAYMENT FOR SUBSTANCE USE DIS-23 ORDER TREATMENT PROVIDERS.
- 24 (a) Loan Repayment for Substance Use Treat-25 ment Providers.—The Secretary shall enter into con-

- 1 tracts under section 338B of the Public Health Service Act
- 2 (42 U.S.C. 254l-1) with eligible health professionals pro-
- 3 viding substance use disorder treatment services in sub-
- 4 stance use disorder treatment facilities, as defined by the
- 5 Secretary.
- 6 (b) Provision of Substance Use Disorder Treat-
- 7 MENT.—In carrying out the activities described in sub-
- 8 section (a)—
- 9 (1) each such facility shall be located in or serv-
- ing a mental health professional shortage area des-
- ignated under section 332 of the Public Health Serv-
- ice Act (42 U.S.C. 254e), or, as the Secretary deter-
- mines appropriate, an area with an age-adjusted rate
- of drug overdose deaths that is above the national
- 15 overdose mortality rate;
- 16 (2) section 331(a)(3)(D) of such Act (42 U.S.C.
- 17 254d(a)(3)(D)) shall be applied as if the term "pri-
- 18 mary health services" includes health services regard-
- ing substance use disorder treatment and infections
- 20 associated with illicit drug use;
- 21 (3) section 331(a)(3)(E)(i) of such Act (42)
- 22 U.S.C. 254d(a)(3)(E)(i)) shall be applied as if the
- 23 term "behavioral and mental health professionals" in-
- 24 cludes masters level, licensed substance use disorder
- 25 treatment counselors, and other relevant professionals

1	or paraprofessionals, as the Secretary determines ap-
2	propriate; and
3	(4) such professionals and facilities shall pro-
4	vide—
5	(A) directly, or through the use of telehealth
6	technology, and pursuant to Federal and State
7	law, counseling by a program counselor or other
8	certified professional who is licensed and quali-
9	fied by education, training, or experience to as-
10	sess the psychological and sociological back-
11	ground of patients, to contribute to the appro-
12	priate treatment plan for the patient, and to
13	monitor progress; and
14	(B) medication-assisted treatment, includ-
15	ing, to the extent practicable, all drugs approved
16	by the Food and Drug Administration to treat
17	substance use disorders, pursuant to Federal and
18	$State\ law.$
19	(c) Authorization of Appropriations.—There is
20	authorized to be appropriated to carry out this section
21	\$25,000,000 for each of fiscal years 2019 through 2023.
22	SEC. 416. PROTECTING MOMS AND INFANTS.
23	(a) Report.—
24	(1) In General.—Not later than 60 days after
25	the date of enactment of this Act, the Secretary shall

1	submit to the appropriate committees of Congress and
2	make available to the public on the internet website
3	of the Department of Health and Human Services a
4	report regarding the implementation of the rec-
5	ommendations in the strategy relating to prenatal
6	opioid use, including neonatal abstinence syndrome,
7	developed pursuant to section 2 of the Protecting Our
8	Infants Act of 2015 (Public Law 114–91). Such re-
9	port shall include—
10	(A) an update on the implementation of the
11	recommendations in the strategy, including in-
12	formation regarding the agencies involved in the
13	implementation; and

- (B) information on additional funding or authority the Secretary requires, if any, to implement the strategy, which may include authorities needed to coordinate implementation of such strategy across the Department of Health and Human Services.
- 20 (2) Periodic Updates.—The Secretary shall
 21 periodically update the report under paragraph (1).
 22 (b) Residential Treatment Programs for Preg23 Nant and Postpartum Women.—Section 508(s) of the
 24 Public Health Service Act (42 U.S.C. 290bb-1(s)) is amend25 ed by striking "\$16,900,000 for each of fiscal years 2017

14

15

16

17

18

19

1	through 2021" and inserting "\$29,931,000 for each of fiscal
2	years 2019 through 2023".
3	SEC. 417. EARLY INTERVENTIONS FOR PREGNANT WOMEN
4	AND INFANTS.
5	(a) Development of Educational Materials by
6	Center for Substance Abuse Prevention.—Section
7	515(b) of the Public Health Service Act (42 U.S.C. 290bb-
8	21(b)) is amended—
9	(1) in paragraph (13), by striking "and" at the
10	end;
11	(2) in paragraph (14), by striking the period at
12	the end and inserting "; and"; and
13	(3) by adding at the end the following:
14	"(15) in cooperation with relevant stakeholders
15	and the Director of the Centers for Disease Control
16	and Prevention, develop educational materials for cli-
17	nicians to use with pregnant women for shared deci-
18	sionmaking regarding pain management during preg-
19	nancy.".
20	(b) Guidelines and Recommendations by Center
21	FOR SUBSTANCE ABUSE TREATMENT.—Section 507(b) of
22	the Public Health Service Act (42 U.S.C. 290bb(b)) is
23	amended—
24	(1) in paragraph (13), by striking "and" at the
25	end:

1	(2) in paragraph (14), by striking the period at
2	the end and inserting a semicolon; and
3	(3) by adding at the end the following:
4	"(15) in cooperation with the Secretary, imple-
5	ment and disseminate, as appropriate, the rec-
6	ommendations in the report entitled Protecting Our
7	Infants Act: Final Strategy' issued by the Depart-
8	ment of Health and Human Services in 2017; and".
9	(c) Support of Partnerships by Center for Sub-
10	STANCE ABUSE TREATMENT.—Section 507(b) of the Public
11	Health Service Act (42 U.S.C. 290bb(b)), as amended by
12	subsection (b), is further amended by adding at the end the
13	following:
14	"(16) in cooperation with relevant stakeholders,
15	support public-private partnerships to assist with
16	education about, and support with respect to, sub-
17	stance use disorder for pregnant women and health
18	care providers who treat pregnant women and ba-
19	bies.".
20	SEC. 418. REPORT ON INVESTIGATIONS REGARDING PARITY
21	IN MENTAL HEALTH AND SUBSTANCE USE
22	DISORDER BENEFITS.
23	(a) In General.—Section 13003 of the 21st Century
24	Cures Act (Public Law 114–255) is amended—

1	(1) in subsection (a), by striking "with findings
2	of any serious violation regarding" and inserting
3	"concerning"; and
4	(2) in subsection (b)(1)—
5	(A) by inserting "complaints received and
6	number of" before "closed"; and
7	(B) by inserting before the period ", and,
8	for each such investigation closed, which agency
9	conducted the investigation, whether the health
10	plan that is the subject of the investigation is
11	fully insured or not fully insured and a sum-
12	mary of any coordination between the applicable
13	State regulators and the Department of Labor,
14	the Department of Health and Human Services,
15	or the Department of the Treasury, and ref-
16	erences to any guidance provided by the agencies
17	addressing the category of violation committed".
18	(b) APPLICABILITY.—The amendments made by sub-
19	section (a) shall apply with respect to the second annual
20	report required under such section 13003 and each such an-
21	nual report thereafter.
22	TITLE V—PREVENTION
23	SEC. 501. STUDY ON PRESCRIBING LIMITS.
24	Not later than 2 years after the date of enactment of
25	this Act. the Secretary in consultation with the Attorney

1	General, shall submit to the Committee on Health, Edu-
2	cation, Labor, and Pensions of the Senate and the Com-
3	mittee on Energy and Commerce of the House of Represent-
4	atives a report on the impact of Federal and State laws
5	and regulations that limit the length, quantity, or dosage
6	of opioid prescriptions. Such report shall address—
7	(1) the impact of such limits on—
8	(A) the incidence and prevalence of overdose
9	related to prescription opioids;
10	(B) the incidence and prevalence of overdose
11	related to illicit opioids;
12	(C) the prevalence of opioid use disorders;
13	(D) medically appropriate use of, and ac-
14	cess to, opioids, including any impact on travel
15	expenses and pain management outcomes for pa-
16	tients, whether such limits are associated with
17	significantly higher rates of negative health out-
18	comes, including suicide, and whether the impact
19	of such limits differs based on clinical indication
20	for which opioids are prescribed;
21	(2) whether such limits lead to a significant in-
22	crease in burden for prescribers of opioids or pre-
23	scribers of treatments for opioid use disorder, includ-
24	ing any impact on patient access to treatment, and

1	whether any such burden is mitigated by any factors
2	such as electronic prescribing or telemedicine; and
3	(3) the impact of such limits on diversion or
4	misuse of any controlled substance in schedule II, III,
5	or IV of section 202(c) of the Controlled Substances
6	Act (21 U.S.C. 812(c)).
7	SEC. 502. PROGRAMS FOR HEALTH CARE WORKFORCE.
8	(a) Program for Education and Training in Pain
9	Care.—Section 759 of the Public Health Service Act (42
10	U.S.C. 294i) is amended—
11	(1) in subsection (a), by striking "hospices, and
12	other public and private entities" and inserting "hos-
13	pices, tribal health programs (as defined in section 4
14	of the Indian Health Care Improvement Act), and
15	other public and nonprofit private entities";
16	(2) in subsection (b)—
17	(A) in the matter preceding paragraph (1),
18	by striking "award may be made under sub-
19	section (a) only if the applicant for the award
20	agrees that the program carried out with the
21	award will include" and inserting "entity re-
22	ceiving an award under this section shall develop
23	a comprehensive education and training plan
24	that includes";
25	(B) in paragraph (1)—

1	(i) by inserting "preventing," after
2	"diagnosing,"; and
3	(ii) by inserting "non-addictive med-
4	ical products and non-pharmacologic treat-
5	ments and" after "including";
6	(C) in paragraph (2)—
7	(i) by inserting "Federal, State, and
8	local" after "applicable"; and
9	(ii) by striking "the degree to which"
10	and all that follows through "effective pain
11	care" and inserting "opioids";
12	(D) in paragraph (3), by inserting ", inte-
13	grated, evidence-based pain management, and, as
14	appropriate, non-pharmacotherapy" before the
15	semicolon;
16	(E) in paragraph (4), by striking "; and"
17	and inserting ";"; and
18	(F) by striking paragraph (5) and inserting
19	$the\ following:$
20	"(5) recent findings, developments, and advance-
21	ments in pain care research and the provision of pain
22	care, which may include non-addictive medical prod-
23	ucts and non-pharmacologic treatments intended to
24	treat pain; and

1	"(6) the dangers of opioid abuse and misuse, de-
2	tection of early warning signs of opioid use disorders
3	(which may include best practices related to screening
4	for opioid use disorders, training on screening, brief
5	intervention, and referral to treatment), and safe dis-
6	posal options for prescription medications (including
7	such options provided by law enforcement or other in-
8	novative deactivation mechanisms).";
9	(3) in subsection (d), by inserting "prevention,"
10	after "diagnosis,"; and
11	(4) in subsection (e), by striking "2010 through
12	2012" and inserting "2019 through 2023".
13	(b) Mental and Behavioral Health Education
14	AND TRAINING PROGRAM.—Section 756(a) of the Public
15	Health Service Act (42 U.S.C. 294e–1(a)) is amended—
16	(1) in paragraph (1), by inserting ", trauma,"
17	after "focus on child and adolescent mental health";
18	and
19	(2) in paragraphs (2) and (3), by inserting
20	"trauma-informed care and" before "substance use
21	disorder prevention and treatment services".
22	SEC. 503. EDUCATION AND AWARENESS CAMPAIGNS.
23	Section 102 of the Comprehensive Addiction and Re-
24	covery Act of 2016 (Public Law 114–198) is amended—

1	(1) by amending subsection (a) to read as fol-
2	lows:
3	"(a) In General.—The Secretary of Health and
4	Human Services, acting through the Director of the Centers
5	for Disease Control and Prevention and in coordination
6	with the heads of other departments and agencies, shall ad-
7	vance education and awareness regarding the risks related
8	to misuse and abuse of opioids, as appropriate, which may
9	include developing or improving existing programs, con-
10	ducting activities, and awarding grants that advance the
11	education and awareness of—
12	"(1) the public, including patients and con-
13	sumers;
14	"(2) patients, consumers, and other appropriate
15	members of the public, regarding such risks related to
16	unused opioids and the dispensing options under sec-
17	tion 309(f) of the Controlled Substances Act, as appli-
18	cable;
19	"(3) providers, which may include—
20	"(A) providing for continuing education on
21	$appropriate\ prescribing\ practices;$
22	"(B) education related to applicable State
23	or local prescriber limit laws, information on the
24	use of non-addictive alternatives for pain man-

1	agement, and the use of overdose reversal drugs,
2	as appropriate;
3	"(C) disseminating and improving the use
4	of evidence-based opioid prescribing guidelines
5	across relevant health care settings, as appro-
6	priate, and updating guidelines as necessary;
7	"(D) implementing strategies, such as best
8	practices, to encourage and facilitate the use of
9	prescriber guidelines, in accordance with State
10	and local law;
11	"(E) disseminating information to pro-
12	viders about prescribing options for controlled
13	substances, including such options under section
14	309(f) of the Controlled Substances Act, as appli-
15	cable; and
16	"(F) disseminating information, as appro-
17	priate, on the National Pain Strategy developed
18	by or in consultation with the Assistant Sec-
19	retary for Health; and
20	"(4) other appropriate entities."; and
21	(2) in subsection (b)—
22	(A) by striking "opioid abuse" each place
23	such term appears and inserting "opioid misuse
24	and abuse"; and

1	(B) in paragraph (2), by striking "safe dis-
2	posal of prescription medications and other" and
3	inserting "non-addictive treatment options, safe
4	disposal options for prescription medications,
5	and other applicable".
6	SEC. 504. ENHANCED CONTROLLED SUBSTANCE
7	OVERDOSES DATA COLLECTION, ANALYSIS,
8	AND DISSEMINATION.
9	Part J of title III of the Public Health Service Act
10	is amended by inserting after section 392 (42 U.S.C. 280b-
11	1) the following:
12	"SEC. 392A. ENHANCED CONTROLLED SUBSTANCE
13	OVERDOSES DATA COLLECTION, ANALYSIS,
13 14	OVERDOSES DATA COLLECTION, ANALYSIS, AND DISSEMINATION.
14 15	AND DISSEMINATION.
14 15 16	AND DISSEMINATION. "(a) In General.—The Director of the Centers for
14 15 16	AND DISSEMINATION. "(a) In General.—The Director of the Centers for Disease Control and Prevention, using the authority pro-
14 15 16 17	AND DISSEMINATION. "(a) In General.—The Director of the Centers for Disease Control and Prevention, using the authority provided to the Director under section 392, may—
14 15 16 17	"(a) In General.—The Director of the Centers for Disease Control and Prevention, using the authority provided to the Director under section 392, may— "(1) to the extent practicable, carry out and ex-
114 115 116 117 118	"(a) In General.—The Director of the Centers for Disease Control and Prevention, using the authority provided to the Director under section 392, may— "(1) to the extent practicable, carry out and expand any controlled substance overdose data collec-
114 115 116 117 118 119 220	"(a) In General.—The Director of the Centers for Disease Control and Prevention, using the authority provided to the Director under section 392, may— "(1) to the extent practicable, carry out and expand any controlled substance overdose data collection, analysis, and dissemination activity described
14 15 16 17 18 19 20 21	"(a) In General.—The Director of the Centers for Disease Control and Prevention, using the authority provided to the Director under section 392, may— "(1) to the extent practicable, carry out and expand any controlled substance overdose data collection, analysis, and dissemination activity described in subsection (b);

1	"(3) award grants to States, localities, and In-
2	dian tribes for the purpose of carrying out any such
3	activity.
4	"(b) Controlled Substance Overdose Data Col-
5	LECTION AND ANALYSIS ACTIVITIES.—A controlled sub-
6	stance overdose data collection, analysis, and dissemination
7	activity described in this subsection is any of the following
8	activities:
9	"(1) Improving the timeliness of reporting aggre-
10	gate data to the public, including data on fatal and
11	nonfatal controlled substance overdoses.
12	"(2) Enhancing the comprehensiveness of con-
13	trolled substance overdose data by collecting informa-
14	tion on such overdoses from appropriate sources such
15	as toxicology reports, autopsy reports, death scene in-
16	vestigations, and emergency department services.
17	"(3) Modernizing the system for coding causes of
18	death related to controlled substance overdoses to use
19	an electronic-based system.
20	"(4) Using data to help identify risk factors as-
21	sociated with controlled substance overdoses, including
22	the delivery of certain health care services.
23	"(5) Supporting entities involved in reporting
24	information on controlled substance overdoses, such as
25	coroners and medical examiners, to improve accurate

1	testing and standardized reporting of causes and con-
2	tributing factors of such overdoses, and analysis of
3	various opioid analogues to controlled substances
4	overdoses.
5	"(6) Working to enable and encourage the access,
6	exchange, and use of data regarding controlled sub-
7	stances overdoses among data sources and entities.
8	"(c) Definitions.—In this section—
9	"(1) the term 'controlled substance' has the
10	meaning given that term in section 102 of the Con-
11	trolled Substances Act; and
12	"(2) the term 'Indian tribe' has the meaning
13	given that term in section 4 of the Indian Self-Deter-
14	mination and Education Assistance Act.".
15	SEC. 505. PREVENTING OVERDOSES OF CONTROLLED SUB-
16	STANCES.
17	Part J of title III of the Public Health Service Act
18	(42 U.S.C. 280b et seq.), as amended by section 504, is fur-
19	ther amended by inserting after section 392A the following:
20	"SEC. 392B. PREVENTING OVERDOSES OF CONTROLLED
21	SUBSTANCES.
22	"(a) Prevention Activities.—
23	"(1) In General.—The Director of the Centers
24	for Disease Control and Prevention (referred to in

1	this section as the 'Director'), using the authority
2	provided to the Director under section 392, may—
3	"(A) to the extent practicable, carry out and
4	expand any prevention activity described in
5	paragraph (2);
6	"(B) provide training and technical assist-
7	ance to States, localities, and Indian tribes to
8	carrying out any such activity; and
9	"(C) award grants to States, localities, and
10	Indian tribes for the purpose of carrying out any
11	such activity.
12	"(2) Prevention activities.—A prevention ac-
13	tivity described in this paragraph is an activity to
14	improve the efficiency and use of a new or currently
15	operating prescription drug monitoring program,
16	such as—
17	"(A) encouraging all authorized users (as
18	specified by the State or other entity) to register
19	with and use the program;
20	"(B) enabling such users to access any data
21	updates in as close to real-time as practicable;
22	"(C) providing for a mechanism for the pro-
23	gram to notify authorized users of any potential
24	misuse or abuse of controlled substances and any

1	detection	of	in appropriate	prescribing	or	dis-
2	pensing p	rac	tices relating to	such substan	ıces;	•

- "(D) encouraging the analysis of prescription drug monitoring data for purposes of providing de-identified, aggregate reports based on such analysis to State public health agencies, State alcohol and drug agencies, State licensing boards, and other appropriate State agencies, as permitted under applicable Federal and State law and the policies of the prescription drug monitoring program and not containing any protected health information, to prevent inappropriate prescribing, drug diversion, or abuse and misuse of controlled substances, and to facilitate better coordination among agencies;
- "(E) enhancing interoperability between the program and any health information technology (including certified health information technology), including by integrating program data into such technology;
- "(F) updating program capabilities to respond to technological innovation for purposes of appropriately addressing the occurrence and evolution of controlled substance overdoses;

1	"(G) developing or enhancing data exchange
2	with other sources such as the Medicaid agency,
3	the Medicare program, pharmacy benefit man-
4	agers, coroners' reports, and workers' compensa-
5	tion data;
6	"(H) facilitating and encouraging data ex-
7	change between the program and the prescription
8	drug monitoring programs of other States;
9	"(I) enhancing data collection and quality,
10	including improving patient matching and
11	proactively monitoring data quality; and
12	"(J) providing prescriber and dispenser
13	practice tools, including prescriber practice in-
14	sight reports for practitioners to review their
15	prescribing patterns in comparison to such pat-
16	ters of other practitioners the specialty.
17	"(b) Additional Grants.—The Director may award
18	grants to States, localities, and Indian tribes—
19	"(1) to carry out innovative projects for grantees
20	to rapidly respond to controlled substance misuse,
21	abuse, and overdoses, including changes in patterns of
22	controlled substance use; and
23	"(2) for any other evidence-based activity for
24	preventing controlled substance misuse, abuse, and
25	overdoses as the Director determines appropriate.

1	"(c) Research.—The Director, in coordination with
2	the Assistant Secretary for Mental Health and Substance
3	Use and the National Mental Health and Substance Use
4	Policy Laboratory established under section 501A, as ap-
5	propriate and applicable, may conduct studies and evalua-
6	tions to address substance use disorders, including pre-
7	venting substance use disorders or other related topics the
8	Director determines appropriate.
9	"(d) Public and Prescriber Education.—Pursu-
10	ant to section 102 of the Comprehensive Addiction and Re-
11	covery Act of 2016, the Director may advance the education
12	and awareness of prescribers and the public regarding the
13	risk of abuse and misuse of prescription opioids.
14	"(e) Definitions.—In this section—
15	"(1) the term 'controlled substance' has the
16	meaning given that term in section 102 of the Con-
17	trolled Substances Act; and
18	"(2) the term 'Indian tribe' has the meaning
19	given that term in section 4 of the Indian Self-Deter
20	mination and Education Assistance Act.
21	"(f) Authorization of Appropriations.—For pur-
22	poses of carrying out this section, section 392A of this Act
23	and section 102 of the Comprehensive Addiction and Recov-
24	ery Act of 2016, there is authorized to be appropriated

25 \$486,000,000 for each of fiscal years 2019 through 2024.".

1 SEC. 506. CDC SURVEILLANCE AND DATA COLLECTION FOR 2 CHILD, YOUTH, AND ADULT TRAUMA.

- 3 (a) Data Collection.—The Director of the Centers
- 4 for Disease Control and Prevention (referred to in this sec-
- 5 tion as the "Director") may, in cooperation with the States,
- 6 collect and report data on adverse childhood experiences
- 7 through the Behavioral Risk Factor Surveillance System,
- 8 the Youth Risk Behavior Surveillance System, and other
- 9 relevant public health surveys or questionnaires.
- 10 (b) Timing.—The collection of data under subsection
- 11 (a) may occur in fiscal year 2019 and every 2 years there-
- 12 after.
- 13 (c) Data From Tribal and Rural Areas.—The Di-
- 14 rector shall encourage each State that participates in col-
- 15 lecting and reporting data under subsection (a) to collect
- 16 and report data from tribal and rural areas within such
- 17 State, in order to generate a statistically reliable represen-
- 18 tation of such areas.
- 19 (d) Authorization of Appropriations.—To carry
- 20 out this section, there are authorized to be appropriated
- 21 such sums as may be necessary for the period of fiscal years
- 22 2019 through 2021.
- 23 SEC. 507. REAUTHORIZATION OF NASPER.
- 24 Section 3990 of the Public Health Service Act (42
- 25 U.S.C. 280g-3) is amended—
- 26 (1) in subsection (a)—

	_ 0 0
1	(A) in paragraph (1), in the matter pre-
2	ceding subparagraph (A), by striking "in con-
3	sultation with the Administrator of the Sub-
4	stance Abuse and Mental Health Services Ad-
5	ministration and Director of the Centers for Dis-
6	ease Control and Prevention" and inserting "in
7	coordination with the Director of the Centers for
8	Disease Control and the heads of other depart-
9	ments and agencies as appropriate"; and
10	(B) by adding at the end the following:
11	"(4) States and local governments.—

"(A) In General.—In the case of a State that does not have a prescription drug monitoring program, a county or other unit of local government within the State that has a prescription drug monitoring program shall be treated as a State for purposes of this section, including for purposes of eligibility for grants under paragraph (1).

"(B) Plan for interoperability.—For purposes of meeting the interoperability requirements under subsection (c)(3), a county or other unit of local government shall submit a plan outlining the methods such county or unit of local government will use to ensure the capability of

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1	data sharing with other counties and units of
2	local government within the State and with other
3	States, as applicable.";
4	(2) in subsection (c)—
5	(A) in paragraph (1)(A)(iii)—
6	(i) by inserting "as such standards be-
7	come available," after "interoperability
8	standards,"; and
9	(ii) by striking "generated or identified
10	by the Secretary or his or her designee" and
11	inserting "recognized by the Office of the
12	National Coordinator for Health Informa-
13	tion Technology"; and
14	(B) in paragraph (3)(A), by inserting "in-
15	cluding electronic health records," after "tech-
16	nology systems,";
17	(3) in subsection $(d)(1)$, by striking "not later
18	than 1 week after the date of such dispensing" and
19	inserting "in as close to real time as practicable";
20	(4) in subsection (f)—
21	(A) in paragraph (1)(D), by striking "med-
22	icaid" and inserting "Medicaid"; and
23	(B) in paragraph (2)—
24	(i) in subparagraph (A), by striking
25	"and" at the end;

1	(ii) in subparagraph (B), by striking
2	the period and inserting a semicolon; and
3	(iii) by adding at the end the fol-
4	lowing:
5	"(C) may conduct analyses of controlled
6	substance program data for purposes of pro-
7	viding appropriate State agencies with aggregate
8	reports based on such analyses in as close to
9	real-time as practicable, regarding prescription
10	patterns flagged as potentially presenting a risk
11	of misuse, abuse, addiction, overdose, and other
12	aggregate information, as appropriate and in
13	compliance with applicable Federal and State
14	laws and provided that such reports shall not in-
15	clude protected health information; and
16	"(D) may access information about pre-
17	scriptions, such as claims data, to ensure that
18	such prescribing and dispensing history is up-
19	dated in as close to real-time as practicable, in
20	compliance with applicable Federal and State
21	laws and provided that such information shall
22	not include protected health information.";
23	(5) in subsection (i), by inserting ", in collabora-
24	tion with the National Coordinator for Health Infor-
25	mation Technology and the Director of the National

1	Institute of Standards and Technology," after "The
2	Secretary"; and
3	(6) in subsection (n), by striking "2021" and in-
4	serting "2026".
5	SEC. 508. JESSIE'S LAW.
6	(a) Best Practices.—
7	(1) In general.—Not later than 1 year after
8	the date of enactment of this Act, the Secretary, in
9	consultation with appropriate stakeholders, including
10	a patient with a history of opioid use disorder, an ex-
11	pert in electronic health records, an expert in the con-
12	fidentiality of patient health information and records,
13	and a health care provider, shall identify or facilitate
14	the development of best practices regarding—
15	(A) the circumstances under which informa-
16	tion that a patient has provided to a health care
17	provider regarding such patient's history of
18	opioid use disorder should, only at the patient's
19	request, be prominently displayed in the medical
20	records (including electronic health records) of
21	such patient;
22	(B) what constitutes the patient's request
23	for the purpose described in subparagraph (A);
24	and

1	(C) the process and methods by which the
2	information should be so displayed.
3	(2) Dissemination.—The Secretary shall dis-
4	seminate the best practices developed under para-
5	graph (1) to health care providers and State agencies.
6	(b) Requirements.—In identifying or facilitating
7	the development of best practices under subsection (a), as
8	applicable, the Secretary, in consultation with appropriate
9	stakeholders, shall consider the following:
10	(1) The potential for addiction relapse or over-
11	dose, including overdose death, when opioid medica-
12	tions are prescribed to a patient recovering from
13	opioid use disorder.
14	(2) The benefits of displaying information about
15	a patient's opioid use disorder history in a manner
16	similar to other potentially lethal medical concerns,
17	including drug allergies and contraindications.
18	(3) The importance of prominently displaying
19	information about a patient's opioid use disorder
20	when a physician or medical professional is pre-
21	scribing medication, including methods for avoiding
22	alert fatigue in providers.
23	(4) The importance of a variety of appropriate
24	medical professionals, including physicians, nurses,
25	and pharmacists, having access to information de-

1	scribed in this section when prescribing or dispensing
2	opioid medication, consistent with Federal and State
3	laws and regulations.
4	(5) The importance of protecting patient pri-
5	vacy, including the requirements related to consent
6	for disclosure of substance use disorder information
7	under all applicable laws and regulations.
8	(6) All applicable Federal and State laws and
9	regulations.
10	SEC. 509. DEVELOPMENT AND DISSEMINATION OF MODEL
11	TRAINING PROGRAMS FOR SUBSTANCE USE
12	DISORDER PATIENT RECORDS.
13	(a) Initial Programs and Materials.—Not later
14	than 1 year after the date of the enactment of this Act, the
15	Secretary, in consultation with appropriate experts, shall
16	identify the following model programs and materials (or
17	if no such programs or materials exist, recognize private
18	or public entities to develop and disseminate such programs
19	and materials):
20	(1) Model programs and materials for training
21	health care providers (including physicians, emer-
22	gency medical personnel, psychiatrists, psychologists,
23	counselors, therapists, nurse practitioners, physician
24	assistants, behavioral health facilities and clinics,
25	care managers, and hospitals, including individuals

- 1 such as general counsels or regulatory compliance 2 staff who are responsible for establishing provider pri-3 vacy policies) concerning the permitted uses and dis-4 closures, consistent with the standards and regula-5 tions governing the privacy and security of substance 6 use disorder patient records promulgated by the Sec-7 retary under section 543 of the Public Health Service 8 Act (42 U.S.C. 290dd-2) for the confidentiality of patient records. 9
- 10 (2) Model programs and materials for training 11 patients and their families regarding their rights to 12 protect and obtain information under the standards 13 and regulations described in paragraph (1).
- 14 (b) REQUIREMENTS.—The model programs and mate-15 rials described in paragraphs (1) and (2) of subsection (a) 16 shall address circumstances under which disclosure of sub-17 stance use disorder patient records is needed to—
 - (1) facilitate communication between substance use disorder treatment providers and other health care providers to promote and provide the best possible integrated care;
- 22 (2) avoid inappropriate prescribing that can 23 lead to dangerous drug interactions, overdose, or re-24 lapse; and

18

19

20

21

1	(3) notify and involve families and caregivers
2	when individuals experience an overdose.
3	(c) Periodic Updates.—The Secretary shall—
4	(1) periodically review and update the model
5	program and materials identified or developed under
6	subsection (a); and
7	(2) disseminate such updated programs and ma-
8	terials to the individuals described in subsection
9	(a)(1).
10	(d) Input of Certain Entities.—In identifying, re-
11	viewing, or updating the model programs and materials
12	under this section, the Secretary shall solicit the input of
13	relevant stakeholders.
14	(e) Authorization of Appropriations.—There is
15	authorized to be appropriated to carry out this section, such
16	sums as may be necessary for each of fiscal years 2019
17	through 2023.
18	SEC. 510. COMMUNICATION WITH FAMILIES DURING EMER-
19	GENCIES.
20	(a) Promoting Awareness of Authorized Disclo-
21	Sures During Emergencies.—The Secretary shall annu-
22	ally notify health care providers regarding permitted disclo-
23	sures during emergencies, including overdoses, of certain
24	health information to families and caregivers under Federal
25	health care privacy laws and regulations.

1	(b) Use of Material.—For the purposes of carrying
2	out subsection (a), the Secretary may use material produced
3	under section 509 of this Act or under section 11004 of the
4	21st Century Cures Act (42 U.S.C. 1320d-2 note).
5	SEC. 511. PRENATAL AND POSTNATAL HEALTH.
6	Section 317L of the Public Health Service Act (42
7	U.S.C. 247b–13) is amended—
8	(1) in subsection (a)—
9	(A) by amending paragraph (1) to read as
10	follows:
11	"(1) to collect, analyze, and make available data
12	on prenatal smoking, alcohol and substance abuse and
13	misuse, including—
14	"(A) data on—
15	"(i) the incidence, prevalence, and im-
16	plications of such activities; and
17	"(ii) the incidence and prevalence of
18	implications and outcomes, including neo-
19	natal abstinence syndrome and other mater-
20	nal and child health outcomes associated
21	with such activities; and
22	"(B) to inform such analysis, additional in-
23	formation or data on family health history,
24	medication exposures during pregnancy, demo-
25	graphic information, such as race, ethnicity, geo-

graphic location, and family history, and other
relevant information, as appropriate;";
(B) in paragraph (2)—
(i) by striking "prevention of" and in-
serting "prevention and long-term outcomes
associated with"; and
(ii) by striking "illegal drug use" and
inserting "substance abuse and misuse";
(C) in paragraph (3), by striking "and ces-
sation programs; and" and inserting ", treat-
ment, and cessation programs;";
(D) in paragraph (4), by striking "illegal
drug use." and inserting "substance abuse and
misuse; and"; and
(E) by adding at the end the following:
"(5) to issue public reports on the analysis of
data described in paragraph (1), including analysis
of—
"(A) long-term outcomes of children affected
by neonatal abstinence syndrome;
"(B) health outcomes associated with pre-
natal smoking, alcohol, and substance abuse and
misuse; and

1	"(C) relevant studies, evaluations, or infor-
2	mation the Secretary determines to be appro-
3	priate.";
4	(2) in subsection (b), by inserting "tribal enti-
5	ties," after "local governments,";
6	(3) by redesignating subsection (c) as subsection
7	(d);
8	(4) by inserting after subsection (b) the fol-
9	lowing:
10	"(c) Coordinating Activities.—To carry out this
11	section, the Secretary may—
12	"(1) provide technical and consultative assist-
13	ance to entities receiving grants under subsection (b);
14	"(2) ensure a pathway for data sharing between
15	States, tribal entities, and the Centers for Disease
16	Control and Prevention;
17	"(3) ensure data collection under this section is
18	consistent with applicable State, Federal, and Tribal
19	privacy laws; and
20	"(4) coordinate with the National Coordinator
21	for Health Information Technology, as appropriate,
22	to assist States and tribes in implementing systems
23	that use standards recognized by such National Coor-
24	dinator, as such recognized standards are available,
25	in order to facilitate interoperability between such

1	systems and health information technology systems,
2	including certified health information technology.";
3	and
4	(5) in subsection (d), as so redesignated, by
5	striking "2001 through 2005" and inserting "2019
6	through 2023".
7	SEC. 512. SURVEILLANCE AND EDUCATION REGARDING IN-
8	FECTIONS ASSOCIATED WITH ILLICIT DRUG
9	USE AND OTHER RISK FACTORS.
10	Section 317N of the Public Health Service Act (42
11	U.S.C. 247b–15) is amended—
12	(1) by amending the section heading to read as
13	follows: "Surveillance and education re-
14	GARDING INFECTIONS ASSOCIATED WITH IL-
15	LICIT DRUG USE AND OTHER RISK FACTORS";
16	(2) in subsection (a)—
17	(A) in the matter preceding paragraph (1),
18	by inserting "activities" before the colon;
19	(B) in paragraph (1)—
20	(i) by inserting "or maintaining" after
21	``implementing";
22	(ii) by striking "hepatitis C virus in-
23	fection (in this section referred to as 'HCV
24	infection')" and inserting "infections com-
25	monly associated with illicit drug use,

1	which may include viral hepatitis, human
2	immunodeficiency virus, and infective endo-
3	carditis,"; and
4	(iii) by striking "such infection" and
5	all that follows through the period at the
6	end and inserting "such infections, which
7	may include the reporting of cases of such
8	infections.";
9	(C) in paragraph (2), by striking "HCV in-
10	fection" and all that follows through the period
11	at the end and inserting "infections as a result
12	of illicit drug use, receiving blood transfusions
13	prior to July 1992, or other risk factors.";
14	(D) in paragraphs (4) and (5), by striking
15	"HCV infection" each place such term appears
16	and inserting "infections described in paragraph
17	(1)"; and
18	(E) in paragraph (5), by striking "pediatri-
19	cians and other primary care physicians, and
20	obstetricians and gynecologists" and inserting
21	"substance use disorder treatment providers, pe-
22	diatricians, other primary care providers, and
23	obstetrician-gyne cologists";
24	(3) in subsection (b)—

1	(A) by striking "directly and" and insert-
2	ing "directly or"; and
3	(B) by striking "hepatitis C," and all that
4	follows through the period at the end and insert-
5	ing "infections described in subsection (a)(1).";
6	and
7	(4) in subsection (c), by striking "such sums as
8	may be necessary for each of the fiscal years 2001
9	through 2005" and inserting "\$40,000,000 for each of
10	fiscal years 2019 through 2023".
11	SEC. 513. TASK FORCE TO DEVELOP BEST PRACTICES FOR
12	TRAUMA-INFORMED IDENTIFICATION, REFER-
13	RAL, AND SUPPORT.
	RAL, AND SUPPORT. (a) Establishment.—There is established a task
13 14	
13 14 15	(a) Establishment.—There is established a task
13 14 15 16	(a) Establishment.—There is established a task force, to be known as the Interagency Task Force on Trau-
13 14 15 16 17	(a) Establishment.—There is established a task force, to be known as the Interagency Task Force on Trauma-Informed Care (in this section referred to as the "task"
13 14 15 16 17	(a) ESTABLISHMENT.—There is established a task force, to be known as the Interagency Task Force on Trauma-Informed Care (in this section referred to as the "task force") that shall identify, evaluate, and make recommenda-
13 14 15 16 17 18	(a) ESTABLISHMENT.—There is established a task force, to be known as the Interagency Task Force on Trauma-Informed Care (in this section referred to as the "task force") that shall identify, evaluate, and make recommendations regarding best practices with respect to children and
13 14 15 16 17 18	(a) ESTABLISHMENT.—There is established a task force, to be known as the Interagency Task Force on Trauma-Informed Care (in this section referred to as the "task force") that shall identify, evaluate, and make recommendations regarding best practices with respect to children and youth, and their families as appropriate, who have experi-
13 14 15 16 17 18 19 20	(a) Establishment.—There is established a task force, to be known as the Interagency Task Force on Trauma-Informed Care (in this section referred to as the "task force") that shall identify, evaluate, and make recommendations regarding best practices with respect to children and youth, and their families as appropriate, who have experienced or are at risk of experiencing trauma.
13 14 15 16 17 18 19 20 21	(a) Establishment.—There is established a task force, to be known as the Interagency Task Force on Trauma-Informed Care (in this section referred to as the "task force") that shall identify, evaluate, and make recommendations regarding best practices with respect to children and youth, and their families as appropriate, who have experienced or are at risk of experiencing trauma. (b) Membership.—

1	(A) The Centers for Medicare & Medicaid
2	Services.
3	(B) The Substance Abuse and Mental
4	Health Services Administration.
5	(C) The Agency for Healthcare Research
6	and Quality.
7	(D) The Centers for Disease Control and
8	Prevention.
9	(E) The Indian Health Service.
10	(F) The Department of Veterans Affairs.
11	(G) The National Institutes of Health.
12	(H) The Food and Drug Administration.
13	(I) The Health Resources and Services Ad-
14	ministration.
15	(J) The Department of Defense.
16	(K) The Office of Minority Health.
17	(L) The Administration for Children and
18	Families.
19	(M) The Office of the Assistant Secretary
20	for Planning and Evaluation.
21	(N) The Office for Civil Rights at the De-
22	partment of Health and Human Services.
23	(O) The Office of Juvenile Justice and De-
24	linquency Prevention of the Department of Jus-
25	tice.

1	(P) The Office of Community Oriented Po-
2	licing Services of the Department of Justice.
3	(Q) The Office on Violence Against Women
4	of the Department of Justice.
5	(R) The National Center for Education
6	Evaluation and Regional Assistance of the De-
7	partment of Education.
8	(S) The National Center for Special Edu-
9	cation Research of the Institute of Education
10	Science.
11	(T) The Office of Elementary and Sec-
12	ondary Education of the Department of Edu-
13	cation.
14	(U) The Office for Civil Rights at the De-
15	partment of Education.
16	(V) The Office of Special Education and
17	Rehabilitative Services of the Department of
18	Education.
19	(W) The Bureau of Indian Affairs of the
20	Department of the Interior.
21	(X) The Veterans Health Administration of
22	the Department of Veterans Affairs.
23	(Y) The Office of Special Needs Assistance
24	Programs of the Department of Housing and
25	Urban Development.

1	(Z) The Office of Head Start of the Admin-
2	istration for Children and Families.
3	(AA) The Children's Bureau of the Admin-
4	istration for Children and Families.
5	(BB) The Bureau of Indian Education of
6	the Department of the Interior.
7	(CC) Such other Federal agencies as the
8	Secretaries determine to be appropriate.
9	(2) Date of appointments.—The heads of Fed-
10	eral departments and agencies shall appoint the cor-
11	responding members of the task force not later than
12	6 months after the date of enactment of this Act.
13	(3) Chairperson.—The task force shall be
14	chaired by the Assistant Secretary for Mental Health
15	and Substance Use.
16	(c) Task Force Duties.—The task force shall—
17	(1) solicit input from stakeholders, including
18	frontline service providers, educators, mental health
19	professionals, researchers, experts in infant, child, and
20	youth trauma, child welfare professionals, and the
21	public, in order to inform the activities under para-
22	graph (2); and
23	(2) identify, evaluate, make recommendations,
24	and update such recommendations not less than an-
25	nually, to the general public, the Secretary of Edu-

1	cation, the Secretary of Health and Human Services,
2	the Secretary of Labor, the Secretary of the Interior,
3	the Attorney General, and other relevant cabinet Sec-
4	retaries, and Congress regarding—
5	(A) a set of evidence-based, evidence-in-
6	formed, and promising best practices with re-
7	spect to—
8	(i) the identification of infants, chil-
9	dren and youth, and their families as ap-
10	propriate, who have experienced or are at
11	risk of experiencing trauma; and
12	(ii) the expeditious referral to and im-
13	plementation of trauma-informed practices
14	and supports that prevent and mitigate the
15	effects of trauma;
16	(B) a national strategy on how the task
17	force and member agencies will collaborate,
18	prioritize options for, and implement a coordi-
19	nated approach which may include data sharing
20	and the awarding of grants that support infants,
21	children, and youth, and their families as appro-
22	priate, who have experienced or are at risk of ex-
23	periencing trauma; and
24	(C) existing Federal authorities at the De-
25	partment of Education, Department of Health

1	and Human Services, Department of Justice,
2	Department of Labor, Department of Interior,
3	and other relevant agencies, and specific Federal
4	grant programs to disseminate best practices on,
5	provide training in, or deliver services through,
6	trauma-informed practices, and disseminate such
7	information—
8	(i) in writing to relevant program of-
9	fices at such agencies to encourage grant
10	applicants in writing to use such funds,
11	where appropriate, for trauma-informed
12	practices; and
13	(ii) to the general public through the
14	internet website of the task force.
15	(d) Best Practices.—In identifying, evaluating,
16	and recommending the set of best practices under subsection
17	(c), the task force shall—
18	(1) include guidelines for providing professional
19	development for front-line services providers, includ-
20	ing school personnel, early childhood education pro-
21	gram providers, providers from child- or youth-serv-
22	ing organizations, housing and homeless providers,
23	primary and behavioral health care providers, child
24	welfare and social services providers, juvenile and
25	family court personnel, health care providers, individ-

1	uals who are mandatory reporters of child abuse or
2	neglect, trained nonclinical providers (including peer
3	mentors and clergy), and first responders, in—
4	(A) understanding and identifying early
5	signs and risk factors of trauma in infants, chil-
6	dren, and youth, and their families as appro-
7	priate, including through screening processes;
8	(B) providing practices to prevent and
9	mitigate the impact of trauma, including by fos-
10	tering safe and stable environments and relation-
11	ships; and
12	(C) developing and implementing policies,
13	procedures, or systems that—
14	(i) are designed to quickly refer in-
15	fants, children, youth, and their families as
16	appropriate, who have experienced or are at
17	risk of experiencing trauma to the appro-
18	priate trauma-informed screening and sup-
19	port, including age-appropriate treatment,
20	and to ensure such infants, children, youth,
21	and family members receive such support;
22	(ii) utilize and develop partnerships
23	with early childhood education programs,
24	local social services organizations, such as
25	organizations serving youth, and clinical

1	mental health or health care service pro-
2	viders with expertise in providing support
3	services (including age-appropriate trauma-
4	informed and evidence-based treatment)
5	aimed at preventing or mitigating the ef-
6	fects of trauma;
7	(iii) educate children and youth to—
8	(I) understand and identify the
9	signs, effects, or symptoms of trauma;
10	and
11	(II) build the resilience and cop-
12	ing skills to mitigate the effects of expe-
13	riencing trauma;
14	(iv) promote and support multi-
15	generational practices that assist parents,
16	foster parents, and kinship and other care-
17	givers in accessing resources related to, and
18	developing environments conducive to, the
19	prevention and mitigation of trauma; and
20	(v) collect and utilize data from
21	screenings, referrals, or the provision of
22	services and supports to evaluate and im-
23	prove processes for trauma-informed sup-
24	port and outcomes that are culturally sen-
25	sitive, linguistically appropriate, and spe-

1	cific to age ranges and sex, as applicable;
2	and
3	(2) recommend best practices that are designed
4	to avoid unwarranted custody loss or criminal pen-
5	alties for parents or guardians in connection with in-
6	fants, children, and youth who have experienced or
7	are at risk of experiencing trauma.
8	(e) Operating Plan.—Not later than 1 year after the
9	date of enactment of this Act, the task force shall hold the
10	first meeting. Not later than 2 years after such date of en-
11	actment, the task force shall submit to the Secretary of Edu-
12	cation, Secretary of Health and Human Services, Secretary
13	of Labor, Secretary of the Interior, the Attorney General,
14	and Congress an operating plan for carrying out the activi-
15	ties of the task force described in subsection $(c)(2)$. Such
16	operating plan shall include—
17	(1) a list of specific activities that the task force
18	plans to carry out for purposes of carrying out duties
19	described in $subsection$ $(c)(2)$, $which$ may $include$
20	public engagement;
21	(2) a plan for carrying out the activities under
22	subsection (c)(2);
23	(3) a list of members of the task force and other
24	individuals who are not members of the task force
25	that may be consulted to carry out such activities;

1	(4) an explanation of Federal agency involve-
2	ment and coordination needed to carry out such ac-
3	tivities, including any statutory or regulatory bar-
4	riers to such coordination;
5	(5) a budget for carrying out such activities; and
6	(6) other information that the task force deter-
7	mines appropriate.
8	(f) Final Report.—Not later than 3 years after the
9	date of the first meeting of the task force, the task force shall
10	submit to the general public, Secretary of Education, Sec-
11	retary of Health and Human Services, Secretary of Labor,
12	Secretary of the Interior, the Attorney General, and other
13	relevant cabinet Secretaries, and Congress, a final report
14	containing all of the findings and recommendations re-
15	quired under this section.
16	(g) Definition.—In this section, the term "early
17	childhood education program" has the meaning given such
18	term in section 103 of the Higher Education Act of 1965
19	(20 U.S.C. 1003).

- 20 (h) Authorization of Appropriations.—To carry
- 21 out this section, there are authorized to be appropriated
- 22 such sums as may be necessary for each of fiscal years 2019
- 23 through 2022.

1	(i) Sunset.—The task force shall on the date that is
2	60 days after the submission of the final report under sub-
3	section (f), but not later than September 30, 2022.
4	SEC. 514. GRANTS TO IMPROVE TRAUMA SUPPORT SERV-
5	ICES AND MENTAL HEALTH CARE FOR CHIL-
6	DREN AND YOUTH IN EDUCATIONAL SET-
7	TINGS.
8	(a) Grants, Contracts, and Cooperative Agree-
9	MENTS AUTHORIZED.—The Secretary, in coordination with
10	the Assistant Secretary for Mental Health and Substance
11	Use, is authorized to award grants to, or enter into con-
12	tracts or cooperative agreements with, State educational
13	agencies, local educational agencies, Head Start agencies
14	(including Early Head Start agencies), State or local agen-
15	cies that administer public preschool programs, Indian
16	tribes or their tribal educational agencies, a school operated
17	by the Bureau of Indian Education, a Regional Corpora-
18	tion (as defined in section 3 of the Alaska Native Claims
19	Settlement Act (43 U.S.C. 1602)), or a Native Hawaiian
20	educational organization (as defined in section 6207 of the
21	Elementary and Secondary Education Act of 1965 (20
22	U.S.C. 7517)), for the purpose of increasing student access
23	to evidence-based trauma support services and mental

24 health care by developing innovative initiatives, activities,

25 or programs to link local school systems with local trauma-

- 1 informed support and mental health systems, including
- 2 those under the Indian Health Service.
- 3 (b) Duration.—With respect to a grant, contract, or
- 4 cooperative agreement awarded or entered into under this
- 5 section, the period during which payments under such
- 6 grant, contract or agreement are made to the recipient may
- 7 not exceed 4 years.
- 8 (c) Use of Funds.—An entity that receives a grant,
- 9 contract, or cooperative agreement under this section shall
- 10 use amounts made available through such grant, contract,
- 11 or cooperative agreement for evidence-based activities,
- 12 which shall include any of the following:
- 13 (1) Collaborative efforts between school-based
- service systems and trauma-informed support and
- 15 mental health service systems to provide, develop, or
- improve prevention, screening, referral, and treatment
- 17 and support services to students, such as by providing
- 18 universal trauma screenings to identify students in
- 19 need of specialized support.
- 20 (2) To implement schoolwide multi-tiered posi-
- 21 tive behavioral interventions and supports, or other
- 22 trauma-informed models of support.
- 23 (3) To provide professional development to teach-
- 24 ers, teacher assistants, school leaders, specialized in-

1	structional support personnel, and mental health pro-
2	fessionals that—
3	(A) fosters safe and stable learning environ-
4	ments that prevent and mitigate the effects of
5	trauma, including through social and emotional
6	learning;
7	(B) improves school capacity to identify,
8	refer, and provide services to students in need of
9	trauma support or behavioral health services; or
10	(C) reflects the best practices developed by
11	the Interagency Task Force on Trauma-Informed
12	Care established under section 513.
13	(4) Engaging families and communities in ef-
14	forts to increase awareness of child and youth trau-
15	ma, which may include sharing best practices with
16	law enforcement regarding trauma-informed care and
17	working with mental health professionals to provide
18	interventions, as well as longer term coordinated care
19	within the community for children and youth who
20	have experienced trauma and their families.
21	(5) To provide technical assistance to school sys-
22	tems and mental health agencies.
23	(6) To evaluate the effectiveness of the program
24	carried out under this section in increasing student

1	access to evidence-based trauma support services and
2	mental health care.
3	(d) Applications.—To be eligible to receive a grant,
4	contract, or cooperative agreement under this section, an
5	entity described in subsection (a) shall submit an applica-
6	tion to the Secretary at such time, in such manner, and
7	containing such information as the Secretary may reason-
8	ably require, which shall include the following:
9	(1) A description of the innovative initiatives,
10	activities, or programs to be funded under the grant,
11	contract, or cooperative agreement, including how
12	such program will increase access to evidence-based
13	trauma support services and mental health care for
14	students, and, as applicable, the families of such stu-
15	dents.
16	(2) A description of how the program will pro-
17	vide linguistically appropriate and culturally com-
18	petent services.
19	(3) A description of how the program will sup-
20	port students and the school in improving the school
21	climate in order to support an environment conducive
22	to learning.
23	(4) An assurance that—

- (A) persons providing services under the grant, contract, or cooperative agreement are adequately trained to provide such services; and
 - (B) teachers, school leaders, administrators, specialized instructional support personnel, representatives of local Indian tribes or tribal organizations as appropriate, other school personnel, and parents or guardians of students participating in services under this section will be engaged and involved in the design and implementation of the services.
- (5) A description of how the applicant will support and integrate existing school-based services with the program in order to provide mental health services for students, as appropriate.

(e) Interagency Agreements.—

(1) Designation of Lead agency.—A recipient of a grant, contract, or cooperative agreement under this section shall designate a lead agency to direct the establishment of an interagency agreement among local educational agencies, agencies responsible for early childhood education programs, juvenile justice authorities, mental health agencies, child welfare agencies, and other relevant entities in the State or Indian tribe, in collaboration with local entities.

1	(2) Contents.—The interagency agreement
2	shall ensure the provision of the services described in
3	subsection (c), specifying with respect to each agency,
4	authority, or entity—
5	(A) the financial responsibility for the serv-
6	ices;
7	(B) the conditions and terms of responsi-
8	bility for the services, including quality, account-
9	ability, and coordination of the services; and
10	(C) the conditions and terms of reimburse-
11	ment among the agencies, authorities, or entities
12	that are parties to the interagency agreement,
13	including procedures for dispute resolution.
14	(f) EVALUATION.—The Secretary shall reserve not to
15	exceed 3 percent of the funds made available under sub-
16	section (l) for each fiscal year to—
17	(1) conduct a rigorous, independent evaluation
18	of the activities funded under this section; and
19	(2) disseminate and promote the utilization of
20	evidence-based practices regarding trauma support
21	services and mental health care.
22	(g) Distribution of Awards.—The Secretary shall
23	ensure that grants, contracts, and cooperative agreements
24	awarded or entered into under this section are equitably
25	distributed among the geographical regions of the United

- 1 States and among tribal, urban, suburban, and rural popu-2 lations.
- 3 (h) Rule of Construction.—Nothing in this section 4 shall be construed—
- 5 (1) to prohibit an entity involved with a pro-6 gram carried out under this section from reporting a 7 crime that is committed by a student to appropriate 8 authorities; or
- 9 (2) to prevent Federal, State, and tribal law en10 forcement and judicial authorities from exercising
 11 their responsibilities with regard to the application of
 12 Federal, tribal, and State law to crimes committed by
 13 a student.
- 14 (i) SUPPLEMENT, NOT SUPPLANT.—Any services pro-15 vided through programs carried out under this section shall 16 supplement, and not supplant, existing mental health serv-17 ices, including any special education and related services 18 provided under the Individuals with Disabilities Education 19 Act (20 U.S.C. 1400 et seq.).
- 20 (j) Consultation With Indian Tribes.—In car-21 rying out subsection (a), the Secretary shall, in a timely 22 manner, meaningfully consult, engage, and cooperate with 23 Indian tribes and their representatives to ensure notice of 24 eligibility.
- 25 (k) Definitions.—In this section:

- 1 (1) ELEMENTARY OR SECONDARY SCHOOL.—The
 2 term "elementary or secondary school" means a pub3 lic elementary and secondary school as such term is
 4 defined in section 8101 of the Elementary and Sec5 ondary Education Act of 1965 (20 U.S.C. 7801).
 - (2) EVIDENCE-BASED.—The term "evidence-based" has the meaning given such term in section 8101(21)(A)(i) of the Elementary and Secondary Education Act of 1965 (20 U.S.C. 7801(21)(A)(i)).
 - (3) Native Hawaiian educational or-Tion.—The term "Native Hawaiian educational organization" has the meaning given such term in section 6207 of the Elementary and Secondary Education Act of 1965 (20 U.S.C. 7517).
 - (4) SCHOOL LEADER.—The term "school leader" has the meaning given such term in section 8101 of the Elementary and Secondary Education Act of 1965 (20 U.S.C. 7801).
 - (5) Secretary.—The term "Secretary" means the Secretary of Education.
 - (6) Specialized instructional support personnel" has the meaning given such term in 8101 of the Elementary and Secondary Education Act of 1965 (20 U.S.C. 7801).

- 1 (1) AUTHORIZATION OF APPROPRIATIONS.—There is
- 2 authorized to be appropriated to carry out this section, such
- 3 sums as may be necessary for each of fiscal years 2019
- 4 through 2023.
- 5 SEC. 515. NATIONAL CHILD TRAUMATIC STRESS INITIATIVE.
- 6 Section 582(j) of the Public Health Service Act (42
- 7 U.S.C. 290hh-1(j)) (relating to grants to address the prob-
- 8 lems of persons who experience violence related stress) is
- 9 amended by striking "\$46,887,000 for each of fiscal years
- 10 2018 through 2022" and inserting "\$53,887,000 for each
- 11 of fiscal years 2019 through 2023".

Calendar No. 398

115TH CONGRESS **S. 2680**

A BILL

To address the opioid crisis.

May 7, 2018

Reported with an amendment